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Abstract 
In this study, the influence of rooibos on the catalytic activity of enzymes 17β -hydroxysteroid 
dehydrogenase type 3 (17βHSD3), 17β-hydroxysteroid dehydrogenase type 5 (AKR1C3), 
17β-hydroxysteroid dehydrogenase type 2 (17βHSD2), 5α-reductase type 1 (SRD5A1) and 
5α-reductase type 2 (SRD5A2), which catalyse prostate androgen metabolism, was investigated. 
The activities of both 17βHSD3 and AKR1C3 heterologously expressed in CHO-K1 and HEK293 
cells were inhibited significantly by rooibos, with rooibos reducing the conversion of 
androstenedione (A4) and 11keto-androstenedione (11KA4) to testosterone (T) and 11keto-
testosterone (11KT), respectively. The catalytic activity of 17βHSD2 towards T, 11hydroxy-
testosterone (11OHT) and 11KT was also significantly inhibited by rooibos in transiently 
transfected HEK293 cells. In transiently transfected HEK293 cells rooibos did not inhibit SRD5A1 
while the rate of T conversion to dihydrotestosterone (DHT) by SRD5A2 was decreased. Analysis 
of steroid metabolism in PNT2 cells also suggests that rooibos does not modulate the catalytic 
activity of endogenously expressed SRD5A towards A4, however, the conversion of T to DHT was 
reduced. In addition, reductive 17βHSD activity towards A4 was inhibited in the presence of 
rooibos in both PNT2 and BPH-1 cells. In contrast, the conversion of 11KA4 to 11KT was inhibited 
in BPH-1, PC-3 and LNCaP cells, with negligible conversion of 11KA4 in PNT2 cells. Interestingly, 
data suggests inhibition of 3α-hydroxysteroid dehydrogenase type 3 (AKR1C2) activity in the 
production of androsterone (AST) from 5α–androstenedione (5α-dione), as well as the 
dehydrogenase reaction of T to A4 in PNT2 cells by rooibos. Androgen metabolism pathways were 
subsequently investigated in LNCaP cells to determine androgen metabolism by endogenous 
enzymes. Rooibos resulted in the reduced conversion of A4 in LNCaP cells to the same extent as 
indomethacin, a known AKR1C3 inhibitor. Rooibos also modulated T, DHT and AST metabolism in 
LNCaP cells. Furthermore, uridine diphosphate glucuronosyltransferase (UGT) activity in LNCaP 
cells was inhibited by rooibos, decreasing T-, DHT– and AST-glucuronide formation. These data 
prompted subsequent investigations into the influence of rooibos at cellular level, and prostate-
specific antigen (PSA) levels were assayed in the presence of rooibos. PSA was significantly 
inhibited by rooibos in the absence and presence of DHT, suggesting possible interaction of 
rooibos with the mutated androgen receptor (AR) or estrogen receptor-β (ERβ) expressed in 
LNCaP cells.  
Taken together, rooibos inhibited the catalytic activity of key enzymes that catalyse the activation 
of androgens in the prostate, as well as inhibiting enzymes involved in the conjugation of 
androgens. At cellular level, PSA levels were also decreased by rooibos, possibly through AR or 
ERβ interactions – clearly indicating a modulatory role for rooibos in active androgen production. 
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Opsomming 
In hierdie studie was die invloed van rooibos ten opsigte van die katalitiese aktiwiteite van die 
ensieme 17β-hidroksi-steroïed-dehidrogenase tipe 2, tipe 3 en tipe 5 (17βHSD2, 17βHSD3, 
AKR1C3), asook 5α-reduktase tipe 1 en tipe 2 (SRD5A1, SRD5A2) ondersoek. Hierdie ensieme is 
betrokke in die produksie van androgene in die prostaat. Rooibos het die katalitiese aktiwiteit van 
17βHSD3 en AKR1C3 in CHO-K1 en HEK293 selle beïnvloed en het vermindere omskakeling van 
androstenedioon (A4) en 11keto-androstenedioon (11KA4) na testosteroon (T) en 11-keto-
testosteroon (11KT), afsonderlik, veroorsaak. Die katalitiese aktiwiteit van 17βHSD2 teenoor T, 
11-hidroksie-testosteroon (11OHT) en 11KT was ook beïnvloed in die teenwoordigheid van rooibos 
in HEK293 selle. Die katalitiese aktiwiteit van SRD5A1 teenoor A4 en T is nie beïnvloed deur 
rooibos nie, alhoewel dit voorkom asof rooibos die omsettingstempo van T na dihidrotestosteroon 
(DHT) deur SRD5A2, getransfekteer in HEK293 selle, verminder het. Verdere ondersoeke is in 
normale prostaat epiteel selle, in die teenwoordigheid van rooibos uitgevoer. Rooibos het geen 
invloed op die katalitiese aktiwiteit van SRD5A teenoor A4 gehad nie, alhoewel vermindere 
omskakeling van T na DHT aangetoon kon word. Rooibos het ook die omskakeling van A4 na T in 
beide PNT2 en BPH-1 selle tot „n mate geïnhibeer. Die omskakeling van 11KA4 na 11KT was ook 
verminder in BPH-1, PC-3 en LNCaP selle. Die omskakeling van 11KA4 na 11KT was beduidend 
laer in PNT2 selle en kon die invloed van rooibos nie aangetoon word nie. Bykomende data toon 
dat rooibos ook die omskakeling van 5α-androstenedioon (5α-dione) na androsteroon (AST), 
gekataliseer deur 3α-hidroksi-dehidrogenase tipe 3 (AKR1C2), verminder, gesamentlik met die 
vermindere omskakeling van T na A4, deur 17βHSD2, in PNT2 selle. Hierdie studie het ook 
ondersoek ingestel, na die metabolisme van androgene in LNCaP selle. Vermindere A4 
metabolisme is in die teenwoordigheid van rooibos asook in die teenwoordigheid van 
indometasien, „n bekende AKR1C3 inhibitor, gevind. Rooibos verminder dus die aktiwiteit van 
reduktiewe 17βHSD in LNCaP selle. Verandering in die metabolisme van T, DHT en AST in 
LNCaP selle, in die teenwoordigheid van rooibos, is ook gevind. Verdere ondersoek in LNCaP 
selle het gewys dat rooibos „n vermindering in die produksie van gekonjugeerde T, DHT en AST 
veroorsaak. Die studie het die invloed van rooibos op prostaat-spesifieke antigeen (PSA) ook 
ondersoek. Daar is vasgestel dat rooibos die vlakke van PSA verminder in die afwesigheid en 
teenwoordigheid van DHT in LNCaP selle. Hierdie resultaat dui op moontlike interaksie van 
rooibos met die androgeen (AR) of estrogeen-reseptor-β (ERβ), teenwoordig in LNCaP selle. 
Rooibos het die katalitiese aktiwiteit van ensieme, wat bydra tot androgeen produksie, geïnhibeer, 
asook die konjugasie van androgene. Op „n sellulêre vlak, het rooibos die vlakke van PSA-sekresie 
verminder, wat moontlike interaksie met die AR en ERβ aandui. Hierdie bevindings dui daarop dat 
rooibos wel n rol het om te speel in die modulasie van aktiewe androgene in die prostaat. 
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Chapter 1 
Introduction 
Prostate cancer (PCa) is the most common malignancy found in men, with a median age for 
diagnosis, set at 66, and a median age of death set at 88. According to The American Cancer 
Society, 1 in every 7 men will be diagnosed with PCa during their lifetime, with 1 in every 36 of 
these men dying from PCa (American Cancer Society, 2014). A patient‟s cancer stage at diagnosis 
determines subsequent treatment options, with the cancer termed as localized (stage 1) if it has 
not metastasised and is located only in the tissue of origin. However, if the cancer has spread, it is 
termed regional or distant. Localized cancer accounts for ±81% of PCa cases, regional for ±12% 
and distant for ±4%, with ±3% of cancers being difficult to diagnose within the aforementioned 
groups. As such, localized and regional cancers have a 100% 5-year relative survival rate, 
compared to distant cancers which only have a 28% 5-year relative survival rate (National Cancer 
Institute, 2014). 
Androgens play important roles in the pathogenesis of PCa, with diseases of the prostate - both 
benign prostatic hyperplasia (BPH) and PCa - considered as hormone-dependent diseases 
(Penning, 2010). Once diagnosed the option of castration is suggested, as a means of depleting 
the prostate of active androgens which promote cell proliferation. Many treatment strategies, such 
as castration and androgen-deprivation therapy (ADT), are currently employed against PCa, but 
irrespective of the treatment regimen, in about 30–40% of cases the cancer can re-emerge (2–5 
years later) and is termed: castration resistant prostate cancer (CRPC) (Sharifi & Auchus, 2012). 
CRPC is in almost all cases fatal, with PSA, which serves as a clinical tool to analyse whether a 
patient is progressing to PCa, increasing once again with CRPC (Mohler et al., 2004). Cell growth 
and proliferation as it occurs in the prostate, is either due to the conversion of T into the potent 
active androgen, DHT, by the enzyme SRD5A or the conversion of 5α-dione, the SRD5A product 
of A4, to DHT by the enzyme 17βHSD. DHT is able to bind the AR and translocate into the nucleus 
and subsequently activate AR-dependent gene transcription (Hsing, Chu, & Stanczyk, 2008). 
Under normal circumstances, the testes provides T that circulates to the prostate, however, with 
CRPC, it is the adrenal that provides androgen precursors dehydroepiandrosterone (DHEA), A4 
and to a lesser extent, T (Luu-The, Bélanger, & Labrie, 2008; Montgomery et al., 2008; Stanbrough 
et al., 2006; Stein, Goodin, & Dipaola, 2012). In addition, de novo steroid biosynthesis has also 
been suggested in prostatic tissue, representing yet another metabolic route supplying AR ligands 
to the androgen pool (Cai et al., 2011). Together these routes provide sufficient androgens to 
support cell growth under normal condition as well as driving PCa, and have also been suggested 
to drive the progression of CRPC. As mentioned, ADT is currently the treatment strategy against 
PCa, which include enzyme inhibitors or the use of AR antagonists, in order to reduce androgen 
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production and inactivate AR transcription. New approaches, however, need to be explored and 
implemented in an effort to increase survival rates. 
There exists epidemiologic and case-controlled evidence that suggests that diet may be a modifier 
of PCa risk (Ornish et al., 2005; Saxe et al., 2006; Shimizu et al., 1991; Strom et al., 1999). In 
2008, Ornish et al., reported a pilot study examining changes in prostate gene expression in men 
with low-risk PCa who participated in an intensive nutrition and lifestyle intervention, in which 48 
up-regulated and 453 down-regulated transcripts, including oncogenes, were identified after the 
intervention. These gene changes comprised genes involved in tumourigenesis, which included 
genes involved in protein metabolism and modification, intracellular trafficking and protein 
phosphorylation. The lifestyle changes included a diet low in fat, comprised of whole-foods and 
plant-based nutrition, stress maintenance, together with exercise routines as well as attending a 
psychosocial support group. This study suggested that intensive nutrition and lifestyle changes 
may modulate gene expression in the prostate (Ornish et al., 2008). The participant‟s diets were 
supplemented with soy, fish oil, selenium and vitamin C and E and included soy products rich in 
polyphenols, as in the case of rooibos. It is interesting to note that the incidence of clinically 
significant PCa is less prevalent in world populations where people consume a predominant plant-
based diet (Hebert et al., 1998; Parkin, Bray, Ferlay, & Pisani, 2005; Parkin, Pisani, & Ferlay, 
1999). 
Indeed the anti-carcinogenic properties of rooibos have been widely investigated and reported 
(Larsen et al., 2011; Marnewick et al., 2005). The anti-carcinogenic properties of rooibos in terms 
of PCa have, however, not been extensively investigated. As PCa is driven by androgens, the only 
plausible evidence to suggest a role for rooibos in PCa, are reports of rooibos and its role in the 
modulation of adrenal steroidogenesis together with the inhibition of steroid-metabolizing enzymes 
(Perold, 2009; Schloms & Swart, 2014; Schloms et al., 2013; Schloms et al., 2012). As mentioned, 
in the battle against PCa, new treatment approaches against PCa progression are sought and the 
use of herbal medicinal products preferred to mainstream pharmaceuticals, has led to increased 
interest in recent years in natural plant products.  
Chapter 2 presents an overview of the flavonoid composition of rooibos together with the 
bioavailability and metabolism of the major polyphenolic compounds of rooibos. The roles that 
have been attributed to polyphenols and rooibos in steroid-dependent cancer development and the 
modulation of steroidogenic enzymes will be presented and this chapter concludes with the 
discussion of potential applications of rooibos in PCa. 
Chapter 3 provides an overview of testicular, adrenal and prostatic steroidogenesis and highlights 
prostate androgen metabolism pathways and the enzyme machinery involved therein. Activities of 
SRD5As, 17βHSDs and UGTs together with the activation of the AR and downstream implications 
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thereof will be presented. This chapter furthermore highlights the progression of PCa to CRPC and 
concludes with a discussion of CRPC treatment strategies. 
Chapter 4 and Chapter 5 describe the study into the influence of rooibos on androgen metabolism 
in normal and PCa cells in which the following aims are addressed: 
 to determine the influence of rooibos on cell viability in CHO-K1, COS-1, HEK293 and 
LNCaP cells; 
 to determine the influence of rooibos on the activities of reductive 17βHSD3 and AKR1C3, 
as well as on the oxidative activity of 17βHSD2, heterologously expressed in CHO-K1 and 
HEK293 cells; 
 to determine the influence of rooibos on the conversion of steroids to their respective 
5α-reduced androgens, catalysed via SRD5A1 and SRD5A2, heterologously expressed in 
U2OS and HEK293 cells; 
 to investigate the influence of rooibos on androgen metabolism and endogenous enzyme 
activity in prostate cell models - PNT2, BPH-1, PC-3 and LNCaP cells; 
 to determine PSA levels in the presence and absence of DHT, followed by the investigation 
into the influence of rooibos on basal and DHT-stimulated PSA levels in LNCaP cells. 
 
The influence of rooibos on the catalytic activity of 17βHSD3, AKR1C3, 17βHSD2, SRD5A1 and 
SRD5A2, heterologously expressed in cell models, is described in chapter 4. The influence of 
rooibos on androgen metabolism in normal epithelial, PNT2, and in BPH-1 prostate cells, 
specifically on the catalytic conversion of androgens by endogenously expressed 17βHSDs and 
SRD5As, as well as the influence of rooibos on cell viability will be discussed in this chapter.  
In chapter 5, the influence of rooibos on prostate androgen metabolism in the androgen-dependent 
PCa cell line, LNCaP, is discussed. This chapter reports on the metabolism of A4, T, DHT, AST 
and 3α-adiol in terms of endogenous enzyme activity and the preferential conversion of steroids in 
metabolic pathways in this cell model. The inhibitory effect of rooibos on endogenously expressed 
reductive 17βHSDs and the modulation of AKR1C2, as well as UGTs, are subsequently described, 
together with the influence of rooibos on AR-regulated gene expression of PSA. 
Chapter 6 concludes the thesis with an overview of the findings of this study and presents 
conclusions based on the data presented, together with the potential role of rooibos in therapeutic 
approaches to PCa. 
Chapter 7 presents detailed experimental procedures undertaken throughout this study. 
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Chapter 2 
The bioactivity of rooibos and its potential application in PCa 
2.1 Introduction 
The discovery that rooibos, a polyphenol-rich herbal tea, soothed Annetjie Theron baby‟s colic, in 
1968, launched rooibos‟ reputation as a „health gimmick‟ in modern times, 300 years after the 
Khoisan tribe had already discovered that an aromatic tea can be brewed from the wild rooibos 
plant (Joubert, 2011). Rooibos tea is currently enjoyed in 37 countries, including Germany, the 
Netherlands, the United Kingdom, Japan and the United States of America, with the 
aforementioned countries representing 86% of the rooibos export market. Rooibos is consumed as 
an herbal tea competing with coffee and varieties of Camellia sinensis. Rooibos is caffeine free 
and compared to the before mentioned beverages, very low in tannins. Rooibos grows naturally in 
the Cederberg area in the Western Province of South Africa and is produced from the stems and 
leaves of Aspalathus linearis, belonging to the genus Fabaceae, Tribe Crotalarieae, endemic to the 
Cape Floristic Region (Joubert & de Beer, 2011). 
Rooibos was first marketed in 1904 in its fermented „oxidized‟ form, with the unfermented „green‟ 
rooibos form currently emerging as a growing market. Green rooibos was first produced during the 
1990s to achieve higher antioxidant levels, and is consumed as a functional beverage. Green 
rooibos extracts are also marketed in the food and cosmetic industries (Joubert, 2011). Green 
rooibos is popular as it contains high levels of flavonoids and is caffeine-free, and together with 
fermented rooibos aids in the alleviation of depression, anxiety and insomnia. Its popularity has 
grown to such a degree that rooibos extracts, usually combined with other ingredients, are 
available today in tablet form, functioning as dietary supplements. 
2.2 Bioavailability and metabolism of the major polyphenolic compounds in rooibos 
Plants possess the ability to acquire polyphenolic precursor compounds and to produce flavonoids, 
which include flavonols, anthocyanins and tannins, through the phenylpropanoid pathway. This 
pathway forms part of secondary metabolite biosynthesis maintained by plants and is therefore not 
required to sustain plant life, but contributes to aiding in the plant‟s defences and reproduction 
(Kubasek et al., 1992). Flavonoids are polyphenols that occur naturally in fruits, vegetables, teas 
and herbs, with flavonoid biosynthesis starting from phenylalanine to produce 4-coumaroyl-CoA, 
via cinnamic acid and p-coumaric acid. Condensation of 4-coumaryol-CoA and malonyl-CoA 
subsequently yields the intermediate chalcones, which are precursors of different flavonoid 
subgroups, such as flavones, flavanones, isoflavones and flavans (fig. 2.1) (Brožič et al., 2009). 
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Figure 2.1: General structures of flavonoids. 
Over 4000 flavonoids have been identified in foods such as soy, apples, red wine, tea and onions 
(Zand et al., 2002), with 46 flavonoids identified in rooibos to date (Beelders et al., 2012; Joubert, 
Gelderblom, Louw, & de Beer, 2008). Flavonoids in rooibos are derivatives of 2-phenyl-4-
benzopyrone (flavone), with phenolic hydroxyl or methoxyl substituents at positions 3 – 6 (ring A 
and C) and 3‟ – 5‟ (ring B) of the two aromatic ring systems (fig. 2.1). These moieties are often 
glycosylated (Kachlicki et al., 2008; Xiao et al., 2009). Rooibos contains two unique polyphenolic 
compounds, aspalathin, a dihydrochalcone C-glucoside, and aspalalinin, a cyclic dihydrochalcone. 
Nothofagin is a rare dihydrochalcone C-glucoside also present in rooibos, and one other specie, 
Nothofagus fusca (Joubert & de Beer, 2011). Major flavonoid compounds present in rooibos 
include flavones, flavanones and flavonols, together with the aforementioned dihydrochalcones, as 
shown in table 2.1. 
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Table 2.1: Chemical structures of the major rooibos flavonoids. Reproduced with permission from (Joubert 
& de Beer, 2011; Schloms & Swart, 2014). 
Compound 
Polyphenol subgroup and 
substitution 
Structure 
 
Aspalathin 
 
 
Dihydrochalcone (R1 = OH; 
R2 = C-β-ᴅ-glucopyranosyl) 
 
 
Nothofagin 
 
 
Dihydrochalcone (R1 = H; R2 
= C-β-ᴅ-glucopyranosyl) 
 
 
Orientin 
 
 
Flavone (R1 = C-β-ᴅ-
glucopyranosyl; R2, R4 = OH; 
R3 = H) 
 
 
Isoorientin 
 
 
Flavone (R1 = H; R2, R4 = 
OH; R3 = C-β-ᴅ-
glucopyranosyl) 
 
 
Quercetin 
 
 
Flavonol (R1 = H; R2, R3 = 
OH) 
 
 
Rutin 
 
 
Flavonol (R1 = H; R2 = OH; 
R3 = O-rutinosyl) 
 
 
Isovitexin 
 
 
Flavone (R1, R4 = H; R2 = 
OH, R3 = C-β-ᴅ-
glucopyranosyl) 
 
 
Vitexin 
 
 
Flavone (R1 = C-β-ᴅ-
glucopyranosyl; R2= OH, R3, 
R4 =H) 
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As previously mentioned, rooibos is processed as either unfermented or fermented (oxidised), with 
a higher polyphenol content found in unfermented „green‟ rooibos. This is due to reduced exposure 
to the sun when the leaves are dried, thus reducing possible oxidative changes. The main 
polyphenols in unfermented rooibos are: aspalathin, isoorientin, orientin and rutin, with isovitexin, 
vitexin, isoquercitrin, hyperoside, quercetin, luteolin and chrysoeryol being present at lower levels. 
Aspalathin is ±50 times higher in the unfermented form of rooibos, compared to the fermented 
form. The fermentation process results in substantial degradation of aspalathin. One of the 
changes that occur is the oxidation of aspalathin to its flavanone analogues isoorientin and 
orientin, with dihydro-isoorientin ((R) and (S)-eriodictyol-6-C-glucoside as intermediates (fig. 2.2). 
Orientin forms irreversibly from isoorientin, with the latter undergoing opening of its vinyl ester 
structure to form a chalcone intermediate. Given the degradation and studies reporting poor 
bioavailability of aspalathin (Breiter et al., 2011; Courts & Williamson, 2009; Kreuz et al., 2008; 
Stalmach et al., 2009), the importance of this rooibos flavonoid is highlighted by in vivo evidence of 
its bioactivity, including anti-mutagenic effects, its hypoglycaemic activity and moderate 
phytoestrogenic effects (Joubert & de Beer, 2011). 
 
Figure 2.2: Mechanism of aspalathin oxidation. Reproduced with permission from (Joubert & de Beer, 
2011). 
The C-glycosyl-flavones isoorientin, orientin, vitexin and isovitexin are degraded less when 
compared with the main flavonol-glycoside rutin, which is partly degraded to form quercetin 
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(Bramati, Aquilano, & Pietta, 2003). Fermentation therefore causes a definitive shift from a 
flavonoid rich tea to a flavonoid poor tea extract, resulting in quantitative changes in phenolic 
composition.  
Bioavailability of polyphenols is a concept that incorporates bioaccessibility, absorption, 
metabolism, tissue distribution and bioactivity. Bioaccessibility refers to the amount of an ingested 
compound that becomes available for absorption in the gut compared to bioavailability which is the 
concentration of a compound or its metabolite at the peripheral target tissue (Manach et al., 2004; 
Scholz & Williamson, 2007; Stahl et al., 2002). The definition of bioavailability often encompasses 
the liberation, absorption, distribution, metabolism and excretion of a compound. Liberation 
suggests the release of a compound from its matrix, absorption is the transport of a compound 
from the site of administration into the systemic circulation and distribution is the transportation of a 
compound by the systemic circulation to body tissue. Metabolism is the biotransformation of a 
compound and excretion is the elimination of a compound from the body via renal, biliary- or 
pulmonary processes (Holst & Williamson, 2008). There exist exogenous and endogenous factors 
that can influence the bioavailability of compounds. Exogenous factors include the complexity of 
the food matrix, the dosage and chemical form of the compound and endogenous factors include 
intestinal transit time, rate of gastric emptying, metabolism and extent of conjugation (Holst & 
Williamson, 2008). 
Many studies have considered the absorption and metabolism of rooibos flavonoids – as their 
potency and eventual effect is determined by their metabolism. Considering a single oral dose 
administered to human subjects, researchers reported that an unfermented aqueous drink 
produced a single methylated and a single methylated-glucuronidated metabolite excreted in urine 
(Courts & Williamson, 2009), while unfermented and fermented aqueous extracts in ready-to-drink 
beverages led to the identification of eight metabolites in urine. The eight metabolites identified 
included: O-linked-methyl, sulfate, and glucuronide metabolites of aspalathin and an eriodictyol-O-
sulfate (Stalmach et al., 2009). No metabolite could, however, be identified in plasma, due to the 
great affinity of flavonoids to proteins. Notably, in circulation polyphenols are mostly conjugated 
derivatives extensively bound to albumin (van der Merwe, 2012) with protein-polyphenol 
complexes forming readily as flavonoids exhibit a high affinity towards proteins, as shown in in vitro 
studies (Manach et al., 1995). 
It was subsequently shown that rooibos tea and an isolated active fraction from unfermented 
rooibos yielded the following metabolites in urine: methylated-, glucuronidated-, methylated-
glucuronidated- and sulphated aspalathin derivatives; three aglycone forms of aspalathin 
glucuronidated at three different positions; the glucuronidated form of nothofagin as well as 
unmetabolised aspalathin and nothofagin. The main excreted metabolite was methylated 
aspalathin, which suggests methylation as a significant conjugation pathway. Aspalathin, orientin, 
Stellenbosch University  https://scholar.sun.ac.za
9 
 
isoorientin, (S)-eriodictyol-8-C-glucoside, vitexin and an isomer of rutin were also detected in 
plasma. These metabolites were detected 24 h after consumption of the different rooibos drinks 
and on average 0.26% of total flavonoids consumed were detected in plasma samples after intake 
of rooibos tea. However, recovery rates were low and marked inter-individual variation in 
absorption patterns of the human subjects in the study were evident. The data nevertheless 
indicated flavonoid bioavailability (Breiter et al., 2011). 
It is assumed that the intact flavonoids reach the large intestine, whereupon exposure to the action 
of intestinal bacteria, leads to the metabolites which are detected in urine. This is for instance the 
case with rutin that is metabolized by bacterial enzymes to form quercetin, which is further 
metabolised to yield phenolic acids, together with methylated and glucuronidated metabolites 
(Breiter et al., 2011; Stalmach et al., 2009). Following absorption, flavonoids can be metabolized 
by both phase I and phase II metabolising enzymes (Williamson et al., 2000). Cytochrome P450 
(CYP450) enzymes are phase I monooxygenases fundamental in metabolism of drugs and foreign 
compounds and mediate flavonoid metabolism (Moon et al., 2006; van der Merwe, 2012). The 
CYP450-mediated oxidation, however, has not been shown to be as important as glucuronidation 
and sulphation in vivo or in intact cells (Walle, 2004). Metabolism by phase II enzymes includes 
UGTs, sulfotransferases (SULT) and catechol-O-methyltransferase, leading to mono- or multiple 
glucuronidated, sulphated and methylated conjugates (Kroon et al., 2004; Zhang et al., 2007). 
Glucuronidation is, however, considered as one of the most important metabolic pathways in the 
liver and intestine (Zhang et al., 2007), with sulphation having a higher affinity, but a lower-capacity 
pathway compared to glucuronidation, resulting in a shift from sulphation towards glucuronidation 
when the ingested dose increases (Koster et al., 1981). 
The question remains whether these phenolic compounds reach peripheral target tissue in their 
intact form, at physiological relevant concentrations, or whether effects are due to their 
metabolites. In addition increasing the dosage does not necessarily mean that more compounds 
will reach specific peripheral target tissues, as polyphenols taken in high dosages have been linked 
to hepatotoxic effects, potential drug interactions as well as estrogenic effects (Mennen et al., 
2005). These side effects are, however, only seen when high doses of supplements are taken and 
do not occur with the daily consumption of teas. Therefore, even though the bioavailability and 
toxicity level of flavonoid ingestion is uncertain, the bioactivity of polyphenols and rooibos extracts 
has been reported extensively and will be discussed further. 
2.3 Physiological activity of polyphenols 
Flavonoids are phenolic compounds characterized by their diaryl nucleus – mimicking the chemical 
structures of natural human steroid hormones, hence the scientific interest in these compounds, 
and their potential application in the prevention of hormone-dependent cancers. Potential targets of 
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phytoestrogens include steroid hormone receptors, steroidogenic enzymes, elements involved in 
signal transduction and apoptotic pathways as well as DNA processing mechanisms. 
2.3.1 The influence of polyphenols and rooibos extract on hormone-dependent cancers 
The first association between flavonoids and steroid-hormone dependent cancers was made when 
studies highlighted the low incidence of cancers, such as breast and colon cancer, in Asian 
countries, with their diet consisting predominantly of high polyphenol soy-based foods. Flavonoids 
present in significant amounts in the human diet, include: soy isoflavones (genistein, daidzein and 
biochanin A), flavonols (quercetin, myricetin, kaempferol) and flavones (luteolin and apigenin). An 
ecological study found a negative correlation between soy consumption and the incidence of 
cancer. The specific cancers included in the study were; breast, colon, cervix and ovary, however, 
data did not show a negative correlation with PCa (Messina et al., 1994). Another study which 
included 34 000 vegetarians and omnivores, showed a significantly reduced risk of colon cancer 
and reduced PCa rates (Zand et al., 2002). Another study undertaken with 83 PCa patients found 
that a higher intake of phytoestrogens, including isoflavones and flavonoids, had a slightly 
protective effect on PCa risk (Strom et al., 1999). 
The number of hydroxyl substitutions found on the chemical structure of a flavonoid has been 
linked to their anti-oxidant properties, with hydroxyl substitutions at C3‟ and C4‟ (fig. 2.1, ring B) 
being shown to be important to peroxyl radical absorbing activity. However, pro-oxidant activities 
have also been linked to flavonoids (Cao et al., 1997). Structure-function relationships are 
important as diphenolic structures and hydroxyl groups at C7 (fig. 2.1, ring A) or C4‟ (fig.2.1, ring B) 
of the flavonoid molecule are necessary for their estrogenic activity. Quercetin, one of the 
flavonoids found in rooibos, possesses a hydroxy group at C3 (fig. 2.1, ring C), hindering binding to 
the ER, accounting for its low binding affinity (Zand et al., 2002). These data leads one to question 
whether quercetin might have a potential role to play in AR binding and if this flavonoid would 
possess androgenic activity. 
The androgenic and anti-androgenic activity of flavonoids has only recently been investigated. An 
investigation into the anti-androgenic properties of rooibos was conducted with TM3 mouse 
testicular Leydig cells treated with fermented and unfermented extracts under both basal and 
stimulated conditions. Stimulated conditions were achieved in cell cultures by adding human 
chorionic gonadotropin (hCG). Both unfermented and fermented rooibos extract resulted in a 
decrease in T production, under both hCG stimulated (3.9 – 31.8%) and basal (16.3 – 37.9%) 
conditions. Using a 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyl tetrazolium bromide (MTT) assay it 
was shown that rooibos maintained cell viability at 0.25 – 1 mg/mL, but reached cytotoxic levels at 
5 mg/mL. The mechanism by which T production was inhibited was suggested to be by the 
inhibition of CYP11A1 (cytochrome P450 short-chain cleavage enzyme), the reduction of cyclic 
adenine monophosphate levels and the inhibition of 3β-hydroxysteroid dehydrogenase (3βHSD) 
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and/or 17βHSD (Opuwari & Monsees, 2014). This study showing the anti-androgenic activity of 
rooibos, suggest a role for rooibos in T-dependent cancers, and that rooibos influences steroid-
metabolizing enzymes and pathways. 
Flavonoids have also been shown to influence cell growth. In T47-D breast cancer cells, 20 µM 
genistein and quercetin markedly inhibited growth, with quercetin being able to inhibit cell growth 
over the entire concentration range of 100 nM to 20 µM. The suggestive mechanism seems to be 
through apoptosis, due to the detected chromatin fragmentation (Wang et al., 1994). Another study 
showed that the core structure of the flavones, 2-phenyl-4H-1-benzopyran-4-one, were highly 
selective towards transformed cells only, showing a role for flavonoids in chemotherapeutic uses 
(Wenzel et al., 2000). To date no structure-function relationships have been observed for effects of 
flavonoids on proliferation. Cell cycle arrest has been suggested to form part of this inhibition, 
specifically for quercetin. This compound was shown to arrest the cell cycle at the G1 and S-phase 
boundary, which is involved in gene expression and protein synthesis as well as in cell DNA 
synthesis (Zand et al., 2002). 
The anti-cancer properties of flavonoids was already reported in 1980 when a significant reduction 
of mammary cancer by X-irradiation was demonstrated in rats fed a raw soybean diet (Troll et al., 
1980). In this study 74% of the control rats, on a casein diet, developed tumours while 44% of the 
experimental rats developed tumours. Another study evaluated the anti-carcinogenic effects in the 
colon of quercetin and rutin. Female mice were fed a diet supplemented with quercetin (0.1, 0.5 or 
2.0%) or rutin (1.0 or 4.0%) for 50 weeks to assess inhibition of azoxymethanol (AOM)-induced 
colonic neoplasia. No changes were observed in mice fed flavonoid-supplemented diets without 
AOM treatment. However, both quercetin (2.0%) and rutin (4.0%) significantly inhibited hyper-
proliferation and the shift of S-phase cells to middle and upper portions of the crypts in AOM-
treated mice (Deschner et al., 1991).  
Although a number of in vivo studies have investigated the effects of flavonoids on cancer, very 
few studies have the potential of utilizing a flavonoid rich diet to reduce PCa risk (Zand et al., 
2002). However, various studies have been conducted in PCa cell models. In a study conducted in 
two androgen-dependent PCa human prostate tumour cell lines, the AR-positive LNCaP and the 
AR-negative PC-3 cell lines, the effect of a flavonoid rich diet on PCa was investigated. Four 
phytoestrogens, genistein, daidzein, coumestrol and equol, inhibited cell growth in both cell lines, 
exposed to 100 µM for three or six days. Growth inhibition was achieved at lower phytoestrogen 
concentrations in LNCaP cells than in PC-3 cells, suggesting a potential role for the interaction of 
phytoestrogens and the AR. The authors suggested the mutated AR present in LNCaP cells to be 
relaxed in specificity, allowing other ligands such as phytoestrogens to bind. However, when 
phytoestrogen concentrations reached 100 µM, the inhibition of cell growth was similar in both cell 
lines, suggesting a non-receptor-related action (Mitchell et al., 2009). Zand et al., (2000; 2001), 
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evaluated the inhibition of PSA, a biomarker of cancer progression in breast cancer and PCa cells, 
the latter transfected with human AR, showing the inhibitory effect of 72 flavonoids at 10 µM (Zand 
et al., 2001, 2000). Another group showed inhibition of PSA secretion by genistein in LNCaP cells. 
This result was seen at all concentrations, however, in androgen independent VeCaP prostate 
cells, genistein was only able to suppress PSA production at high concentrations. The inhibition of 
cell proliferation, however, was independent of PSA signalling pathways in VeCaP cells (Davis et 
al., 2000). Similar androgen action was also obtained with green tea polyphenols (Gupta et al., 
1999). 
A plausible link between phytoestrogen intake and PCa risk was suggested in a case-control study, 
which included 83 cases and 107 frequency-matched controls. The flavonoids in this study were 
provided for the most part by cranberry juice/cranberries, black tea, onions and apples. This study 
suggested an inverse association between PCa risk, coumestrol and two isoflavonoids, genistein 
and daidzein. The authors concluded with the suggestion that at-risk populations should modify 
their diet behaviour (Strom et al., 1999). 
The synergistic effect of flavonoids against hormone-dependent cancers, such as PCa, has not 
been extensively investigated. However, a recent study into the synergistic effect of flavonoids 
demonstrated improved efficacy when PCa cells were exposed to a combination of flavonoid 
compounds. A combination of genistein, quercetin and biochanin A was used in this study, either 
as single, double combination or triple combination. The combination of 8.33 µM of genistein, 
quercetin and biochanin A was shown to be more potent than single compound exposure in 
inhibiting the growth of LNCaP cells, as well as DU-145 and PC-3 PCa cells. Although mutations of 
the AR occur in PCa progression, increased ER expression occurs concurrently. The authors 
therefore suggested that the action of phytoestrogens was mediated through ER and AR 
dependent pathways, since the phytoestrogen combination inhibited cell proliferation even in the 
presence of fulvestrant, a potent estrogen antagonist. They concluded that a combination of 
phytoestrogens exhibiting anti-cancer properties could significantly increase the efficacy of 
individual compounds resulting in improved efficacy at achievable physiological concentrations 
(Kumar et al., 2011). 
Taken together, polyphenols, flavonoids and rooibos definitively have a role to play in the 
modulation of the development and progression of hormone-dependent cancers, especially PCa. 
The mechanism by which they act, whether through estrogenic or androgenic activity, modulation 
of ER and/or AR activation, cell cycle arrest or apoptotic pathways, remain unclear. 
2.3.2 The modulation of steroidogenic enzymes by polyphenolic compounds 
As the estrogenic activity of flavonoids and polyphenols are dependent on their phytoestrogenicity 
given their chemical structures are similar to those of natural occurring hormones, so too their 
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androgenic activity relies on this characteristic. There exists the strong possibility that the 
modulation of the catalytic activity of steroidogenic enzymes by flavonoids is a contributing factor to 
the mechanism, underlying their anti-cancer properties. 
A recent study by Schloms et al., (2012), focused on the influence of rooibos and dihydrochalcones 
on adrenal steroidogenesis, investigating the influence of these compounds on steroid hormone 
biosynthesis. Results showed that under both basal and forskolin stimulated conditions, rooibos, 
aspalathin and nothofagin decreased total steroid production in H295R cells, a human adrenal 
carcinoma cell line. In addition rooibos inhibited the levels of 11β-hydroxyandrostenedione 
(11OHA4), A4 and T, suggesting modulation of endogenous enzyme activity. This study also 
showed the inhibition of the catalytic activity of heterologously expressed CYP17A1 (17α-
hydroxylase/17,-20-lyase) towards pregnenolone (PREG) and CYP21A2 (cytochrome P450 steroid 
21-hydroxylase) towards progesterone (PROG) (table 2.2), by rooibos extracts, aspalathin and 
nothofagin in COS-1 cells  (Schloms et al., 2012). These results are comparable to results reported 
by Ohno et al. (2002) and Perold (2009). Ohno et al., (2002), showed that flavonoid compounds, 
such as diadzein, genistein and 6-hydroxyflavone, selectively inhibit key steroidogenic enzymes 
including: 3βHSD type 2 (3βHSD2) and CYP21A2 in H295R cells (Ohno et al., 2002). Perold 
(2009), also showed inhibition of CYP21A2 activity by flavonoids, rutin, vitexin and orientin in COS-
1 cells transiently transfected with baboon CYP21A2 (Perold, 2009). 
Another study conducted by Schloms & Swart, (2014), determined the inhibitory effect of rooibos 
and its phenolic compounds on the enzymes 3βHSD2, CYP17A1, CYP21A2 and CYP11B1 
(cytochrome P450 11β-hydroxylase). All the flavonoids significantly inhibited 3βHSD2 and 
CYP17A1, while the inhibition of CYP21A2 and CYP11B1 was both substrate and flavonoid 
specific. The dihydrochalcones, aspalathin and nothofagin, inhibited the activity of CYP21A2 but 
not that of CYP11B1. Rutin, orientin and vitexin inhibited CYP11B1, albeit at low levels (20%), 
however, no inhibition was detected with CYP21A2. In contrast rooibos inhibited both CYP21A2 
and CYP17A1 significantly. This study also reported that rutin had the highest inhibitory effect on 
steroid production in forskolin stimulated H295R cells. In addition nothofagin and vitexin inhibited 
overall steroid production more so compared to aspalathin and orientin. This study also suggests 
17βHSD inhibition due to reduced basal T levels that were observed in H295R cells, although the 
adrenal is not the primary site for 17βHSD expression. All the flavonoids decreased T production, 
with rutin exerting the greatest inhibitory effect (Schloms & Swart, 2014).  
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Table 2.2: Steroidogenic enzymes: general conversions and localization in human tissue (Luu-The, 2001; 
Mostaghel, 2014; Payne & Hales, 2004; Walle & Walle, 2002) 
Steroidogenic 
enzyme 
General conversion Tissue expression 
Cytochrome P450 enzymes 
CYP11B1 11-deoxycortisol → cortisol 
Adrenal gland (zona 
fasiculata, zona 
reticularis), skin 
CYP17A1 
PREG → 17OH-PREG 
PROG → 17OH-PROG 
17OH-PREG → DHEA 
Adrenal gland (zona 
fasiculata, zona 
reticularis), testis, skin 
CYP21A2 
PROG → deoxycorticosterone 
17OH-PROG → deoxycortisol 
Adrenal gland (zona 
glomerulosa, zona 
fasiculata), skin 
Hydroxysteroid dehydrogenases 
3αHSD2 DHT → 3α-adiol Prostatic tissue, testis 
3βHSD2 
PREG → PROG 
17OH-PREG → 17OH-PROG 
DHEA → A4 
Adrenal gland (zona 
glomerulosa, zona 
fasiculata, zona 
reticularis), testis, skin 
11βHSD1 Cortisone → cortisol 
Adrenal gland (zona 
glomerulosa, zona 
fasiculata, zona 
reticularis), testis 
11βHSD2 Cortisol → cortisone 
Adrenal gland (zona 
glomerulosa, zona 
fasiculata, zona 
reticularis) 
17βHSD1 Estrone → estradiol Ovary, mammary gland 
17βHSD3 A4 → T 
Adrenal gland (zona 
reticularis), testis, 
prostatic tissue 
AKR1C3 A4 → T 
Adrenal gland (zona 
reticularis), testis, 
prostatic tissue 
Uridine diphosphate glucuronosyltransferase 
UGT1A1 
Glucuronidation of various endogenous and 
exogenous compounds 
Hepatic cells, Intestinal 
cells 
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As the inhibitory mechanism of flavonoid compounds are not fully understood, structural-
relationships are central in understanding the inhibitory effect. As many flavonoids are 
phytoestrogens and their chemical structures are similar to that of natural estrogens and 
androgens, it is possible for the phenolic compounds in rooibos to either bind the active site or co-
factor redox partner binding sites of the specific enzyme, thereby influencing the enzyme‟s catalytic 
activity. A study showed the inhibition of human CYP450 by green tea catechins, specifically 
epigallocatechin gallate, which was achieved by the inhibition of the enzyme activity of CYP450 
and also partially by inhibition of human nicotinamide adenine dinucleotide phosphate (NADPH)-
CYP450 reductase (Muto, Fujita, Yamazaki, & Kamataki, 2001), a complex that forms when P450 
enzymes receive electrons from NADPH via a single 2-flavin protein termed P450 oxidoreductase 
(POR) (Miller, 2005). According to Middleton et al. (2000), enzymes of importance as targets of 
polyphenols are enzymes with NADPH as a cofactor, as is the case for CYP450 enzymes as well 
as reductive 17βHSD and SRD5A enzymes (Middleton Jr., Kandaswami, & Theoharides, 2000). 
The study by Schloms et al., (2013), suggested that structural differences regarding the number 
and position of hydroxyl and glucose moieties as well as structural flexibility could impact the 
manner in which these flavonoids influence the activity of adrenal steroidogenic enzymes. This 
could possibly account for the inhibition of T production by rutin in H295R cells, presumably by 
inhibiting the catalytic activity of 17βHSD (Schloms et al., 2013). In a recent study, inhibitors of 
17βHSD3 and AKR1C3, which are key enzymes involved in adrenal and prostate androgen 
metabolism were screened virtually. It was shown that the substrate binding domain of 17βHSD3 
and AKR1C3 were able to accommodate structurally diverse substrates which bind to different 
regions in the active site. The crystal structure of 17βHSD3 and AKR1C3 was depicted with rutin, 
bound at the base of the substrate binding domain, with water molecules forming a network of 
hydrogen bonds with the flavonoid (Schuster et al., 2011). Ohno et al., (2002), also report on 
structural relationships, suggesting the hydroxy groups at C6 on ring A and at C4‟ on ring B (fig. 
2.1) play an important role in the inhibition of steroidogenic enzymes (Ohno et al., 2002). Another 
study showed that a range of flavones with hydroxy groups at positions C6 or C7 of ring A and C4‟ 
on ring B (fig. 2.1) inhibited 3βHSD2 (Hasegawa, Nakagawa, Sato, Tachikawa, & Yamato, 2013). 
Schloms & Swart, (2014), suggested that a hydroxy group on position C4‟ on ring B (fig. 2.1) of the 
flavonoid may be involved in the binding of these compounds in the active pocket of steroidogenic 
CYP450 enzymes, with hydrogen bonds stabilizing the orientation of flavonoid compounds in the 
active site. They also pointed out that conclusions could not be drawn regarding the orientation of 
flavonoids within the active site, and as the type of inhibition was uncertain, the binding of 
flavonoids to the same site as the substrate could not be assumed (Schloms & Swart, 2014). 
Focusing on the steroidogenic 17βHSD enzymes, another study showed flavonoids as inhibitors of 
17βHSD type 1 (17βHSD1). They focused on 17βHSD1 as this enzyme is involved in the 
conversion of estrone to estradiol (table 2.2), a potent ligand for ERs, playing a pivotal role in 
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estrogen-dependent diseases. They reported on 10 flavonoids, which included a flavonoid with a 
hydroxy group on C7 of ring A and on C4‟ of ring B (fig. 2.1), with this flavonoid showing more than 
70% inhibition of 17βHSD1 at 6 µM. This study reported that inhibitors possess one or two 
substituents on B ring, with one methoxy group on the flavone ring (fig. 2.1) (Brožič et al., 2009). 
Krazeisen et al., (2001), specifically considered the enzyme AKR1C3, and showed the best 
phytoestrogen inhibitors of AKR1C3 were; zearalone, coumestrol, biochanin A and quercetin at 
concentrations ranging from 100 nM to 20 µM, influencing the conversion of A4 to T (table 2.2), 
involved in androgen metabolism. They suggested that within the flavones, the inhibitor potency 
increased with increasing hydroxy groups on ring A, the most effective being a hydroxy group at 
C7 (fig. 2.1). They noted that under reductive conditions, a double bond in ring C (fig. 2.1), as is the 
case with flavones, increased the inhibitory effect. In contrast, the flavanones, with no double bond 
in ring C, show a stronger inhibitory effect on the oxidative activity of AKR1C3. For both reductive 
and oxidative 17βHSD activities, inhibitor potency decreases when ring B is found at C3 (fig. 2.1), 
as it is in isoflavones. In addition the isoflavones, methylation of hydroxy group at C4 on ring B (fig. 
2.1), results in greater inhibitor activity. They also suggested that the phytoestrogens bind to the 
hydrophilic redox partner binding site of the enzyme and not to the substrate binding site. However, 
the hydroxy group at C7 (fig. 2.1) of the flavonoids may bind to the active site (Krazeisen, Breitling, 
Moller, & Adamski, 2001).  
PCa is a hormone-dependent cancer, and PSA is the most common biomarker to date, to assess 
PCa progression. PSA is an AR regulated gene and is therefore associated with cell proliferation 
and growth, which is also dependent on the AR activation. Prostate steroid metabolism results in 
active androgens which activate the AR. The prostate has enzymatic machinery in place regulating 
the levels of active androgens. These enzymes comprise of 3α-hydroxysteroid dehydrogenases 
(3αHSDs) and UGTs (phase II inactivation). A study was undertaken to investigate the influence of 
biochanin A on UGTs and also PSA production in PCa cells. Biochanin A, the precursor of 
genistein, increased the production of the glucuronidated form of T at twice the normal rate in 
LNCaP cells, and subsequently decreased the T-stimulated release of PSA by 40%. They also 
showed a 10-fold increase in glucuronidated T formation, as well as an increase in UGT transcript 
after 5 days treatment with 5 µM biochanin A. Interestingly, the same result was not observed with 
the addition of genistein or quercetin in LNCaP cells. Quercetin only resulted in a 2-fold increase in 
glucuronidated T formation (Sun, Plouzek, Henry, Wang, & Phang, 1998). Zhang et al., (2007), 
also reported that polyphenols induced phase II enzymes, UGTs, together with Walle & Walle 
(2002), that reported that UGT1A1 (table 2.2) was induced by flavonoids (Walle & Walle, 2002; 
Zhang et al., 2007).  
A mechanism controlling the ratio of the concentration of biologically active cortisol, which is able 
to bind the glucocorticoid and  mineralocorticoid receptor (GR, MR) and its inactive 11-keto form, 
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cortisone, is orchestrated by 11β-hydroxysteroid dehydrogenase (11βHSD) type 1 (table 2.2). 
11βHSD1 is therefore essential for GR and MR activation. 11βHSD type 2 (11βHSD2) catalyses 
the oxidation of cortisol (table 2.2), thereby preventing activation of the GR and MR by cortisol 
(Schweizer, Atanasov, Frey, & Odermatt, 2003). In human studies, a significant reduction in the 
cortisol:cortisone ratio of both male and female subjects following rooibos consumption, suggesting 
that rooibos favours the inactivation of cortisol. This could be attributed to the modulation of 
11βHSD activity. This prompted the authors to examine the effect of rooibos on both 11βHSD 
isozymes at cellular level. Co-transfection of 11βHSD1 and hexose-6-phosphate dehydrogenase 
(H6PDH) in CHO-K1 cells simulated in vivo conditions in which the oxoreductase activity of 
11βHSD1 predominates, while nearly eliminating the dehydrogenase activity. Rooibos significantly 
reduced the cortisol:cortisone ratio in cells expressing 11βHSD1, suggesting that rooibos 
modulates 11βHSD1 activity. Furthermore, the authors found that 11βHSD2 activity was 
unaffected (Schloms & Swart, 2014). This result was also found by Schweizer et al., (2003), where 
a rapid screening of inhibitors of 11βHSD found flavanones to selectively inhibit 11βHSD1 and not 
11βHSD2. They concluded that the C2 and C3 double bond (ring C) (fig. 2.1) reduced the 
inhibitory effect of flavones for 11βHSD1 and 11βHSD2 activities (Schweizer et al., 2003). 
However, as previously mentioned, this chemical characteristic increases the inhibitory effect of 
flavones, found in rooibos, on 17βHSD activity. 
Taking into account all the above mentioned flavonoid and enzyme interactions, a strong case for 
the role flavonoids in diseases driven by steroid hormones is provided, as the modulation of 
steroid-metabolizing enzymes favouring the production of an inactive steroid over an active steroid, 
could lead to decreased risk in the development of hormone-dependent cancers, such as PCa. 
2.4 Potential health applications of Rooibos in PCa 
Rooibos‟s potential in the pharmaceutical domain is determined by its bioactivity that encompasses 
its antioxidant capacity, chemopreventive potential, immune boosting effects, anti-allergic actions, 
together with recent findings of cardiovascular protection and aiding in the treatment of metabolic 
diseases (Breiter et al., 2011; Hessellng & Joubert, 1982; Khan & Gilani, 2006; Komatsu et al., 
1994; Kunishiro et al., 2001; Schulz et al., 2003). In recent years, the shift towards natural and 
herbal medicinal products, away from mainstream pharmaceuticals, by the general public has led 
to increased interest in indigenous natural plant products which included rooibos. Sales of herb 
and botanical dietary supplements in the United States increased ± 5.5% in 2012, with this growth 
being greater than the 5% increase in sales noted for the year 2011. The 2012 increase marks the 
9
th
 year in a row since 2004 in which herb sales increased over the previous year (Lindstrom et al., 
2013). Furthermore, total retail sales of teas in the United States increased by 5.9% in 2013, with 
rooibos showing a double-digit annual sales increase in its loose form (Keating et al., 2013). 
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The nutraceutical value of rooibos lies in its application as an anti-diabetic agent (Kawano et al., 
2009; Larsen et al., 2011), in topical skin products (Marnewick et al., 2005) and in the treatment of 
neurological and psychiatric disorders of the central nervous system (Frank & Dimpfel, 2010). 
Rooibos is commonly used to treat asthma, eczema, headache, nausea and mild depression. 
Although the anti-cancer and anti-mutagenic properties of rooibos has been widely reported and 
linked to the anti-oxidant capacity of rooibos (Marnewick et al., 2000; Sasaki et al., 1993; Shimoi et 
al., 1996), few studies have linked the bioactivity of rooibos to the human endocrine system. Our 
group has shown that rooibos influences adrenal steroidogenic enzymes (Schloms & Swart, 2014; 
Schloms et al., 2013, 2012), modulating steroid hormone biosynthesis and may as such have 
applications as a natural herbal product aiding metabolic diseases driven by hormonal imbalances. 
As rooibos affects steroidogenic enzymes, rooibos may impact hormone driven cancers such as 
PCa, since PCa development is dependent on steroid hormone biosynthesis and subsequent 
steroid receptor activation.  
As previously mentioned multiple studies, including our group, have shown specific inhibition of 
CYP17A1, CYP21A2 and 3βHSD2 steroidogenic enzymes, both in cell systems and transfected 
cells. Notably, these aforementioned enzymes, together with CYP11A1 and SRD5A1 and SRD5A2 
have been shown to be expressed in the skin (Dumont et al., 1992; Slominski et al., 1996; 
Thiboutot et al., 2003; Thigpen et al., 1993). CYP11A1 have been shown on the gene and protein 
level (Slominski et al., 2004), evidence that the skin itself is able to allow cutaneous 
steroidogenesis. SRD5A1 is expressed in newborn skin and then again in nongenital skin after 
puberty, compared to SRD5A2 that is expressed in fetal genital skin (Thigpen et al., 1993). Studies 
have shown conversion of cholesterol to PREG, but only if a 3βHSD inhibitor is added, therefore 
PREG metabolism is evident in the skin (Slominski et al., 2004). The skin is, thus, capable of in situ 
steroid biosynthesis and is an extra-adrenal site for steroid production (Slominski et al., 2007). 
Rooibos has been reported to slow down tumour growth and to decrease skin cancer tumour size 
(Marnewick et al., 2005), an anti-cancer effect of rooibos which could be linked to the inhibition of 
steroidogenic enzymes, possibly contributing to the mechanism of action. 
The level of consumption and manner in which rooibos is administered, be it infusions or as a 
supplementary tablet, that would result in anti-carcinogenic effects is still unclear. Techniques for 
quantifying flavonoid uptake and absorption are, however, improving together with more 
comprehensive databases being available for analyses. In the case of animal studies, the high 
levels of flavonoid compounds required to elicit protective effects are at concentrations humans are 
unable to attain through whole food consumption. Consumption of nutraceuticals or functional 
foods has thus been suggested to supplement the daily intake of flavonoid compounds. Although 
rooibos has the potential to contribute towards healthy living when used as a dietary supplement, 
there may be risks involved in excessive polyphenol consumption. For example, commonly found 
on the internet, are recommendations of a daily intake of 1-6 tablets containing 300 mg quercetin, 
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1 g citrus flavonoids or 20 mg resveratrol. This, however, leads to a flavonoid consumption ±100 
times greater than would otherwise be present in a western diet (Mennen et al., 2005), levels which 
could possibly be toxic. 
A consequence of excessive flavonoid consumption, for example, is that of reduced iron absorption 
in populations with marginal iron stores, as polyphenols inhibit non-heme iron absorption and may 
lead to iron depletion (Temme & Van Hoydonck, 2002). In addition the safety of the flavonoid 
supplement may also be influenced by the method of extraction of polyphenols from source 
material as well as subsequent processing. It was, for example, reported that a hydroalcoholic 
extract of tea buds, sold as a slimming supplement, led to severe liver toxicity (Van der Woude et 
al., 2003). 
Flavonoids have also been reported to inhibit thyroid peroxidase and impede thyroid hormone 
biosynthesis as was shown by the administration of vitexin to rats, resulting in increased thyroid 
weight and decreased plasma thyroid hormone levels (Doerge & Sheehan, 2002; Ferreira et al., 
2002). However, two clinical studies failed to show significant effects on thyroid hormones after a 
3-6 month period of isoflavone-containing soy proteins consumption, among adults (Duncan et al., 
1999; Persky et al., 2002). Another point of concern is that polyphenol consumption could affect 
drug bioavailability and pharmacokinetics, with drugs such as benzodiazepines showing an 
increase in plasma concentrations with a single dose of grapefruit juice (Lilja et al., 2000). It was 
also shown that green tea catechins, comprising 1.0% or 0.1% of the diet, enhanced tumour 
development in the colon of F344 male rats (Hirose et al., 2001). Epidemiologic studies have, 
however, not shown any carcinogenic effects of polyphenols to date (Hertog et al., 1993). It should 
be noted that the dose which would result in a positive effect in vitro may have a different effect in 
vivo. Furthermore, a dose applied in an experimental study may be unachievable in vivo, since 
consumption would perhaps not reach comparable levels together with factors such as, 
bioavailability and transport the target sites being uncertain (Mennen et al., 2005). 
Studies regarding the efficacy and safety are therefore central to future research strategies 
regarding the use of herbal products, specifically herbal products aimed at being used in functional 
foods, nutraceuticals or other therapeutic applications (Van der Merwe, 2012). 
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2.5 Summary 
It is apparent that the manner in which flavonoids may prevent steroid-hormone dependent 
cancers, such as PCa, include modulation of steroid hormones, inhibition of proliferation and anti-
carcinogenic and antioxidant activities, as was illustrated by the data reported. It is furthermore 
clear that the specific modulation of steroidogenic enzymes can be attributed to polyphenols either, 
binding in the active site or to redox partner binding sites of the enzymes. The main structural 
characteristics to which these inhibitory effects are proposed to be attributed to are the number and 
position of hydroxyl moieties, together with the structural flexibility of the flavonoid carbon 
backbone.  
Reports to date suggest that there is a potential role for rooibos in steroid hormone dependent 
cancers, such as PCa, which may be beneficial. Investigating the effect of rooibos on steroid 
hormone levels and on steroidogenic enzymes will contribute not only to the basic understanding 
of steroid metabolism in the prostate but also to the understanding of the cellular mechanisms 
underlying rooibos‟s anti-cancer properties. 
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Chapter 3 
Androgen hormones in PCa: biosynthesis of C19 steroids and metabolism in 
the prostate and in PCa 
3.1 Introduction 
In 1966, Huggins and Hodges won the Nobel Prize for medicine with their observation that 
orchiectomy (surgical castration) led to regression of metastatic PCa. Their finding demonstrated 
that nearly all PCas require circulating androgens for survival (Huggins & Bergenstal, 1952; 
Huggins, 1946). Androgens are C19 steroid hormones that induce the differentiation of the male 
reproductive organs as well as male secondary sex characteristics, and are formed primarily in the 
testes. In addition, in men, androgens are also formed in peripheral tissues, including the prostate 
and the skin (Hsing et al., 2002). 
All steroids are derived from 27-carbon cholesterol, which when oxidised forms 21-carbon steroids, 
represented by glucocorticoids and mineralocorticoids. These 21-carbon steroids can subsequently 
be further oxidised to 19-carbon and 18-carbon steroids, represented by androgens and estrogens, 
respectively. These steps occur due to intricate enzyme machinery present in adrenal and gonadal 
tissue. These two tissues are able to convert cholesterol to PREG, which represents the first step 
for the subsequent production of glucocorticoids, mineralocorticoids, androgens and estrogens. 
Two of the most important hormones in adult males are T and DHT. T is primarily produced by 
Leydig cells in the testes and is released into circulation. In target tissue T is reduced to DHT which 
is the most potent natural androgen (Hsing et al., 2002). 
The androgen pathway – from the generation of T and DHT up until the transcription of AR-
regulated genes – is a prerequisite for the development and differentiation of the normal prostate, 
as well as for the development and progression of PCa (Sharifi & Auchus, 2012). The androgen 
signalling pathway is intimately involved in tumour initiation and invasion, and the subsequent 
development of metastatic disease. The mechanisms that regulate the androgen axis, which 
include the generation of ligands, AR expression and AR-regulated gene responses, therefore all 
represent potential sites of intervention for the development of new pharmacologic therapies to be 
employed against PCa (Sharifi, 2012). 
This chapter will summarise steroid metabolism, as it occurs in the prostate, and will focus on 
pathways and enzymes that drive prostate steroid metabolism and the implication thereof in PCa. 
3.2 Physiology of prostatic tissue 
The principal function of the prostate is to provide proteins and ions that form the bulk of the 
seminal fluid. Fertility is impaired in the absence of the prostate. The primary functions of the 
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prostatic secretions relate to semen gelation, coagulation, and liquefaction with the prostate and 
seminal vesicles producing most of the ejaculate. The adult human prostate is a tubuloalveolar 
gland composed of ducts lined with a pseudostratified columnar epithelium. Lining the ducts are tall 
columnar and secretory cells with basal nuclei, with a nearly continuous layer of basal epithelial 
cells lying on top of the epithelial basement membrane (Hayward & Cunha, 2000) (fig. 3.1).  
 
Figure 3.1: Physiology of normal prostatic tissue, representing corpora amylacea in the gland lumen (pink 
laminated concretions) and infoldings of the columnar epithelium (Prostate, 2014.) 
The development of the prostate begins with the growth of prostatic buds at about 10 weeks of 
fetal development in humans. ARs in the urogenital sinus mesenchyme are stimulated by testicular 
androgens to induce epithelial budding, proliferation and differentiation to form ductal structures. 
Androgenic stimulation is therefore an absolute requirement for prostatic development. At puberty 
there is a growth spurt characterised by an increase in prostatic wet weight but only a small 
increase in the number of ductal tips. At this stage the prostate grows from weighing 2 g to ±20 g, 
representing a phase of exponential growth, corresponding to the rise in serum T reaching adult 
levels. Mean prostatic weight subsequently stabilizes and remains fairly constant until the end of 
the third decade of life, when mean prostatic weight begins to rise slowly. The prostate is, however, 
a slow growing organ, with this slow rate of growth balanced by a slow rate of apoptosis, resulting 
in a growth-dominant gland (Hayward & Cunha, 2000). However, the disruption of this balance is 
reflected by the onset of pathogenesis of BPH.  
Prostate diseases are chronic diseases developing over time. As males age, there is a slow 
decline in circulating T from the gonads and diseases of the prostate, such as BPH and PCa 
become prevalent in the aging male. Both conditions are androgen dependent with BPH affecting 
90% of all men above the age of 80 while PCa, occurs in men older than 50 years of age. BPH and 
PCa are two separate diseases. BPH originates in the transitional zone, where obstruction of the 
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urinary bladder occurs due to outgrowth of the stromal and epithelial cells. In contrast, PCa 
originates in the peripheral zone (outer prostate), which allows PCa to metastasize into the 
adjacent lymph glands and bone. Of interest, both diseases are dependent upon intra-tumoural 
conversion of T to the higher-affinity ligand DHT (Penning, 2010). 
ADT is currently the primary treatment followed in PCa, and involves medical and surgical 
castration in order to reduce circulating T levels. This approach is initially effective, however, most 
cases progress to CRPC. CRPC is androgen dependent and proliferates in the absence of 
testicular T (Sharifi & Auchus, 2012). There is growing evidence that it is not only testicular T 
contributing towards PCa but also C19 steroids of adrenal origin that play an important role in the 
proliferation of CRPC, as these metabolites may serve as substrates for the intratumoral 
biosynthesis of potent AR agonists (Luu-The et al., 2008; Montgomery et al., 2008; Stanbrough et 
al., 2006; Stein, Goodin, & Dipaola, 2012). 
3.3 Androgen biosynthesis 
The generation of active androgens in the prostate is dependent on C19 steroids from the testes 
and adrenal. Following castration, and the elimination of all testicular androgens, 30-50% of DHT 
remains in the prostate, denoting the importance of adrenal androgens (Labrie, 1993; Larsen et al., 
1990). Furthermore, the de novo production of androgens in the prostate has been suggested to 
play a role in the pathogenesis and development of PCa (Lopez-Otin & Diamandis, 1998). 
3.3.1 Androgen biosynthesis in the testes  
Testicular Leydig cells account for ±95% of androgen biosynthesis and secretion, and are the main 
site of T production in men under normal physiological conditions. T regulates spermatogenesis, 
sperm maturation and sexual function in the adult male. The hypothalamic-pituitary-gonadal axis is 
controlled by pulses from gonadotropin-releasing hormone (GnRH). Each pulse of GnRH results in 
a pulse of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary 
gonadotropes. LH stimulates T production from Leydig cells, and consequently T provides negative 
feedback at the hypothalamus and pituitary to suppress LH and T production (Sharifi & Auchus, 
2012). 
Testicular biosynthesis of T begins with the transfer of a 27-carbon cholesterol molecule from the 
outer to the inner mitochondrial membrane by steroidogenic acute regulatory protein (StAR). 
Cholesterol is converted to the C21 steroid, PREG, via CYP11A1 utilizing ferredoxin reductase 
which receives electrons from a phosphorylated cofactor (NADPH) and transfers electrons to a 
soluble iron-sulfur protein ferredoxin in the mitochondrial matrix (fig. 3.2). Once PREG is produced 
from cholesterol, it may undergo 17α-hydroxylation by CYP17A1 to yield 17α-
hydroxypregnenolone (17OH-PREG). CYP17A1 is the microsomal P450 enzyme that catalyses 
both 17α-hydroxylase and 17,-20-lyase activities, the latter resulting in the conversion of 17OH-
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PREG to DHEA. The 17,-20-lyase activity of CYP17A1 is augmented by the presence of the small 
hemoprotein, cytochrome b5 (cyt b5). Testicular cells express two hydroxysteroid dehydrogenases 
which are essential to T production. Leydig cells express 3βHSD2 which converts 3β-hydroxy-Δ5-
steroids to their 3-keto-Δ4-congeners, converting DHEA to A4. Secondly, 17βHSD3, directs 
steroidogenesis towards T, with the main substrates for 17βHSD3 being A4 and DHEA. T is 
produced directly from A4, while androsta-5-ene-3β, 17β-diol (androstenediol) is produced from 
DHEA and is subsequently converted to T via 3βHSD2 (Miller & Auchus, 2011; Sharifi & Auchus, 
2012). T is subsequently secreted into circulation and upon reaching peripheral tissues, such as 
the prostate, is able to exert physiological effects. 
 
Figure 3.2: T biosynthesis in testicular Leydig cells. 
3.3.2 Androgen precursor biosynthesis in the adrenal 
Similar to testicular Leydig cells, steroid biosynthesis in the adrenal begins with the transfer of a 
27-carbon cholesterol molecule from the outer to the inner mitochondrial membrane by StAR. 
However, due to the expression of steroidogenic enzymes in the adrenal cortex viz.: steroidogenic 
CYP450 enzymes (type 1, in mitochondria and type 2, in endoplasmic reticulum) and 
hydroxysteroid dehydrogenases (belonging to either the aldo-keto reductases or short-chain 
dehydrogenase reductase families) the adrenal also produces mineralocorticoids and 
glucucorticoids besides the androgen precursors, in a zone-specific manner, driven by the 
expression of specific enzymes and catalytic co-factors. 
The steroid hormone output of the adrenal is important in the maintenance of hormonal 
homeostasis. Corticotropin-releasing hormone (CRH) from the hypothalamus stimulates 
adrenocorticotropin (ACTH) release from the pituitary corticotropes, derived from proteolytic 
processing of the precursor proopiomelanocortin. ACTH subsequently stimulates the zona 
fasiculata (ZF) and the zona reticularis (ZR) cells to produce cortisol and dehydroepiandrosterone 
sulphate (DHEA-S), respectively. It is possible for cortisol to exert negative feedback on CRH and 
ACTH. In addition cortisol can bind and activate the MR and GR and various metabolic pathways 
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lead to cortisol inactivation. In contrast, DHEA-S itself is not an AR agonist (Sharifi & Auchus, 
2012), and does not contribute significantly to the androgen precursor pool as the regeneration of 
DHEA from DHEA-S seems to be a path rarely taken in adults, with low levels of steroid sulfatase 
expression and activity having been reported in human tissue (Miki et al., 2002). 
The first step in adrenal steroidogenesis is catalysed by CYP11A1 which is expressed in the 
mitochondria and converts cholesterol to PREG (fig. 3.3). The production of PREG occurs in the 
three zones of the adrenal cortex viz., zona glomerulosa (ZG), ZF and ZR, with androgen 
precursor production occurring only in the ZR. Once PREG is produced it may undergo 17α-
hydroxylation by CYP17A1, a microsomal P450 enzyme, to yield 17OH-PREG, or it may be 
converted to PROG, the first biologically important steroid in the pathway. 3βHSD2 converts PREG 
to PROG, 17OH-PREG to 17α-hydroxyprogesterone (17OH-PROG), DHEA to A4, and 
androstenediol to T. Although the SULT2A1 sulfonates most of the DHEA formed, A4 and low 
levels of T and other 19-carbon steroids are produced by the adrenal. Furthermore, CYP17A1 
catalyses the subsequent conversion of 17OH-PREG to DHEA, also augmented by cyt b5 as in 
Leydig cells. The 17,-20-lyase activity is enhanced by cyt b5 by promoting the interaction between 
CYP17A1 and POR. Especially during adrenarche, cyt b5 is up-regulated, together with the down-
regulation of 3βHSD2, thereby ensuring the 17,-20-lyase reaction converts 17OH-PREG to DHEA, 
since 17OH-PROG is not a substrate for the 17,-20-lyase reaction (Auchus, Lee, & Miller, 1998; 
Pandey & Miller, 2005). This 17,-20-lyase reaction is therefore vital for the production of all 
androgens and androgen precursors. The characteristic 17α-hydroxylase and 17,-20-lyase 
activities of CYP17A1 place this enzyme at a key branch point in steroid hormone biosynthesis. 
Neither activity of CYP17A1 is present in the adrenal ZG, hence PREG is converted to the 
mineralocorticoid, aldosterone. In the ZF, the 17α-hydroxylase activity is present, but 17,-20-lyase 
activity is not, hence PREG is converted to the glucocorticoid, cortisol. In the ZR, both activities are 
present, enabling the conversion of PREG to androgens. The principal factor regulating the 17,-20-
lyase reaction is electron transport from NADPH via POR. All microsomal (type 2) CYP450 
enzymes, which include steroidogenic CYP17A1 and CYP21A2 receive electrons from POR, a 
membrane-bound flavoprotein which differs from the mitochondrial flavoprotein, ferredoxin 
reductase, supplying electrons to the mitochondrial (type 1) P450 enzyme. POR receives two 
electrons from NADPH and transfers one electron at a time to P450.  
Microsomal CYP21A2 catalyse the 21-hydroxylation of the Δ4 steroids, PROG to 11-
deoxycorticosterone (DOC), and 17OH-PROG to 11-deoxycortisol, in the biosynthesis of 
mineralocorticoids and glucocorticoids, respectively (Sharifi & Auchus, 2012).  
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Figure 3.3: Steroid hormone biosynthesis pathways represented in the zones of the adrenal cortex.  
The final steps in the biosynthesis of glucocorticoids and mineralocorticoids are catalysed by two 
closely related mitochondrial enzymes, CYP11B1 and CYP11B2 (P450c11AS, aldosterone 
synthase). Both forms of CYP11B use ferredoxin and ferredoxin reductase to accept electrons 
from NADPH to allow catalysis. The more abundant of the two isoenzymes is CYP11B1, which is 
the classical 11β-hydroxylase that converts 11-deoxycortisol to cortisol and DOC to corticosterone 
(CORT), and is expressed predominantly in the ZF, and to a lesser extent in the ZR and in the ZG. 
Our research group has recently shown that the conversion of adrenal A4 to 11OHA4 and T to 
11OHT (Schloms et al., 2012), is catalysed by CYP11B1. The less abundant CYP11B2, is 
expressed in the ZG only, where it exhibits 11β-hydroxylase, 18-hydroxylase and 18-methyl 
oxidase activities, and thus catalyses the conversion of DOC to aldosterone (Sharifi & Auchus, 
2012). CYP11B2 also catalyses the C11-hydroxylation of A4 and T, and although the level of the 
11β-hydroxylation of T may be negligible in the adrenal due to the zone specific enzyme 
expression, it is quite possible that circulating T may be hydroxylated by CYP11B2 in the ZG and 
thus contribute to 11OHT production (Swart et al., 2013a).  
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Androgen precursors 
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Although 17βHSDs, termed 17-oxidoreductases or 17-ketosteroid reductases, interconvert DHEA 
and androstenediol, as well as A4 and T, expression levels are, low in the adrenal. 17βHSD2 is a 
microsomal oxidase that uses NAD+ in the catalysis of the conversion and inactivation of 
androgens (T to A4 and 11OHT to 11OHA4), while AKR1C3, catalyses the conversion of A4 to T 
and DHEA to androstenediol (Miller & Auchus, 2011, and the references therein). In the adrenal, 
the interconversion of 11KA4 and 11KT is also possible due to the presence of 17βHSDs in the ZR 
(Rege & Rainey, 2012; Rege et al., 2013).  
The adrenal also expresses low levels of the two isoenzymes of 11βHSD which catalyse the 
interconversion of cortisol and cortisone. These isoenzymes exhibit oxidase and reductase activity, 
depending on whether NADP+ or NADPH is available as co-factor. 11βHSD1 catalyses both the 
oxidation of cortisol to cortisone using NADP+ as co-factor and the reduction of cortisone to cortisol 
using NADPH co-factor and H6PDH as co-enzyme. In the endoplasmic reticulum, the ratio of 
NADPH to NADP+ is maintained by H6PDH. 11βHSD2 catalyses the oxidation of cortisol to 
cortisone only, using NAD+, and functions best with low concentrations of steroid (Miller & Auchus, 
2011). Furthermore, it is also possible for 11βHSD to mediate the interconversion between 
11OHA4 and 11KA4 as well as 11OHT and 11KT (Swart et al., 2013a). 
It was recently shown that 17OH-PROG produced in the adrenal may also be converted to DHT, in 
clinical cases of 21-hydroxylase deficiency. This alternative „backdoor‟ route produces DHT without 
going through the conventional intermediates DHEA, A4 or T (fig. 3.4). PROG and 17OH-PROG 
accumulate in the absence of CYP21A2, with this pathway being initiated when either PROG or 
17OH-PROG are reduced by SRD5A1 or SRD5A2. Once 5α-pregnane-3α, 17α-diol-20-one (17OH 
allo-pregnanolone) is formed it can be converted by the 17,-20-lyase activity of CYP17A1 to AST. 
17βHSD3 and AKR1C3 subsequently converts AST to 5α-androstane-3α, 17β-diol (3α-adiol), and 
finally 3αHSD oxidises 3α-adiol to DHT (Auchus, 2004; Kamrath et al., 2012).  
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Figure 3.4: The biosynthesis of DHT via the „backdoor‟ pathway. 
The „backdoor‟ pathway is possible wherein C21 steroids are acted on by the reductive activity of 
SRD5A1 and/or SRD5A2 and AKR1C2 prior to the lyase activity of CYP17A1, with reports of 
17OH-PROG being a better substrate for SRD5A1 than A4 and T (Auchus, 2009). It has, to date, 
not been identified which isoenzymes are responsible for the 5α-reduction of 17OH-PROG in 
patients with 21-hydroxylase deficiency. Interestingly, 5α-pregnane 17α-ol-3, 20-dione (17OH-
dihydroprogesterone) is a poor substrate for the lyase activity of CYP17A1, therefore biosynthesis 
proceeds via AKR1C2, which yields 17OH allo-pregnanolone, an excellent substrate for the lyase 
activity of CYP17A1. It is likely that the „backdoor‟ pathway contributes to DHT biosynthesis in 
androgen excess disorders, particularly in those in which 17OH-PROG accumulates, such as 
polycystic ovary syndrome, 3βHSD deficiency and Antley-Bixler syndrome characterised by 
disordered steroidogenesis due to POR deficiency (Ghayee & Auchus, 2007). The adrenal and 
testes express all the required enzymes for the conversion of 17OH-dihydroprogesterone to DHT 
(Dufort, Rheault, Huang, Soucy, & Luu-The, 1999; Fluck et al., 2011; Penning et al., 2000). Of 
interest, the adrenals express negligible SRD5A with SRD5A2 being expressed at low levels in 
fetal testes and, at high levels in adult testes, while SRD5A1 is expressed at higher levels in the 
fetal testes than in the adult testes (Fluck et al., 2011). In addition in situ steroid biosynthesis, in 
the skin is widely reported, as the skin cells express CYP11B1, CYP17A1, 3βHSD, SRD5A1 and 
SRD5A2 (Dumont et al., 1992; Slominski et al., 1996; Slominski et al., 2004; Thiboutot et al., 2003; 
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Thigpen et al., 1993). The „backdoor‟ pathway could therefore function within skin cells, albeit only 
to produce 17OH-dihydroprogesterone, which could subsequently be released into circulation and 
be metabolised within the „backdoor‟ pathway in peripheral tissue, yielding DHT.  
The adrenals produce androgen precursors which are secreted into circulation and exert 
physiological effects in peripheral target tissue, such as the skin, liver and prostate. These steroid 
precursors include DHEA(S), A4, T and 11OHA4 and have been implicated in the recurrence of 
androgen dependent PCa, subsequent to castration having dramatically reduced circulating 
testicular T. Adrenal steroidogenesis therefore provides androgen precursors that may drive the 
recurrence of PCa, following ADT. 
3.3.3 De novo androgen biosynthesis in the prostate 
It was shown that AR activity in castration-resistant VeCaP (wild type AR positive androgen 
dependent PCa cells) xenografts is driven by CYP17A1 and AKR1C3-dependent intratumoural de 
novo androgen biosynthesis. De novo androgen biosynthesis within CRPC cells may thus yield 
adequate C19 steroids, capable of restoring AR transcriptional activity (Cai et al., 2011). Studies 
carried out in LNCaP cells have also shown that cholesterol biosynthesis and metabolism 
increased as tumours progressed subsequent to androgen deprivation (Bauman et al., 2006; 
Dillard et al., 2008; Ettinger et al., 2004; Leon et al., 2010; Locke et al., 2008). Although mRNA 
transcripts encoding CYP11A1 and CYP17A1, required for de novo biosynthesis of steroids from 
cholesterol, have been detected in PCa cell lines, de novo T production using radioactive tracers, 
was shown to be very low with androgen levels unable to restore AR activity in LNCaP cells 
(Dillard et al., 2008; Locke et al., 2008). It has furthermore also recently been shown that de novo 
steroidogenesis is not possible and not able to support AR transactivation, together with cells 
growth in PCa cells (Kumagai et al., 2013). 
It is therefore possible that de novo androgen biosynthesis from cholesterol in CRPC tissue serves 
as an alternative source of androgens, other than the testicular and adrenal C19 steroids. 
However, the abundance of adrenal precursors in serum, and the requirement for only two to three 
enzymes for the conversion of these C19 precursors to T and DHT, suggests that the adrenals are 
the main source of intratumoural androgens in CRPC (Sharifi et al., 2010). 
3.4 Androgen metabolism in the prostate 
Steroids in circulation are bound to plasma proteins. The unbound hormones are available for 
uptake by target tissues, such as the prostate. The uptake of circulating androgens and 
subsequent metabolism to active steroids by peripheral target tissues such as breast, prostate and 
skin, (termed intracrinology), involves the paracrine diffusion and conversion of steroid substrates 
among neighbouring cell types with different enzyme capacities (Mostaghel, 2013). 
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Steroid metabolism in prostatic tissue and steroid-dependent PCa cells does not necessarily follow 
a single dominant pathway, for instance the conventional C19 pathway. Alternate metabolic 
pathways may differ somewhat from the conventional pathway converging at DHT. Competing 
pathways and enzymes may also exist, and the flux within various routes may vary depending on 
the available precursors and other conditions, such as redox-partners required for catalysis. In 
addition, multiple androgen precursors are available to PCa cells, reducing the number of enzymes 
needed to generate AR ligands (Sharifi & Auchus, 2012). 
3.4.1 The conventional C19 pathway 
DHT, regarded as the most potent natural androgen, is generally accepted to be produced by the 
reduction of T by SRD5A1 and SRD5A2 enzymes (fig. 3.5). Cell growth and proliferation as it 
occurs in the prostate, is due to DHT which is approximately 10-fold more potent than T (Hsing et 
al., 2008). Therefore, the conventional C19 pathway primarily refers to the production of T by the 
testes, and the subsequent biosynthesis of DHT from T in the prostate. 
 
Figure 3.5: C19 steroid metabolism in the conventional C19 pathway. 
In normal physiology the testes provides T that is taken up by the prostate, with adrenal androgens 
making a minimal contribution. The first treatment strategy employed to treat PCa is ADT, as 
mentioned above, which depletes the body of circulating testicular T. However, it is the adrenal 
androgens, DHEA, A4 and to a lesser extent T (Rege et al., 2013; Xing et al., 2011), which 
contribute towards the androgen pool when PCa recurs when patients relapse. Uptake of these 
three androgens into the prostate cells results in A4 and T being interconverted by 17βHSDs and 
A4 being produced from DHEA via 3βHSD2. 17βHSDs play a dominant role in converting A4 to T, 
and in so doing activate T. Both 17βHSD3 and AKR1C3 has been identified in prostate tissue. 
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Together with these reductases, 17βHSD2 is also present in the prostate, and converts T and DHT 
to A4 and 5α-dione, respectively (Wu et al., 1993). In the conventional pathway it is thought that A4 
is converted to T and that T is subsequently reduced via SRD5A1 and SRD5A2 to produce DHT 
(3.4.2). 
3.4.2 The 5α-dione pathway 
The conversion of T to DHT, via SRD5A was thought to be the predominant conversion in the 
biosynthesis of DHT during prostate androgen metabolism. The alternative to DHT biosynthesis 
through T is the 5α-reduction of A4 to 5α-dione, which is subsequently reduced at C17 to form 
DHT (fig. 3.6). Chang et al., (2011), recently showed that A4 is preferentially reduced to 5α-dione 
by SRD5A1, rather than being reduced to T, in multiple models of CRPC, as well as freshly 
biopsied tissue from patients with metastatic CRPC (Chang et al., 2011). 
 
Figure 3.6: C19 steroid metabolism in the „alternative‟ 5α-dione pathway. 
Therefore the preferred route of adrenal precursors being metabolised to DHT is, A4 to 5α -dione 
(via SRD5A1), followed by 5α-dione to DHT (via 17βHSD), rather than from A4 to T (via 17βHSD) 
followed by T to DHT (via SRD5A) as in the conventional C19 pathway. It was shown that silencing 
the expression of SRD5A1 blocked the conversion of A4 to 5α-dione and the eventual biosynthesis 
of DHT in CRPC. These data suggested the up-regulation of SRD5A1 described in multiple clinical 
studies of CRPC tissue, served to increase flux from A4 to 5α-dione, rather than T to DHT (Chang 
et al., 2011; Sharifi, 2012). 
Inactivation of active androgens can follow in two steps, the first step is catalysed by AKR1C2, 
followed by inactivation catalysed by UGT2B15 and UGT2B17. AKR1C2 catalyse the reversible 
reduction of DHT and 5α-dione, to 3α-adiol and AST, respectively, which exhibit only weak 
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androgenic activity. The presence of AKR1C1 also results in the β-conformations of these steroids, 
3β-adiol and epi-AST, being produced (Muthusamy et al., 2011). The enzyme mediating the 
reverse conversion of 3α-adiol and AST is thought to be the retinol dehydrogenase (RoDH) like 
3αHSDs (RL-HSDs, 17βHSD6) (Bauman et al., 2006). In the second step, the conjugating UGT 
enzymes terminate the androgen signal by irreversibly catalysing the glucuronidation of 3α-adiol 
and AST, together with T and DHT (Chouinard et al., 2007). 
3.4.3 The 11OHA4 pathway 
In addition to DHEA(S), A4 and T, the adrenal produces substantial amounts of the C19 steroid, 
11OHA4, which is the product of CYP11B1 catalysed hydroxylation of A4 (Schloms et al., 2012). 
The possibility that 11OHA4 may serve as a potential precursor in the biosynthesis of potent 
androgens in mammals has been overlooked, until recently when it was reported that 11OHA4 is 
converted to active androgens by the 11OHA4 pathway (fig. 3.7) (Storbeck et al., 2013). It was 
recently shown that CYP11B1, as well as CYP11B2 catalyse the hydroxylation of A4 and T to 
11OHA4 and 11OHT, respectively. In addition, 11βHSD2, also expressed in the adrenal, catalyses 
the conversion of these hydroxy-steroids to their keto-forms, producing 11KA4 and 11KT, 
respectively (Swart et al., 2013a). Furthermore AKR1C3 converts A4 to T, and is also able to 
produce 11KT from 11KA4, once 11KA4 is produced in the adrenals. The levels of 11KA4, 11OHT 
and 11KT produced by the adrenal are, however, significantly lower than that of 11OHA4 (Rege et 
al., 2013). Therefore, once in circulation, 11OHA4 will reach peripheral tissues, such as the 
prostate and be metabolised, thus contributing additional steroid metabolites to the androgen pool. 
Interestingly, it has been shown that CYP11B1 and CYP11B2 are expressed in human primary 
prostate carcinomas and metastatic primary prostate carcinomas (Biancolella et al., 2007; 
Mitsiades et al., 2012), which suggests PCa cells may be capable of producing 11OHA4 and 
11OHT from A4 and T, respectively. 
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Figure 3.7: C19 steroid metabolism in the 11OHA4 pathway. Shading indicates AR transactivation relative 
to that of 1 nM DHT. Reproduced with permission from (Bloem et al., 2013). 
Adrenal 11OHA4 is metabolized by three enzymes, viz. 17βHSDs, 11βHSDs and SRD5As in the 
prostate, as shown in LNCaP cells. In the pathway, the conversion of 11OHA4 to produce 11KA4 
is catalysed by 11βHSD2, which in turn is utilized by AKR1C3 and/or 17βHSD3 to produce 11KT. 
11KT and its dihydro-form, the novel steroid 5α-dihydro-11-keto-testosterone (11KDHT), have 
been shown to have androgenic activity, with the 5α-reduced form of 11KT possessing agonist 
activity towards the AR comparable to that of DHT (fig. 3.7). It is also possible for 11OHA4 to be 
reduced by SRD5A to its dihydro-form, 11β-hydroxy-5α-androstanedione (11OH-5α-dione), which 
is subsequently catalysed by 11βHSD2 to produce 11-keto-5α-androstanedione (11K-5α-dione), 
followed by the reduction by 17βHSDs leading again to the production of 11KDHT. 11KA4 and 
11OHT are also metabolized to their novel 5α-reduced forms by SRD5A1 and SRD5A2, viz.: 11K-
5α-dione and 5α-dihydro-11β-hydroxytestosterone (11OHDHT), respectively. 11OHA4, 11KA4, 
11OH-5α-dione and 11K-5α-dione exhibit negligible androgenic activity at 1 nM, however, when 
17βHSDs metabolise these steroids, their androgenic activity increased. While 11OHT at 1 nM 
exhibited minimal androgenic activity, the reduction of this metabolite to 11OHDHT increased the 
androgenic activity. 11KT showed partial agonist activity towards the AR, comparable to that of T, 
and as mentioned previously, 11KDHT is a full agonist, thereby implicating it as a role player in 
CRPC. These data showed that the C11-keto forms of A4, T and DHT, were more androgenic than 
their respective 11-hydroxy forms, indicating that a keto group at C11 may be preferential for 
optimal interaction with the AR ligand binding domain (Storbeck et al., 2013).  
In LNCaP cells, which express only low levels of SRD5A, 11OHA4 was shown to be preferentially 
converted to 11KA4 by 11βHSD2. As mentioned previously two isoenzymes of 11βHSD exist, 
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11βHSD1 expression in the prostate remains questionable, but 11βHSD2 has been detected in 
LNCaP cells (Dovio et al., 2009; Page, Warriar, & Govindan, 1994), and although 11βHSD2 does 
not have an active role in the metabolism of C19 steroids without a C11 hydroxy- or C11 keto-
group, this enzyme has a definitive role in the 11OHA4 pathway. Studies with COS-1 cells 
transfected with SRD5A showed that  although the 11-hydroxy and 11-keto A4 and T steroids may 
all serve as substrates for SRD5A, 11OHA4 and 11KA4 are the preferred substrates, yielding 
11OH-5α-dione and 11K-5α-dione, respectively. This data is comparable to the „alternative‟ 5α-
dione pathway in which the 5α-reduction of A4 is preferred over that of T (3.4.2). Studies with 
17βHSD showed that the hydroxy or keto group at C11 position influences the ability of the 
17βHSD isoforms in accepting these metabolites as substrates. The reductive activity of the 
17βHSDs was only detected for the 11-keto steroids, while the reverse reaction exhibited no 
preference for either a hydroxy or a keto group at C11 and catalysed the conversion of both C11-
hydroxy and C11-keto substrates. It was also observed that the metabolism of the 5α-reduced by 
17βHSD mimics that of their Δ4 parent compounds. Due to the substrate preferences of the 
enzymes involved, the principal metabolites produced by the 11OHA4 pathway are 11KT and the 
novel steroid 11KDHT as confirmed in LNCaP cells. This finding has significant implications in 
CRPC. 11OHA4 thus serves as an additional source of adrenal derived androgens, other than 
DHEA(S), A4 and T, which may drive CRPC through the activation of the AR (Bloem et al., 2013; 
Storbeck et al., 2013; Swart et al., 2013a). 
Whether the 5α-reduced steroids, in the 11OHA4 pathway, are reduced by AKR1C2 at C3 has not 
to date been established, together with the reverse reaction catalysed by 17βHSD6. The catalytic 
activity of UGT2B15 and UGT2B17 towards 11OHT, 11KT, the 5α-reduced steroids 11OHDHT and 
11KDHT as well as the possible 3α-reduced steroids, have also not been established. 
3.5 Prostatic steroidogenic and inactivating enzymes 
The localization of AKR1C3, 3βHSD2 and the AR in the prostate have been firmly established 
(Akinola et al., 1996; Bonkhoff & Remberger, 1993; Dumont et al., 1992; Loda et al., 1994; Martel 
et al., 1992; Pelletier & Tong, 1992) (fig. 3.8). It has been shown by using in situ hybridization and 
immunocytochemistry, that AKR1C3 is expressed in basal cells, the fibroblasts dispersed 
throughout the stroma or in association with the wall of blood vessels and the endothelial cells 
lining blood vessels. Furthermore, the localization and expression of 3βHSD2 was reported to be 
similar to that of AKR1C3 and in all cells expressing 3βHSD2, staining was restricted to the 
cytoplasm, with no significant nuclear staining being detected. The AR appeared to be localized 
exclusively in the nuclei of prostate cells in all the specimens which included: BPH and normal 
prostate tissue as well as cultured epithelial cells. In cultured epithelial cells AKR1C3 showed 
similar pattern of expression as in the epithelial cells of BPH and normal prostate tissue (El-alfy et 
al., 1999). Previous studies reporting on the localization of SRD5A1 and SRD5A2, showed that the 
enzymes are produced by both epithelial and stromal cells in the prostate (Aumüller et al., 1996; 
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Bruchovsky et al., 1996; Habib et al., 1998; Pelletier, Luu-The et al., 1998). The presence of 
AKR1C3, 3βHSD and SRD5A isoenzymes in basal cells suggests that the cell type is actively 
involved in androgen production and is not simply a secretory cell, producing precursors for the 
luminal cells.  
 
Figure 3.8: Androgen metabolism and enzyme location in the human prostate. Abbreviations as follows: 
DHEAS, dehydroepiandrosterone sulphate; DHEA, dehydroepiandrosterone; 5-DIOLS, androst-5-ene-3β, 
17β-diol sulphate; 5-DIOL, androst-5-ene-3β, 17β-diol; 4-DIONE, androstenedione; A-DIONE, 
androstanedione; DHT, dihydrotestosterone; 3α-DIOL, androstane-3α, 17β-diol; ADT, androsterone; ADT-G, 
androsterone-glucuronide; 3α-DIOL-G, androstane-3α, 17β-diol -glucuronide; DHT-G, dihydrotestosterone-
glucuronide. Reproduced with permission from (Bélanger et al., 2003). 
It has been suggested that T synthesized in the basal cells, due to the presence of both AKR1C3 
and 3βHSD2, reaches the luminal cells, in a paracrine manner, and is ultimately transformed into 
DHT in the luminal cells, where androgenic effects are exerted and AR is highly expressed. DHT, 
produced in the luminal cells by SRD5As, would subsequently exert its effects  in the luminal cells, 
which can thus be viewed as an intracrine activity and suggests a two-cell mechanism of androgen 
formation in the human prostate (El-alfy et al., 1999). In this context it is, however, also important 
to consider the inactivation and conjugation of active androgens. AKR1C2 is expressed in the 
basal cells, where the enzyme catalyses the reduction of DHT to 3α-adiol while UGT2B15 is 
expressed in the luminal cells and UGT2B17 is expressed in the basal cells of the human prostate. 
The levels of DHT are therefore modulated independently by UGT2B15 in the luminal cells and by 
UGT2B17 in the basal cells (Barbier & Bélanger, 2008). 
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3.5.1 The SRD5A enzymes 
In 1968 the intraprostatic conversion of T to DHT was characterized which established the 
importance of the enzyme SRD5A and of DHT (Bruchovsky & Wilson, 1968). SRD5A enzymes, are 
NADPH-dependent enzymes that act upon C19 and C21 steroids with C4-C5 double bonds in their 
carbon-backbones (Soronen et al., 2004), irreversibly reducing the double bonds to produce 5α-
reduced steroids.  
Three isoforms of SRD5A exist, with SRD5A2 representing the predominant isoform in normal 
prostatic tissue and SRD5A1 showing increased expression in cancerous prostatic tissue (Chang 
et al., 2011; Stanbrough et al., 2006). Although SRD5A1 expression levels have also been 
reported to remain unchanged, while SRD5A2 levels are reduced, a definite shift from the 
predominant expression of SRD5A2 to that of SRD5A1 exists in recurrent PCa (Titus et al., 2005). 
The third isoform, SRD5A type 3 (SRD5A3), has been suggested to be associated with DHT 
production and AR activation in hormone refractory PCa (Uemura et al., 2008). Its role, however, 
has not been elucidated, but a shift away from SRD5A2 to increased expression of SRD5A1 and 
SRD5A3 in CRPC has also been described (Azzouni et al., 2012; Godoy et al., 2011). Increased 
expression of SRD5A3 was shown in metastatic PCa (Mitsiades et al., 2012) and mean mRNA 
levels in CRPC suggest relative gene expression gradients of SRD5A3>SRD5A1>SRD5A2 (Titus 
& Mohler, 2009). Dutasteride, a bispecific SRD5A1 and SRD5A2 inhibitor, to date the most 
effective SRD5A inhibitor, does not block SRD5A3, suggesting that SRD5A3 may be a possible 
approach in targeting prostate androgen metabolism in CRPC. 
SRD5As are expressed in androgen-responsive tissues and in androgen-stimulated benign 
prostate tissue with expression levels being higher in clinically higher graded PCa compared to 
lower graded PCa (Thomas et al., 2008). SRD5A1 and SRD5A2 are expressed mainly in the 
cytoplasm of PCa cells, while SRD5A1 is located in the nucleus in benign prostate cells. SRD5A1 
and SRD5A2 share approximately 50% amino acid sequence identity and possess similar 
substrate specificity (Titus & Mohler, 2009). However, SRD5A1 has a lower affinity (Km = 1-5 µM) 
for substrates such as T and A4 (Andersson & Russell, 1990), compared to SRD5A2 having a 
higher affinity (Km = 4-50 nM) (Faller et al., 1993; Thigpen et al., 1993) for these substrates 
(Russell & Wilson, 1994). 
Although SRD5As are widely accepted as catalysing the conversion of T to DHT, the conversion of 
A4 to 5α-dione has been shown to be the preferred pathway to DHT production in CRPC (Chang 
et al., 2011; Sharifi, 2012). Within the 11OHA4 pathway both SRD5A1 and SRD5A2, preferably 
convert A4 metabolites, 11OHA4 and 11KA4, to their respective dihydro steroids, while also 
catalysing the 5α-reduction of 11OHT and 11KT. These isoenzymes thus play a significant role in 
the production of active androgens, the C19 5α-reduced steroids and the novel full AR agonist 
steroid hormone 11KDHT (Storbeck et al., 2013). 
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3.5.2 The 17βHSD enzymes 
The 17βHSDs catalyse the reduction of the keto group at the C17 position of the steroid nucleus, 
thereby modulating the potency of these androgen steroids, with the hydroxy-forms being the 
active form of the steroid (Mindnich et al., 2004). To date 14 types of 17βHSDs have been isolated, 
with types 1, 3, 5 and 7 catalysing the reductive reactions and types 2, 4 and 8 catalysing the 
oxidative reactions. 17βHSD3 and AKR1C3 are the most important isoforms in prostate steroid 
metabolism. Of interest, the reductive 17βHSD activity requires NADPH while the oxidative 
17βHSD activity requires NAD+ (Luu-The, 2001). Interestingly, although 17βHSD3 and AKR1C3 
share a high degree of homology (Labrie et al., 2000), 17βHSD3 belongs to the short-chain alcohol 
dehydrogenase reductase superfamily, and AKR1C3 belongs to the aldo-keto reductase family 1. 
Both isoforms function in a unidirectional manner, predominantly determined by their respective 
cofactors (Luu-The, 2001). 
17βHSD3 prefers NADPH as a cofactor and its primary activity is reductive, catalysing the 
production of T in the testes, in the adrenals (minimal) and in peripheral tissues, such as the 
prostate (Mindnich et al., 2004; Moeller & Adamski, 2009; Montgomery et al., 2008). However, in 
the production of T, the role of AKR1C3 is more prominent in the adrenals and prostate.  Indeed, 
the adrenal cortex expresses AKR1C3, with definitive levels detected in the ZR (Nakamura et al., 
2009). This is not surprising as the cells of the ZR are the site of androgen precursor biosynthesis. 
In the prostate, AKR1C3 is also the predominant isoform contributing to T production (Luu-The, 
2001). Of interest, both 17βHSDs catalyse the production of androgens other than T as discussed 
in the sections above. 
A major role in PCa for both 17βHSD2 and 17βHSD3 in PCa tissue was proposed by a study 
which showed higher expression levels of the HSD17B3 gene in malignant prostatic tissue 
compared to normal prostate tissue, while the opposite was shown in the case of 17βHSD2. No 
significant differences in AKR1C3 gene expression in cancerous and noncancerous tissue were 
detected (Koh et al., 2002). Similar results were reported in another study in which the authors 
reported results showing a significant increase in the expression of 17βHSD3 in castration 
resistant metastases (Montgomery et al., 2008).  
Conversely, numerous studies have shown the up-regulation of AKR1C3 in PCas, with the 
expression increasing as the disease progresses (Fung et al., 2006; Lin et al., 2004; Luu-The et 
al., 2008; Mitsiades et al., 2012; Montgomery et al., 2008; Penning et al., 2006; Stanbrough et al., 
2006). The upregulation of AKR1C3 would contribute to intracellular biosynthesis of AR ligands 
and subsequently cell growth and proliferation through AR activation (Byrns et al., 2012). 
Furthermore, AKR1C3 was recently identified as a co-activator of the AR, further emphasizing the 
role of this enzyme in PCa progression, as it may have a dual role of in the promotion of ligand 
biosynthesis and AR activation. In this study AKR1C3 stimulated the growth of both androgen-
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dependent PCa and CRPC xenografts, with reactivation of androgen signalling occurring 
concurrently. AKR1C3 was shown to interact directly with the AR in PCa cells and CRPC 
xenografts and was recruited to the promoter of PSA, an androgen-responsive gene. It was 
suggested that AKR1C3 may be a nuclear hormone receptor co-activator which could be targeted 
pharmacologically (Yepuru et al., 2013). 
AKR1C2, also a hydroxysteroid dehydrogenase expressed in the prostate, reduces the C19 steroid 
C3-keto-group to a C3-hydroxy-group (Penning & Byrns, 2009), with the latter subsequently 
serving as substrates for UGT2B17. The reduction of the keto group at C3 permits further 
conjugation of not only T ligands but allows the glucuronidation of A4 metabolites at C3. Reduction 
of A4 metabolites, which would otherwise not be conjugated, thus facilitates the secretion of not 
only AR ligands but also potential ligands. In this manner AKR1C2 can therefore regulate the 
occupancy of the AR.  
3.5.3 The UGT enzymes 
UGTs are enzymes found in many organs of the human body, and in the prostate, these enzymes 
catalyse the transfer reaction of glucuronic acid from uridine diphosphoglucuronic acid to steroid 
hormones. In the prostate, this irreversible conversion, following the first inactivation step catalysed 
by the enzyme AKR1C2, represents the second inactivation step of the active C19 steroids, 
abolishing their affinity for the AR. UGTs also catalyse reactions with substrates other than steroid 
hormones, such as lipid-soluble drugs and environmental chemicals. Two superfamilies of UGTs 
exist, namely: UGT1 and UGT2. The UGT1 family is generally known to conjugate planar and 
bulky phenol substrates and estrogens and is expressed in the liver and gastrointestinal tract 
(Strassburg et al., 1998; Strassburg et al., 1998). In contrast UGT2 is divided into two subfamilies, 
where the UGT2A subfamily is expressed in the olfactory epithelium and have activity towards at 
least five odorant compounds (Lazard et al., 1991), while the UGT2B subfamily is expressed in the 
liver, skin, kidney and prostate and catalyse the conjugation of C19 steroids, phenols and fatty 
acids (Beaulieu et al., 1996). UGTs are therefore critical in facilitating the secretion of steroid-
conjugates into the circulation, and UGT2B regulating active steroid hormones in the prostate 
(Tukey & Strassburg, 2000).  
Steroid metabolites with a hydroxy-group at C17 or C3 on the C19 steroid nucleus are suitable 
substrates, in the catalyses by UGTs of hydrogen release and glucuronic acid binding to the 
oxygen moiety. In the prostate, enzymes 17βHSD and AKR1C2 yield steroids possessing 17β-
hydroxy and 3α-hydroxy groups, respectively. UGTs are able to conjugate the 17β-hydroxy and 3α-
hydroxy groups or both, depending on which isoform is expressed. In the C19 pathway within 
prostate steroid metabolism, AKR1C2 catalyses the first inactivation step, and produces steroids 
AST from 5α-dione, and 3α-adiol from DHT (fig. 3.5), as previously mentioned. Both AST and 3α-
adiol are ideal substrates for UGTs endogenously expressed in the prostate. In addition, the 
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upstream conversion of A4 to T and 5α-dione to DHT by 17βHSD, results in steroid metabolites 
possessing a hydroxy group at C17 thus also presenting steroids for conjugation (Bélanger et al., 
2003; Byrns et al., 2012; Chouinard et al., 2007).  
In the prostate with UGT2B enzymes catalysing the conjugation of these afore mentioned C19 
steroids, two isoforms are of importance viz.: UGT2B15 and UGT2B17. These isoforms share 95% 
sequence identity at the amino-terminal, which has been proposed to contain the domain 
determining aglycone, as well as substrate specificity. UGT2B17 expressed in HEK293 cells 
exhibited a substrate preference of 3α-adiol>DHT>T>AST (table 3.1) when glucuronide formation 
was detected at 15-, 14-, 9- and 5 pmol/min/mg protein. It was shown that UGT2B17 only was 
capable of conjugating the 3α-hydroxyl group of AST with UGT2B15 being unable to catalyse the 
conjugation of the 3α-hydroxy group of the metabolite (Beaulieu et al., 1996).  
The importance of UGTs was highlighted by Chouinard et al., (2007), when the endogenous 
UGT2B15 and UGT2B17 was knocked out in LNCaP cells, resulting in increased active DHT and 
decreased DHT-G levels, leading to increased cell proliferation and increased expression of eight 
androgen-sensitive genes (Chouinard et al., 2007). The predominant form circulating in adult 
males is 3α-adiol-glucuronide (3α-adiol-G) which acts as a predictor of prostate volume 
(Vandenput et al., 2007). UGT2B15 preferably conjugates 3α-adiol, and also T and DHT. 
UGT2B17 only conjugates AST, together with T and DHT. UGT2B17 also conjugates 3α-adiol, 
however, not as readily UGT2B15 (Turgeon et al., 2001), with the conjugation of 3α-adiol by 
UGT2B15 being 1.8-fold greater than that of UGT2B17 (table 3.1). 
Table 3.1: Relative Vmax of UGT2B15 and UGT2B17 for androgen metabolites in the C19 pathway . 
Reproduced with permission from (Turgeon et al., 2001).  
Substrates 
UGT2B relative Vmax (pmol/min/mg protein) 
UGT2B15 UGT2B17 
T 4.4 ± 1.0 36.7 ± 5.6 
DHT 10.4 ± 2.7 63.1 ± 4.1 
AST - 21.7 ± 2.7 
3α-adiol 125.4 ± 25.3 70.8 ± 18.3 
 
The conjugation of the C19 steroid metabolites in the 11OHA4 pathway has not been clarified to 
date. It has been reported that 11-hydroxy C19-steroids were poor substrates for glucuronidation 
by UGT2B17 in LNCaP cells, with or without the 3α-hydroxy or the 17β-hydroxy group being 
present. Although the conversion rate of 11hydroxy-AST was similar to that of AST by UGT2B17 it 
was nevertheless proposed that, due to the enzyme exhibiting a high degree of stereospecificity in 
terms of  the C3-hydroxy group it may be that the presence of the 11(α/β)-hydroxy group would 
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interfere with the inactivation of these C19 steroids (Beaulieu et al., 1996). Impeded conjugation 
may possibly occur in the 11OHA4 pathway, implying that androgens remain active and capable of 
binding the AR, allowing these steroids to remain in the androgen pool. This suggestion leads one 
to question whether only the C11 hydroxy-group may hinder conjugation and whether the C11 
keto-group may also influence the specificity of the UGTs. 
UGT2B15 and UGT2B17 are differentially regulated during PCa progression, with the latter being 
significantly higher in cancerous tissues when compared to protein levels in BPH and prostate 
intraepithelial neoplasia samples (Paquet et al., 2012). Another study reported an increased 
expression of UGT2B15 in androgen-independent PCa (Stanbrough et al., 2006). Again, when 
comparing CRPC with primary tumours, CRPC samples showed increased expression of 
UGT2B15 (3.5 fold). However, increased expression of both UGT2B15 and UGT2B17 in CRPC 
has also been reported (Mostaghel, 2013). Whether it is therefore UGT2B15 or both UGT2B15 and 
UGT2B17 which are up-regulated in the progression of PCa, higher UGT levels indicate an 
adaptation of prostatic tissue in response to increased levels of active androgens, due to the up-
regulation of enzymes such as AKR1C3, converting A4 to T. The adaptation suggests a 
mechanism by which the cell‟s conjugating ability is increased to compensate for increased active 
androgens present. It is also possible that UGT expression is increased due to both UGT2B15 and 
UGT2B17, being primary androgen-regulated genes. Since they require the AR for both basal and 
androgen-regulated expression (Bao et al., 2008), AR mutations and reduced AR-ligand specificity 
may result in their induction and transcription, unrelated to the amount of active androgens, but 
specific to the receptor and steroid ligand present in the cell. 
3.6 Activation of AR and downstream implications in PCa 
The AR protein is encoded by the AR gene on the Xq11-12 chromosome (Hsing et al., 2002). The 
AR is a member of the steroid hormone receptor family of ligand-activated nuclear transcription 
factor and contains four functional regions, viz.: an amino terminal regulatory domain (amino 
terminal), a DNA-binding domain (DBD), a hinge region containing a nuclear localization signal, 
and a carboxy-terminal ligand-binding domain (LBD) (fig 3.9). ARs localized in the cytoplasm are 
unligated, but bound to heat shock proteins (HSPs), which stabilize the ARs tertiary structure in a 
conformation that allows androgen binding. Once ligand bound, the AR dissociates from the HSPs, 
dimerizes and subsequent to tyrosine kinase phosphorylation, is translocated into the nucleus. In 
the nucleus, the AR forms an active transcription complex by binding the androgen response 
elements (AREs) located in the promoter and enhancer regions of target genes (Taplin, 2007).  
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Figure 3.9: AR structure and function, representing the binding of DHT and the formation of a transcription 
complex of co-regulatory proteins and transcription of androgen-regulated genes. Abbreviations are as 
follows: AES, amino-terminal enhancer of split; C, carboxy terminal; CBP, CREB-binding protein; HAT, 
histone acetylases; HDAC3, histone deacetylase 3; HDAC6, histone deacetylase 6; HEY1, hairy/enhancer-
of-split related with YRPW motif 1; HSP90, heat shock protein 90; N, amino terminal; NCOR, nuclear 
corepressor; PCAF, p300/CBP- associated factor; PSA, prostate-specific antigen; RNA pol II, RNA 
polymerase II; SMRT, silencing mediator of retinoid and thyroid; SRC, nuclear receptor co-activator; TF7L2, 
transcription factor 7-like 2; TLE, transducin-like enhancer of split. Reproduced with permission from (Taplin, 
2007). 
The AR plays a central role in normal and PCa cell growth and proliferation. The AR is expressed 
in all stages of PCa, with somatic mutations of the AR gene involved in the progression and 
aggressiveness of PCa. Therefore, with the onset of PCa, ADT - castration, as well as AR 
blockage through usage of AR antagonists – is included in the treatment regime. When PCa recurs 
it is likely to be more aggressive, with AR amplification reported in one third of the cases, 
demonstrating an adaptation within the PCa cells (Holzbeierlein et al., 2004; Taplin et al., 1995). 
Furthermore, AR mutations can also occur which allow activation of the AR by weak androgens 
which may not have activated the AR prior to CRPC. AR mutation frequencies ranging from 0 to 
44% and 0 to 50% have been reported for androgen-dependent PCa and CRPC, respectively 
(Mohler et al., 2004). In addition, it also possible for increased expression of transcriptional co-
activator proteins, as another adaptation in PCa cells, to allow the activation of signal transduction 
pathways which would enhance AR responses to weak androgens (Yuan & Balk, 2009).  
Together with increased AR expression, an increase in AR-regulated genes such as PSA, also 
occur. Transcription of PSA is positively regulated by the AR, and consistently expressed in PCa. 
PSA, a serum marker for PCa and treatment response, is a serine protease protein which is 
androgen-regulated. PSA, a member of the kallikrein family proteases, is a major part of semen 
(0.5 – 2 mg/mL), with the function to cleave semenogelins in the seminal coagulum. PSA is 
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produced by prostate ductal and acinar epithelium and is secreted into prostatic ducts as an 
inactive 244-amino acid pro-enzyme (proPSA) that is activated by cleavage of seven N-terminal 
amino acids. PSA that enters circulation is rapidly inactivated in the lumen by proteolysis and 
circulates as free PSA, or is bound by protease inhibitors, including α1-antichymotrypsin (ACT) 
(Balk et al., 2003).  
The normal physiology of the human prostate reflects a single layer of secretory epithelial cells, 
which are surrounded by a continuous layer of basal cells and a basement membrane. There is a 
concomitant disruption of the basal cell layer and basement membrane with the onset of PCa, and 
the loss of normal glandular architecture appears to allow direct access of PSA to peripheral 
circulation, as shown in Fig. 3.10 (Balk et al., 2003; Hayward & Cunha, 2000). Partial basal cell 
loss has been reported in prostate intraepithelial neoplasia, while complete basal cell loss is 
characteristic of PCa.  
 
Figure 3.10:  Model of PSA activation in normal prostate epithelium versus cancer. Reproduced with 
permission from (Balk et al., 2003). 
Total PSA serum levels are increased in PCa, hence the screening of PSA as an indicator of PCa 
progression. Analyses of free and total PSA levels can increase the screening accuracy of PSA in 
PCa, allowing for discrimination between levels detected in the case of the healthy prostate and 
levels detected in PCa, as the PSA index (free PSA: total PSA) has been reported to be decreased 
in PCa (Catalona et al., 1998). An initial decline in PSA levels, in response to ADT, is partly due to 
tumour cell death and partly due to reduced AR-stimulated PSA production by surviving tumour 
cells. However, PSA expression continues to be maintained even after ADT. The AR is therefore 
still stabilized and activated by tissue androgens. Indeed, the presence of PSA in CRPC 
consistently correlates with the presence of an activated AR, as differential expression, subtractive 
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hybridization and cDNA microarrays showed PSA expression before and after castration in tumour 
models of androgen-dependent PCa (Mohler et al., 2004). 
In castrate tumours DHT levels, between 0.5 and 1.0 ng/g, are sufficient to activate the AR, which 
subsequently stimulate the expression of AR-driven genes, such as PSA, and thereby mediates 
tumour growth and progression of PCa to CRPC (Culig et al., 1999; Gregory et al., 1998; Gregory 
et al., 2001; Mohler et al., 2004). Two cellular events occur in prostate cells: cellular proliferation 
and PSA production – however, cellular proliferation has been shown at low DHT concentrations, 
and high PSA levels at high DHT concentrations. It is necessary to note, that although the 
secretion of PSA in prostate cells is stimulated by androgens (DHT), it does not correlate with cell 
proliferation. A study by Lee et al., (1995), showed that at low DHT concentrations LNCaP cells 
proliferate at a high rate, but at high DHT concentrations, cell proliferation decreases with a 
concomitant rise in PSA levels (Lee et al., 1995).  
In addition ERs should also be mentioned, especially ERβ, which is anti-proliferative and 
proapoptotic (Imamov et al., 2004) and is expressed in both normal prostate as well as in PCa (Lai 
et al., 2004; Leav et al., 2001). ERβ was reported to be predominantly localized in basal cells and 
to a lesser extent in stromal cell nuclei (Leav et al., 2001). AR mutations occur in invasive prostate 
carcinomas (Haapala et al., 2001; Marcelli et al., 2000), as mentioned above, however, increased 
estrogen sensitiveness as a result of increased expression of ERs occurs concurrently (Lai et al., 
2004). Furthermore, it is possible for ERβ to antagonize androgen-dependent prostate and PCa 
proliferation, as prostatic hyperplasia occurred in ERβ knock-out mice (Krege et al., 1998). Of 
interest, ERβ expression increases in PCa progression, although it has also been reported that 
ERβ expression was diminished in high-grade dysplasia and grade 4/5 carcinoma of the peripheral 
zone of the prostate. The down-regulation of ERβ expression occurring during the late stage of 
prostatic carcinogenesis, possibly contributes the loss of control over growth processes mediated 
by ERβ and subsequently allows the proliferative stimuli to be reactivated mediated through the AR 
(Leav et al., 2001). 
3.7 The progression of PCa to CRPC 
The pathways that drive normal prostate development ultimately drive PCa development as well as 
CRPC. CRPC is the recurrence of PCa after ADT and usually occurs 2-5 years after initial ADT 
treatment. Despite a 94% reduction in serum T with medical castration, intraprostatic T and DHT 
are only reduced by 70% and 80%, respectively. The apparent availability of precursors for the 
biosynthesis of residual intraprostatic androgens in the absence of gonadal T provides a clue as to 
the mechanisms of resistance to gonadal T depletion (Sharifi & Auchus, 2012). A rise in PSA 
levels, that decline initially with ADT, often precedes radiographic changes and is therefore 
employed as a signal for the development and progression of CRPC. Increased PSA shows 
unsuccessful repression of AR signalling despite ADT. In CRPC this can be attributed to: AR 
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mutations in the LBD, which allows the conversion of antagonists to agonists or reduces the 
specificity of the AR to allow stimulation by other ligands; AR gene amplification; expression of 
mutated AR variants that are constitutively active; and finally the production of the most potent 
agonist, DHT (fig. 3.11) (Attar et al., 2009; Sharifi, 2012).  
 
Figure 3.11: Progression of androgen-dependent PCa to CRPC, significant of PCa driven by androgen-
independent factors. Reproduced with permission from (Nelson, De Marzo, & Isaacs, 2003), Copyright 
Massachusetts Medical Society. 
Studies suggest that intratumoural DHT concentrations are approximately 1 nM, abundantly 
sufficient to drive CRPC progression. In addition, studies have shown the concentration of T to be 
higher than that of DHT (Montgomery et al., 2008; Titus et al., 2005), which suggests that the 
agonist activity of T could also play a role in CRPC progression. Elevated T:DHT ratios indicate 
inefficient conversion from T to DHT, which may suggest an alternative dominant pathway. In fact 
T:DHT ratios in CRPC are similar to those in men treated with a SRD5A inhibitor, finasteride 
(McConnell et al., 1992). It has therefore been suggested that research into nuclear androgen 
concentrations in which the AR and agonist ligand are complexed, should be investigated to allow 
complete evaluation of CRPC parameters (Sharifi & Auchus, 2012). 
Progression of CRPC may also be due to modified steroid-metabolizing enzyme activity, due to 
subcellular localization, possible post-translational changes, availability of co-factors and ratios of 
enzyme to redox partner proteins, cellular redox status, competition between enzymes, as well as 
the availability and preference for alternative steroid substrates (Mizrachi & Auchus, 2009; Sharifi, 
2012). As mentioned previously, SRD5A2 which is the dominant isoenzyme in normal prostate, is 
down-regulated in CRPC, together with the concurrent up-regulation of SRD5A1 (Montgomery et 
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al., 2008; Stanbrough et al., 2006; Titus et al., 2005). Evidence showing that the preferred pathway 
in CRPC is the 5α-dione pathway, suggests that together with the up-regulation of SRD5A1 and 
the preference of this enzyme for A4 as substrate, DHT biosynthesis continues unhindered (Chang 
et al., 2011). The 3-keto reduction and inactivation of DHT to 3α-adiol is a reversible reaction, 
which together with the conversion of AST to 5α-dione, might also play a role in CRPC 
progression, especially if glucuronidation of 5α- and 3α-reduced steroids is impaired in CRPC 
(Sharifi & Auchus, 2012). 
3.8 ADT and CRPC treatment therapies 
Strategies employed in the treatment of hormone-dependent cancers include: ADT and 
administration of inhibitors of either the steroid-metabolizing enzymes or antagonist activity at 
steroid receptor level. ADT was first accomplished by surgical castration, but can also be achieved 
using long-acting GnRH agonists (leuprolide acetate and goserelin) and GnRH antagonists such 
as degarelix. Androgen deprivation leads to regression characterised by a loss of secretory 
function and a reduction in glandular size of the prostate in adults. Regression is due to 
widespread apoptosis in the prostate and most extensive in distal regions of prostatic ducts. 
However, castration simultaneously depletes androgens from both epithelial and stromal AR and 
the stroma of the adult prostate undergoes changes toward a more fibroblastic, less muscular 
phenotype. Interestingly, stimulation by androgens of the regressed prostate results in new 
development, growth and secretory activity, including PSA secretion (Hayward & Cunha, 2000). 
Approaches other than or in addition to ADT include: estrogens (diethylstilbestrol) and progestins, 
together with AR antagonists (flutamide, bicalutamide, nilutamide and a next-generation AR 
antagonist, Enzalutamide) (fig. 3.12). Included in the aforementioned list are specific enzyme 
inhibitors that modulate C19 steroid concentrations, including abiraterone, a potent inhibitor of 
CYP17A1 (Sharifi & Auchus, 2012). Exogenous androgen administration will suppress pulsations 
from GnRH and LH, and subsequently impair testicular T biosynthesis, and lead to testicular 
atrophy – but the androgen itself would stimulate PCa growth. Conversely, estrogens and 
progestin accomplish GnRH and LH suppression, without AR activation. As mentioned previously 
GnRH release from the hypothalamus leads to the subsequent release of LH from the pituitary. 
The precise pulsatile rhythm of GnRH release is essential for LH release, and desensitization 
occurs with continued GnRH stimulation – the rationale behind the use of GnRH agonists in 
therapeutic treatments employed in PCa, where long-acting GnRH agonists lead to LH and T 
suppression. The GnRH antagonist, degarelix, together with GnRH agonists has been used 
preferentially instead of estrogens and progestin, as the former show less risk in the development 
of gynecomastia and thromboembolism. Furthermore potent synthetic GR agonists, 
dexamethasone and prednisone, suppress CRH and ACTH release, lowering the production of 
cortisol, DHEA(S) and C19 androgens (Sharifi & Auchus, 2012), and abiraterone, which forms an 
irreversible complex between the iron atom of the heme cofactor in the active site of CYP17A1 and 
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an azole nitrogen atom of the inhibitor (Potter, Banie, Jarman, & Rowlands, 1995), is currently the 
preferred therapeutic approach for the inhibition of androgen biosynthesis. 
 
Figure 3.12: Hypothalamic-pituitary-adrenal and –testicular axes and current pharmacologic inhibition 
mechanisms. Flat line ends indicate inhibitory action. The dotted line indicates that steroids but not GnRH 
analogues act on hypothalamus. Bold arrows indicate stimulation and thins arrows indicate synthesis. Block 
arrows indicate receptor activation. Reproduced with permission from (Sharifi & Auchus, 2012). 
Inherited genetic deficiencies in three genes have shown to impede or completely block normal 
prostate development. Firstly, mutations in HSD17B3, which encodes 17βHSD3, impair T 
biosynthesis in the fetal testes, resulting in female external genitalia (Andersson et al., 1996). 
Secondly, mutations in SRD5A2, which encodes the dominantly expressed SRD5A isoenzyme in 
normal prostate, causes pseudohermaphroditism and interfere with normal prostate development 
(Andersson et al., 1991; Hayward & Cunha, 2000). Thirdly, AR mutations that block activation and 
transcription – whether these affect the LBD or DBD – also suppress virilisation and normal 
prostate development (Mcphaul, 1999).  These genetic deficiencies yield irrefutable evidence for 
the requirement of the two biosynthetic steps for the biosynthesis of DHT, and of a nuclear 
receptor for the normal development of normal prostatic tissue (Sharifi & Auchus, 2012), while 
emphasizing DHT biosynthesis as a target for the treatment of PCa. Therefore apart from 
CYP17A1 inhibition, by abiraterone, the inhibition of other relevant enzymes will hamper CPRC 
progression. 
Lifestyle factors also need to be considered in the treatment of PCa as well as CRPC. These 
factors include: body size, physical activity, cardiovascular disease, smoking and diet (fig. 3.13). 
Diet may possibly prevent early onset of PCa development or curb the recurrence of PCa, due to 
possible gene-environment interactions, such as complex biological interactions among steroid 
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hormones, steroid-metabolizing enzymes, receptor proteins, and exogenous factors (Hsing et al., 
2002). 
 
Figure 3.13: Possible future research on hormones and PCa. This shows the possible role of HSD17B, 
SRD5A2 and the AR genes have to play in PCa development and the involvement of lifestyle factors, 
including diet. Reproduced with permission from (Hsing et al., 2002). 
Diet and lifestyle interventions in men with early-stage PCa have been shown to decrease PSA 
levels as well as the rate at which PSA levels increase. These interventions therefore provide 
some evidence that comprehensive lifestyle changes may have therapeutic potential in early PCas 
(Ornish et al., 2001; Ornish et al., 2005; Saxe et al., 2006). Following castration, a therapeutic 
approach employing AR antagonists and enzyme inhibitors combined with lifestyle changes may 
thus lend itself to greater success in the treatment of CRPC development and progression. 
3.9 Summary 
It is clear that the development of the prostate is controlled by steroid hormones with intricate 
pathways mediating steroid biosynthesis utilizing complex enzyme machinery to drive cell 
proliferation and growth. In the transition from PCa to CRPC, specific enzymes are up-regulated, 
the implication of which is evident in the survival benefit conferred by obstructing DHT biosynthesis 
through the inhibition of upstream enzymes. These findings constitutes the strongest clinical 
evidence implicating an important role of enzymatic changes in CRPC at the current time (Sharifi & 
Auchus, 2012). Although to date, certain treatment strategies employed are targeting enzymes, 
thus reducing active androgens, together with AR antagonists, CRPC remains a devastating 
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disease, and more advanced treatment is required. A therapeutical approach combining clinical 
treatment strategies targeting PCa and its progression with dietary and lifestyle changes may 
potentially have enhanced therapeutic applications. In this scenario, it may be possible to include 
rooibos in a dietary approach. As was discussed in the previous chapter, rooibos and polyphenol 
compounds have been shown to have anti-carcinogenic and antioxidant activities. In addition, 
rooibos has been shown to have an effect on steroid hormone dependent cancers, including PCa, 
in which polyphenols possibly exert androgenic or anti-androgenic effects via receptors. 
Owing to the central role prostatic enzymes play not only in the activation of steroids from the 
precursor androgen pool but also in the progression of PCa and the recurrence of PCa, it is thus 
important to investigate the effect of rooibos on 17βHSD and SRD5A enzymes which have been 
shown to play a prominent role in PCa in order to elucidate the anti-carcinogenic properties of 
rooibos. This investigation will be presented in chapter 4. 
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Chapter 4 
An investigation into the influence of rooibos on 17βHSD and SRD5A 
enzymes 
4.1 Introduction 
The production of active androgens in the prostate, is key to cell growth and proliferation, in both 
normal and PCa tissue (Sharifi & Auchus, 2012). Active androgens activate AR-dependent 
transcription subsequent to binding the AR and translocating into the nucleus. Androgen 
metabolism in the prostate is initiated by the uptake of circulating T from the testes, or by the 
uptake of circulating DHEA, A4 and T from the adrenals. DHEA is metabolised to A4 by 3βHSD2 
and the interconversion of A4 and T is subsequently catalysed by 17βHSDs (fig. 4.1 a). SRD5A1 
and SRD5A2 present in the prostate, convert both A4 and T to their 5α-reduced derivatives, with 
the preferred conversion of A4 to 5α-dione occurring in the „alternative‟ 5α-dione pathway (Chang 
et al., 2011; Sharifi, 2012), followed by the conversion of 5α-dione to DHT by 17βHSD3 or 
AKR1C3. DHT, the most potent androgen known to date, may bind the AR and activate AR-driven 
genes, or inactivating enzymes may metabolise DHT to 3α/β-adiol and DHT-G, respectively 
(Penning, 2010). 
  
Figure 4.1: Prostate androgen metabolism in (a) the C19 pathway; and (b) the 11OHA4 pathway. Boxed 
enzymes common to both pathways and shading indicates AR transactivation relative to that of 1 nM DHT.  
The 11OHA4 pathway which also contributes to prostate androgen metabolism was recently 
identified (Storbeck et al., 2013). While 11OHA4 is one of the major C19 steroid hormones 
Percentage agonist activity at 1 nM 
    61-90%  91-100%   
a b 
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produced by the adrenal (Rege et al., 2013), this pathway is also initiated by the uptake of other 
circulating adrenal androgens, 11KA4, 11OHT and 11KT. Together with the peripheral 
interconversion of 11OHA4 and 11KA4 as well as 11OHT and 11KT by 11βHSD, the conversion of 
these C11-hydroxy metabolites may also be catalysed by 11βHSD2 in the prostate (Swart et al., 
2013a). Similar to the C19 pathway, these metabolites may be further metabolised by SRD5A and 
17βHSD (fig. 4.1 b). Once the 5α-reduced steroid metabolites are produced, their metabolism by 
17βHSD and 11βHSD2 mimic that of their Δ4 parent compounds, and comparable to the 5α-dione 
pathway, both 11OHA4 and 11KA4 are preferred substrates for SRD5A. 11KT and its 5α -reduced 
form, the novel steroid 11KDHT, have been shown to have androgenic activity, with 11KDHT and 
11KT possessing agonist activity towards the AR comparable to that of DHT and T, respectively 
(fig. 4.1 a/b) (Storbeck et al., 2013). 
The peripheral metabolism of A4 to DHT, via the conventional C19 and „alternative‟ 5α-dione 
pathways, relies on the activity of 17βHSD and SRD5A (Chang et al., 2011) as does the peripheral 
metabolism of 11KA4 to 11KDHT via the 11OHA4 pathway. The 17βHSD enzymes act on 
androgens at their C17 position on the steroid nucleus, thereby modulating their potency, by 
allowing the interconversion between the active 17β-hydroxysteroids and less active 17-
ketosteroids (Gianfrilli et al., 2014). Both 17βHSD3 and AKR1C3 function primarily as reductases 
and convert the androgen precursor, A4, to T (Mindnich et al., 2004). Both 17βHSDs are 
expressed in normal and cancerous prostatic tissue, with reported up-regulation of AKR1C3 as 
PCa progresses (Fung et al., 2006; Lin et al., 2004; Luu-The et al., 2008; Mitsiades et al., 2012; 
Montgomery et al., 2008; Penning et al., 2006; Stanbrough et al., 2006). 17βHSD2, an oxidative 
17βHSD, converts the reverse reaction of 17-ketosteroids to 17β-hydroxysteroids, and is 
expressed in BPH (Gianfrilli et al., 2014) and reported in PCa cells, with the conversion of 
oestradiol to oestrone reported in LNCaP and PC-3 cells (Miettinen et al., 1996). SRD5As are 
enzymes that act upon C19 and C21 steroids that have double bonds between C4 and C5 on the 
steroid nucleus (Soronen et al., 2004), and thereby irreversibly reduce the double bonds of 
steroids, producing 5α-reduced steroids. Both isoforms SRD5A1 and SRD5A2 are expressed in 
peripheral tissue, such as the prostate and skin, with the up-regulation of SRD5A1 reported in PCa 
(Chang et al., 2011; Stanbrough et al., 2006; Titus et al., 2005). 
In recent years, diet and lifestyle interventions in men, with early-stage PCa, have been considered 
as a possible treatment strategy against PCa progression (Ornish et al., 2008). This has led to the 
attention being placed on the influence of, amongst others, polyphenolic compounds on 
steroidogenesis. Flavonoids are phenolic compounds characterized by their diaryl nucleus – 
mimicking the chemical structures of natural steroid hormones, hence the scientific interest in 
these compounds, and their potential application in the prevention of hormone-dependent cancers. 
The anti-cancer properties of flavonoids were already reported in 1980 when a significant reduction 
of mammary cancer by X-irradiation was demonstrated in rats fed a raw soybean diet. The study 
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reported 74% of the control rats, on a casein diet, developed tumours while only 44% of the 
experimental rats developed tumours (Troll et al., 1980). Furthermore, it has been shown in 83 
PCa patients that a higher intake of phytoestrogens, including isoflavones and flavonoids, had a 
moderate protective effect on PCa risk (Strom et al., 1999). Rooibos, a polyphenol-rich herbal tea 
produced from the South African fynbos plant Aspalathus linearis, has been previously shown to 
inhibit the steroid production in an adrenal cancer cell line and the catalytic activity of key enzymes 
involved in adrenal steroidogenesis, with specific rooibos flavonoids contributing to the inhibitory 
effects (Perold, 2009; Schloms et al., 2012; Schloms & Swart, 2014). As rooibos affects 
steroidogenic enzymes, rooibos may impact hormone driven cancers such as PCa, since PCa 
development is dependent on steroid hormone biosynthesis and subsequent steroid receptor 
activation. Particularly, the skin expresses steroidogenic enzymes, and is capable of in situ steroid 
biosynthesis (Slominski et al., 2007), with rooibos reported to slow down tumour growth and to 
decrease skin cancer tumour size (Marnewick et al., 2005). This anti-cancer effect may be linked to 
the inhibition of steroidogenic enzymes, possibly contributing to the mechanism of action. Although 
previous studies have investigated the inhibitory effect of rooibos on adrenal enzyme activities, the 
influence of rooibos on steroidogenic enzymes expressed in the prostate have not been 
addressed.  
The aim of this study was to determine the influence of rooibos on androgen biosynthesis 
catalysed by 17βHSD3, AKR1C3, 17βHSD2, SRD5A1 and SRD5A2, in transiently transfected 
CHO-K1, HEK293 and U2OS cell systems. In this study, the effect of rooibos on the conversion of 
A4 and 11KA4 by 17βHSD3 and AKR1C3 was investigated with 11OHA4 not being included as the 
steroid is not readily metabolised by either of the two enzymes (Storbeck et al., 2013; Swart et al., 
2013b). The conversion of T, 11KT and 11OHT by 17βHSD2 to their respective A4-metabolites in 
the presence of rooibos was also investigated. The 5α-reduction of A4 and T by SRD5A1 and 
SRD5A2, a prerequisite for the activation of androgens, was investigated in the presence of 
rooibos to determine the influence of rooibos on adrenal androgens activation. The metabolism of 
A4 and T was subsequently also assayed in PNT2 prostate cells in the presence of rooibos. 
Endogenous levels of SRD5A are greater than those of the 17βHSD isoforms, allowing analyses of 
5α-reduction of androgens in normal prostate cells in the presence of competing enzymes. In 
contrast, BPH-1 cells express higher 17βHSD levels compared to PNT2 cells, and therefore A4 
metabolism was assayed in BPH-1 cells to investigate the influence of rooibos on the metabolism 
of the steroid. In addition, the 17βHSD catalysed conversion of 11KA4 to 11KT was assayed in 
LNCaP, PC-3, BPH-1 and PNT2 prostate cells, in the presence of rooibos.  
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4.2 Materials and methods 
4.2.1 Materials 
Unfermented rooibos plant material was provided by the South African Rooibos Council (Rooibos 
LTD-BPK, Clanwilliam, South Africa). Steroid metabolites (T, A4, DHT, 5α-dione, AST and 3α-
adiol), Dulbecco‟s modified Eagle‟s Medium (DMEM), β-glucuronidase (Type VII-A from E.coli; 
5,292,000 units/g), Ham‟s F12K medium and RPMI-1640 medium were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Dutasteride was purchased from Sequoia Research Products Ltd. 
(Pangbourne, UK). 11KA4, 11KT, 11OHA4 and 11OHT were purchased from Steraloids (Wilton, 
USA). Nucleobond® Midiprep DNA isolation kits were purchased from Macherey-Nagel (Duren, 
Germany) and Corning®CellBIND® Surface 24-well plates were purchased from Corning® Life 
Sciences (NY, USA). CHO-K1 cells were a gift from Dr. Antonio Serafin (University of 
Stellenbosch, Tygerberg, South Africa), U2OS cells were donated by William E Rainey (University 
of Michigan, Ann Harbor, USA) and HEK293 cells were obtained from the American Type tissue 
Culture Collection (Manassas, VA, USA). PNT2, LNCaP and PC-3 cells were obtained from the 
Sigma‟s European Collection of Cell Cultures (St.  Louis, USA) and BPH-1 cells were a gift from 
Simon W Hayward (Vanderbilt University of Medical Center, Nashville, USA). Mirus TransIT®-LT1 
transfection reagent was purchased from Mirus Bio Corporation (Madison, WI, USA) and 
XtremeGene HP® DNA transfecting reagent was purchased from Roche Diagnostics (Mannheim. 
Germany). Penicillin-streptomycin, fetal calf serum, trypsin-EDTA and phosphate buffered saline 
(PBS) were obtained from Oxoid limited (Hampshire, England). Deuterated cortisol (9,11,12,12-D4-
cortisol) and deuterated testosterone (Testosterone 1,2-D2, 98%) were purchased from Cambridge 
isotopes (Andover, MA, USA). A bicinchoninic acid (BCA) protein determination kit was purchased 
from Pierce (Rockford, IL, USA) and trypan blue stain (0.4 %) together with cell count plates were 
purchased from Invitrogen (Eugene, USA). pH indicator strips (non-bleeding) were obtained from 
Merck (Darmstadt, Germany) and all other chemicals were of the finest quality and supplied by 
reliable scientific supply houses. 
4.2.2 Plasmid constructs 
17βHSD3 pcDNA3, AKR1C3 pcDNA3 and 17βHSD2 pcDNA4_mycHis_B, plasmid constructs were 
obtained from Prof J. Adamski (Institute of Experimental Genetics, Neuherberg, Germany). 
SRD5A1 and SRD5A2 pCMV7 plasmid constructs were a gift from Prof D.W Russell 
(Southwestern Medical School, University of Texas, Dallas, USA). The pCINeo plasmid was 
available for use in the laboratory. 
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4.2.3 Methanol extraction of unfermented rooibos 
A rooibos extract was prepared by extracting 20 g unfermented plant material with chloroform (200 
mL) for 8 h, followed by a methanol (200 mL) extraction for 8 h using a Soxhlet extractor fitted with 
a double-wall condenser as previously described (Schloms et al., 2012). The extract was dried at 
reduced pressure in a rotating evaporator and the vacuum released under nitrogen. The dried 
extract was redissolved in analytical quality deionised water (Milli-QTM water purification system), to 
a final concentration of 86 mg extract/mL and centrifuged at 10 000 x g for 5 min at 4°C. The 
supernatant was stored in 1 mL aliquots at -20°C. 
4.2.4 Identification and quantification of rooibos polyphenols 
Unfermented rooibos extracts were analysed using HPLC coupled to a diode-array-detector 
(HPLC-DAD) (Agilent 1200 series instrument) to identify and quantify polyphenolic compounds, as 
previously described (Beelders et al., 2012). The following standards were included: aspalathin, 
nothofagin, 3, 4 dihydroxybenzoic acid, caffeine acid, luteolin, vitexin, quercetin 3-β-D-glucoside, 
quercetin dehydrate, ferulic acid, rutin hydrate, syringic acid, vanillic acid and p-coumaric acid. 
Separation was achieved using a mobile phase consisting of (A) 2% acetic acid in water (v/v) and 
(B) acetonitrile. The instrument was equipped with a diode-array detector (standard 13 µL flow cell, 
10mm path length) controlled by Chemstation software (Agilent Technologies). 
4.2.5 Enzymatic assays in transiently transfected HEK293, CHO-K1 and U2OS cells 
Cells were grown in culture medium supplemented with 10% fetal bovine serum, 1.5 g NaHCO3/L 
(pH 7), and 1% penicillin-streptomycin at 37°C, 5.0% CO2 and 90% relative humidity. HEK293 and 
U2OS cells were grown in supplemented DMEM medium and CHO-K1 cells in supplemented 
Ham‟s F12K medium. After 3-5 passages confluent cells (80%) were plated into 24-well Corning® 
CellBIND® plates (2 x 10⁵ cells/mL, 0.5 mL/well) and incubated for 24 h. The cells were 
subsequently transiently transfected with the appropriate plasmid constructs, 0.5 µg, using the 
Mirus TransIT®-LT1/XtremeGene HP® DNA transfection reagent according to the manufacturer‟s 
instructions. pCIneo (Promega, Madison, USA), containing no insert cDNA, was included as a 
negative control in experiments. The cells were incubated for 72 h, after which 1 µM of the 
appropriate steroid substrates was added to the medium. Steroids dissolved in absolute ethanol (2 
mg/mL) were diluted in culture medium to the desired concentration. Steroid substrates were also 
added to the cells in the presence of unfermented rooibos extracts (4.3 mg/mL). Control assays 
included steroid conversion assays carried out in the presence of an inhibitor, dutasteride (10 µM), 
for SRD5A catalysed enzyme assays. After the appropriate incubation period medium (500 µL) 
was removed and the steroid metabolites were extracted by liquid-liquid extraction using 10:1 
volume of dichloromethane to culture medium. The samples were vortexed for 10 min, centrifuged 
at 3500 rpm for 5 min after which the media was aspirated and dichloromethane phase dried at 
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45°C under nitrogen. The dried steroid residue was redissolved in 150 µL methanol prior to 
analysis by UPLC-MS/MS.  
4.2.6 Steroid conversion assays in PNT2, BPH-1, LNCaP and PC-3 cells 
PNT2 cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum, 1.5 g 
NaHCO3/L (pH 7), 1% penicillin-streptomycin at 37°C, in an atmosphere of 90% humidity and 5% 
CO2. After 3-4 passages confluent cells were plated into 24-well plates (2 x 10
5 cells/mL, 0.5 
mL/well) and incubated for 48 h. The medium was removed and replaced with 0.5 mL RPMI-1640 
medium containing steroid substrates, A4, T and 11KA4 (1 µM). Steroids in absolute ethanol (2 
mg/mL) were diluted in culture medium to the desired concentration. Steroid substrates were also 
added to the cells in the presence of unfermented rooibos extracts (4.3 mg/mL). The cells were 
incubated for 48 h after which 0.5 mL aliquots were removed and steroid metabolites extracted, 
after β-glucuronidase treatment (4.2.9), as described above. Cortisol-D4 (15 ng) and testosterone-
D2 (15 ng), were added to each sample as internal standards. Control assays included steroid 
conversion assays carried out in the presence of dutasteride (10 µM). BPH-1 (growth and 
experimental medium, RPMI-1640), PC-3 (growth and experimental medium, Ham‟s F12K) and 
LNCaP (growth and experimental medium, RPMI-1640) cells were cultured and replated using the 
same experimental protocols. Steroid conversion assays were also conducted in the same manner 
as the assays conducted in PNT2 cells. 
4.2.7 Cell viability 
The trypan blue exclusion assay was used in this study to assess the influence of unfermented 
rooibos extracts on cell viability. Polyphenolic compounds have been shown to interfere with 3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide in the MTT cell viability assay which is 
commonly used to assay cell viability (Wisman, Perkins, Jeffers, & Hagerman, 2008). In order to 
exclude the possible interference by the polyphenolic compounds found in the rooibos extracts, a 
trypan blue exclusion method was thus used which allows the analysis of live cells, non-viable cells 
and total cells and expresses the % of viable cells in the total number of cells counted. Following 
steroid conversion assays in cells trypsin-EDTA (0.5 mL) was used to collect the cells. The cells of 
each well were pipetted into individual micro-centrifuge tubes and centrifuged at 13,000 x g for 10 
min using a bench-top centrifuge (HeraeusTM BiofugeTM, Thermo Scientific, USA). The trypsin-
EDTA was aspirated and the cell pellet was redissolved in PBS (10 mM phosphate buffer, pH 7.4, 
containing 137 mM NaCI and 2.7 mM KCL) (250 µL). Cell counts were subsequently carried out, 
with 10 µL of cell solutions to which 10 µL trypan blue stain were added, using the Countess® 
automated cell counter (Invitrogen, Eugene, USA).  
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4.2.8 Protein determination 
On the completion of steroid conversion assays, cells collected in PBS, were centrifuged at 13,000 
x g for 10 min using a bench-top centrifuge (HeraeusTM BiofugeTM, Thermo Scientific, USA), the 
PBS aspirated, the cells lysed with 50 µL passive lysis buffer (Promega, Madison, USA) and stored 
at -20°C overnight, prior to determining the protein concentration. Samples included the bovine 
serum albumin (BSA) protein standards 1 mg/mL, 0.75 mg/mL and 0.5 mg/mL prepared in PBS, 
together with the same BSA standards prepared with rooibos extract 1 mg/mL and 4.3 mg/mL 
(according to the manufacturer‟s instructions). PBS was added to BSA s tandards to compensate 
for the volume in which rooibos was added. Samples were analysed using the standard BSA curve 
generated by the Pierce BCA method (Pierce Chemical, Rockford, USA) according to the 
manufacturer‟s instructions. 
4.2.9 β-glucuronidase assay 
Utilization of UPLC-MS/MS to separate and detect steroids allows only the identification of 
unconjugated or free steroids. Therefore, in order to analyse total (free + conjugated) steroids 
present in the media, a β-glucuronidase assay was conducted, according to the manufacturer‟s 
instructions. Following steroid conversion assays in prostate cells, aliquots (0.5 mL) were collected 
and the pH adjusted to 6.5 by the addition of 1% acetic acid (± 20 µL). The samples were 
subsequently treated with 400 units (76 µL) of β-glucuronidase (E.coli Type VII-A; Sigma-Aldrich) 
at 37°C for 24 h to deconjugate steroids prior to liquid-liquid extraction, as described above. 
4.2.10 Separation and quantification of steroid metabolites using UPLC-MS/MS 
Stock solutions of A4, 11OHA4, 11KA4, T, 11OHT, 11KT, DHT, 5α-dione, AST and 3α-adiol were 
dissolved in ethanol (2 mg/mL). A series of standards (0.2 - 20 ng/mL) were prepared in methanol 
using stock solutions.  
Steroid metabolites were separated by UPLC (ACQUITY UPLC, Waters, Milford, USA) using a 
Phenomenex UPLC Kinetex PFP column (2.1 mm x 100 mm, 2.6 µm) (Torrance, CA, USA) as 
previously described (Storbeck et al., 2013). Briefly, the mobile phases consisted of 1% formic acid 
(A) and 49%: 49%: 2% methanol: acetonitrile: isopropanol (B). Steroids were eluted at a flow rate 
of 0.4 mL/min and the injection volume was 5 µL and the total run time was 5 min per sample 
injection. A Xevo triple quadrupole mass spectrometer (Waters, Milford, USA) was used for 
quantitative mass spectrometric detection and all steroids were analysed in multiple reaction 
monitoring (MRM) mode. An electrospray in the positive ionization mode (ESI+) was utilized in the 
MRM mode. The capillary voltage of 3.5 kV, cone voltage of 15-35 V and collision energy of 4-36 
eV was set during this quantification. The following settings were used: source temperature 120°C, 
desolvation temperature 400°C, desolvation gas 900 L h-1 and cone gas 50 L h-1. Calibration 
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curves were constructed using weighted (1/x2) linear least squares regression and the data was 
collected with the MassLynx 4.1 software program. 
4.2.11 Statistical analysis 
All experiments were performed in triplicate and the subsequent results are given as means ±SEM. 
Statistics were calculated by an unpaired t-test or by a one-way ANOVA, followed by a Dunnett‟s  
multiple comparison test using GraphPad Prism (version 5) software (GraphPad Software, San 
Diego, California). Differences were considered statistically significant at P<0.05. 
4.3 Results 
Although it has been firmly established by earlier studies that rooibos inhibits adrenal steroidogenic 
enzymes and modulates adrenal steroidogenesis, effects of rooibos on steroid metabolism in the 
prostate has not been investigated.  
4.3.1 Analysis of methanolic extracts of unfermented rooibos 
The methanolic extract of unfermented rooibos used in in vitro experiments was analysed for 
polyphenols using HPLC-DAD as previously described (Beelders et al., 2012). Quantification of the 
major polyphenolic compounds (table 4.1) showed that, per gram of unfermented rooibos plant 
material, the dihydrochalcones were the most abundant flavonoids present in the extract, with 
aspalathin being ±5-fold higher than nothofagin. Isoorientin and orientin levels were higher than 
vitexin and isovitexin. The rutin isomer, quercetin-3-O-robinobiocide was present at levels 2-fold 
higher than rutin.  
Table 4.1: Major polyphenolic compounds (µg) present in the methanolic extract of unfermented rooibos 
plant material and in the extract administered to cells (per mL media and µM) 
Flavonoid 
compounds 
Rooibos
a) 
Cells Cells 
1 mg/mL µM 4.3 mg/mL µM 
Aspalathin 20 150.7 ± 424.0 68.5 ± 1.4 151.50  294.7 ± 6.2 651.46 
Nothofagin      4255.5 ± 61.8 14.5 ± 0.2  33.17 62.2 ± 0.9 142.62 
Isoorientin      2671.5 ± 65.7 9.1 ± 0.2  20.26 39.1 ± 1.0 87.14 
Orientin      2043.2 ± 44.7  6.9 ± 0.2  15.50  29.9 ± 0.7 66.65 
Quercetin-3-
robinobioside 
       958.0 ± 17.2  3.3 ± 0.1  5.34 14.0 ± 0.3 22.95 
Rutin      528.2 ± 7.8  1.8 ± 0.0 2.94 7.7 ± 0.1 12.65 
Isovitexin        485.4 ± 59.5 1.7 ± 0.2   3.82 7.1 ± 0.9 16.42 
Vitexin        404.9 ± 25.1  1.4 ± 0.1  3.18 5.9 ± 0.4 13.69 
Values are expressed as the mean ±SEM (n=6). 
a) Flavonoids (µg) extracted from 1 g unfermented rooibos leaves. 
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The final concentration of these compounds ranged from 12 µM to 652 µM in the media to which 
4.3 mg/mL rooibos extract was administered to the cells. 
4.3.2 The influence of unfermented rooibos extracts on cell viability 
Cell viability was determined using the trypan blue exclusion method, following steroid conversion 
assays in CHO-K1, COS-1, HEK293 and LNCaP cells. The influence of rooibos (4.3 mg/mL) on 
cell viability of CHO-K1 and COS-1 cells was assayed after 3 h and 8 h, and 3 h and 6 h, 
respectively (fig. 4.2 a/b). The addition of rooibos did not result in a significant decrease in cell 
viability, with viability in both cell lines remaining at ±90% in the absence (control) and presence of 
rooibos extract. 
 
Figure 4.2: Viable cell count in the absence and presence of rooibos: (a) CHO-K1 cells at 3 h and 8 h, and 
(b) COS-1 cells at 3 h and 6 h, after substrate conversion assays in the absence (control) and presence of 
rooibos extract (4.3 mg/mL). Results are expressed as the mean ±SEM (a: n=3, b: n=2, ns=not significant). 
Following the investigation in CHO-K1 and COS-1 cells, the influence of rooibos (4.3 mg/mL) on 
cell viability of HEK293 cells were investigated to obtain a time course analysis of a range of 
experimental time intervals within 48 h (fig. 4.3). At 1 h, 2 h, 4 h and 6 h, the addition of rooibos did 
not result in a significant decrease in cell viability, with viability detected at ±80%. At 12 h, however, 
rooibos resulted in a decrease in viability (±10%). Although rooibos did not result in a significant 
decrease in viability, compared to the control, cell viability had decreased to ±70% after 24 h and 
48 h. 
a b 
Stellenbosch University  https://scholar.sun.ac.za
58 
 
 
Figure 4.3: Viable HEK293 cell count in the absence and presence of rooibos. Cells were exposed for 48 h 
to rooibos extract (4.3 mg/mL). Results are expressed as the mean ±SEM (1 h, 4 h, 6 h: n=3, 2 h: n=2, 12 h, 
24 h, 48 h: n=1, ns=not significant). 
Based on the above results, assays in CHO-K1, COS-1 and HEK293 cells were thus restricted to 
shorter incubation periods to limit exposure to rooibos. However, steroid conversion assays in 
prostate cell model systems were undertaken for longer incubation periods, such as 48 h and 96 h, 
which are commonly used experimental periods, enabling the determination of cellular effects. 
Therefore, the influence of rooibos on cell viability was determined in LNCaP cells after 48 h and 
96 h (fig. 4.4). The addition of rooibos extract (4.3 mg/mL) did not significantly decrease the cell 
viability after 48 h with viability remaining ±80%. Assays conducted for longer periods also showed 
that rooibos did not influence cell viability at 1 mg/mL or 4.3 mg/mL which remained at ±80% after 
96 h. 
 
Figure 4.4: Viable LNCaP cell count in the absence and presence of rooibos. Cells were exposed for 48 h 
to rooibos extract (4.3 mg/mL) and for 96 h to rooibos extract (1 mg/mL
a
 and 4.3 mg/mL
b
). Results are 
expressed as the mean ±SEM (48 h: n=3, 96 h: n=1, ns=not significant). 
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The influence of unfermented rooibos extracts on protein levels 
A protein determination assay was completed using the Pierce BCA method following steroid 
conversion assays. During the duration of this study multiple protein determination assays were 
completed, with results showing possible interference of rooibos with the assay (data not shown). 
Therefore, a control analysis was designed and completed to investigate whether rooibos 
interferes with the Pierce BCA method. The addition of rooibos (1 mg/mL and 4.3 mg/mL) resulted 
in a significant increase in protein concentration determined by the method used (fig. 4.5), and 
rooibos at 4.3 mg/mL interfered significantly more compared to rooibos at 1 mg/mL. 
 
 
 
 
Figure 4.5: Protein determination in the absence and presence of rooibos: (a) BCA protein standard (1 
mg/mL); (b) BCA protein standard (0.75 mg/mL); and (c) BCA protein standard (0.5 mg/mL) in the presence 
of rooibos (1 mg/mL
a
 and 4.3 mg/mL
b
). The experiment was performed in triplicate and data was compared 
as shown and analysed by an unpaired t-test. Results are expressed as the mean ±SEM (***P<0.001, n=3). 
The BSA method determines total protein levels and incorporates proteins from both live and non-
viable cells. Cell viability was therefore chosen as a parameter to normalise data to and to 
determine the effect of rooibos on cell integrity. 
Having established the effect of rooibos on cell viability, the effect of rooibos on prostate androgen 
metabolism, and in particular, on androgen production by 17βHSD3, AKR1C3, 17βHSD2, SRD5A1 
and SRD5A2 was subsequently investigated. 
4.3.3 UPLC-MS/MS analyses of steroid metabolites 
The steroids of interest were analysed by UPLC-MS/MS with the C19 steroids in the conventional 
C19 pathway (A4, T, 5α-dione, DHT, AST and 3α-adiol) and the internal standard, D2-testosterone 
(fig. 4.6) and the C19 steroids in the 11OHA4 pathway (11OHA4, 11OHT, 11KA4 and 11KT) 
together with the internal standard, D2-testosterone (fig 4.7). The separation was achieved in a 
single chromatographic step, without prior derivatisation, which allowed the efficient separation and 
quantification of steroids. 
a b c 
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Figure 4.6: UPLC-MS/MS chromatographic separation of A4, T, DHT, 5α -dione, AST, 3α-adiol and the 
internal standard, D2-testosterone are shown. Retention times are indicated on the chromatograms of 
steroid metabolites (5 µL of a 20 ng/mL standard solution) shown in mul tiple reaction monitoring (MRM) 
mode. 
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The chromatographic separation of A4 and T allowed the analyses of the 17βHSD catalysed 
reactions, while the separation of T, DHT, A4 and 5α-dione, allowed the analyses of the SRD5A 
catalysed reactions. In this study the metabolism of the C19 steroids in PNT2 and BPH-1 cells was 
also investigated and therefore necessitated analyses of the downstream metabolites 3α -adiol and 
AST produced by AKR1C2 (fig. 4.6). 
 
 
 
Figure 4.7: UPLC-MS/MS chromatographic separation of 11OHA4, 11KA4, 11OHT, 11KT and the internal 
standard, D2-testosterone are shown. Retention times are indicated on the chromatograms of steroid 
metabolites (5 µL of a 20 ng/mL standard solution) shown in multiple reaction monitoring (MRM) mode.  
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In addition, the quantification of 11OHA4, 11OHT, 11KA4 and 11KT (fig. 4.7) also enabled further 
analyses of the conversions of the C11-keto and C11-hydroxy derivatives of A4 and T, catalysed 
by both reductive and dehydrogenase activities of the 17βHSDs. In order to minimize possible 
cross-talk between steroids the separation of the C19 steroids in the 11OHA4 pathway were 
analysed on a separate method (7.2.10) to the C19 steroids in the conventional C19 pathway. 
4.3.4 The influence of unfermented rooibos extracts on 17βHSD isoforms 
Conversion of A4 and 11KA4 in CHO-K1 cells in the presence of rooibos 
The investigation of the conversion of A4 and 11KA4 to T derivatives, by 17βHSD3 and AKRIC3 
was initially examined in the presence of rooibos extracts (4.3 mg/mL) in CHO-K1 cells. While 
CHO-K1 cells are considered to be a non-steroidogenic cell model, 17βHSD1 and 17βHSD7 are 
expressed endogenously. These enzymes function primarily as reductases, converting A4 to T 
(Peltoketo, Luu-The, Simard, & Adamski, 1999; Y. Zhang, Word, Fesmire, Carr, & Rainey, 1996), 
and may therefore also catalyse the conversion of 11KA4.  
The data shows that in untransfected CHO-K1 cells, 20% A4 was metabolised to T in 8 h (fig. 4.8 
a/b), while the conversion of 11KA4 yielded 15% 11KT after 3 h (fig. 4.9 a/b), demonstrating the 
ability of endogenous 17βHSDs to metabolise the C11-keto C19 steroid. The influence of rooibos 
on endogenous activity of the 17βHSDs was subsequently assayed (fig. 4.8 a/b and fig. 4.9 a/b). 
Rooibos resulted in a significant reduction in the production of T and 11KT from A4 and 11KA4, 
respectively.  
Having establishing the endogenous 17βHSD activity in the CHO-K1 cell line, 17βHSD3 and 
AKR1C3 were expressed in CHO-K1 cells and the catalytic activity towards A4 and 11KA4 
assayed. The expression of 17βHSD3 resulted in 35% A4 being converted to T in 8 h (fig. 4.8 a) 
and 22% of 11KA4 being converted to 11KT in 3 h (fig. 4.9 a). The expression of AKR1C3 yielded 
comparable results when A4 was assayed and yielded 40% T (fig. 4.8 b), however, AKR1C3 
demonstrated significantly greater activity towards 11KA4 than 17βHSD3, resulting in 80% 11KT 
being produced after 3 h (fig. 4.9 b). Interestingly, 17βHSD3 only catalysed the conversion of 20% 
11KA4 (fig. 4.9 a). In the presence of rooibos, significant inhibition (25%) was detected in the levels 
of 11KT with only 55% 11KT being produced by AKR1C3 after 3 h (fig. 4.9 b). The catalytic activity 
of 17βHSD3 towards 11KA4 was low and as such the effect of rooibos was detected at negligible 
levels (±5% inhibition) (fig. 4.9 a). For both 17βHSD3 and AKR1C3 expressed in CHO -K1 cells, 
±15% inhibition was detected when A4 was added as substrate in the presence of rooibos 
(fig. 4.8 a/b). 
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Figure 4.8: A4, 1 µM, conversion in CHO-K1 cells in the absence (control) and presence of rooibos extract 
(4.3 mg/mL) after 8 h: (a) expressed 17βHSD3 activity in transiently transfected cells (light grey) and 
endogenous 17βHSD activity (dark grey); and (b) expressed AKR1C3 activity in transiently transfected cells 
(light grey) and endogenous 17βHSD activity (dark grey). The experiment was performed in triplicate and the 
data was compared as indicated, analysed by an unpaired t-test. Results are expressed as the mean ±SEM 
(*P<0.05, **P<0.01, n=3). 
 
 
Figure 4.9: 11KA4, 1 µM, conversion in CHO-K1 cells in the absence (control) and presence of rooibos 
extract (4.3 mg/mL) after 3 h: (a) expressed 17βHSD3 activity in transiently transfected cells (light grey) and  
endogenous 17βHSD activity (dark grey); and (b) expressed AKR1C3 activity in transiently transfected cells 
(light grey) and endogenous 17βHSD activity (dark grey). The experiment was performed in triplicate and the 
a b 
a b 
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data was compared as indicated, analysed by an unpaired t-test. Results are expressed as the mean ±SEM 
(*P<0.05, ***P<0.001, n=3). 
Following the initial studies into the conversion of A4 and 11KA4 to T derivatives, by endogenous 
and heterologously expressed 17βHSD3 and AKR1C3 in CHO-K1 cells, further investigations were 
conducted in HEK293 cells, which do not express endogenous 17βHSDs. In order to fully 
investigate the influence of rooibos on the catalytic activity of 17βHSD3 and AKR1C3 it was 
necessary to conduct enzymatic assays in cells in which endogenous 17βHSD activity would not 
interfere with the experimental parameters. Although, endogenously expressed SRD5A2 have 
been reported in the HEK293 cell model (Panter, Jose, & Hartmann, 2005), a time course analysis 
of the conversion of A4 and 11KA4 in the presence of rooibos was nevertheless completed in 
HEK293 cells transiently transfected with 17βHSD3 and AKR1C3. Furthermore, these assays 
could also indicate possible inhibition of SRD5A2 by rooibos. 
Conversion of A4 and 11KA4 in the presence of rooibos in HEK293 cells heterologously 
expressing 17βHSD3 
The influence of rooibos extracts (4.3 mg/mL) on the conversion of A4 and 11KA4 to T and 11KT, 
respectively, was investigated in HEK293 cells transiently transfected with 17βHSD3. Rooibos 
inhibited the conversion of A4 to T by 17βHSD3 significantly (fig. 4.10 b), with T levels only 
reaching 61% after 6 h, compared to 92% A4 conversion detected in the control (fig. 4.10 a). 
Rooibos resulted in the decreased metabolism of A4 with 50% conversion to T, detected at ±4.5 h 
in the presence of rooibos compared to 50% conversion to T detected at ±1.8 h in the control 
assay. Significant inhibition of the conversion of A4 to T by 17βHSD3 was detected over the time 
period showing efficient modulation of 17βHSD3 activity by rooibos. 
 
Figure 4.10: Time course of A4, 1 µM, conversion to T by (a) 17βHSD3 expressed in transiently 
transfected HEK293 cells; and (b) 17βHSD3 expressed in transiently transfected HEK293 cells in the 
presence of rooibos extract (4.3 mg/mL). The experiment was performed in triplicate and is expressed as the 
mean ±SEM.  
a b 
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No substrate conversion was detected in untransfected HEK293 cells. 
The conversion of 11KA4 to 11KT by 17βHSD3 was also significantly inhibited in the presence of 
rooibos (fig. 4.11 b). A ±33% inhibition resulted in a conversion only reaching 65.7% after 6 h, 
compared to 98.3% 11KT being detected after 6 h in the control assay (fig. 4.11 a). Rooibos 
decreased the rate of 11KA4 metabolism to 11KT, as 50% conversion to 11KT was detected at 
±4 h in the presence of rooibos, compared to 50% conversion to 11KT detected at ± 1.5 h in the 
control assay. A significant inhibition of the conversion of 11KA4 to 11KT by 17βHSD3 was 
detected throughout the assay period, showing similar modulation of 17βHSD3 activity towards 
11KA4 by rooibos. 
 
Figure 4.11: Time course of 11KA4, 1 µM, conversion to 11KT by (a) 17βHSD3 expressed in transiently 
transfected HEK293 cells; and (b) 17βHSD3 expressed in transiently transfected HEK293 cells in the 
presence of rooibos extract (4.3 mg/mL). The experiment was performed in triplicate and is expressed as the 
mean ±SEM. 
No substrate conversion was detected in untransfected HEK293 cells. 
Conversion of A4 and 11KA4 in the presence of rooibos in HEK293 cells heterologously 
expressing AKR1C3 
The influence of rooibos extracts (4.3 mg/mL) on the conversion of A4 and 11KA4 to T and 11KT, 
respectively, was investigated in HEK293 cells transiently transfected with AKR1C3. In initial A4 
conversion assays in HEK293 cells, low T levels were detected even after 24 h (data not shown). 
The conversion of A4 was therefore assayed for a longer period, up until 48 h. As the 
investigations above (4.3.2) showed cell viability to be compromised during long incubation 
periods, the data presented below were normalised. In the presence of rooibos, the conversion of 
A4 to T by AKR1C3 was significantly inhibited, with the levels of T formation at ±19% after 48 h in 
the presence of rooibos (fig. 4.12 b), compared to ±47% in the control assay without rooibos (fig. 
4.12 a). These results were normalised to 70% cell viability, compensating for the effect of rooibos 
on cell viability, clearly indicating a significant inhibition of ±1.5%, ±6%, ±14% and ±28% of 
AKR1C3 by rooibos at 6 h, 12 h, 24 h and 48 h, respectively. 
a b 
b 
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Figure 4.12: Time course of A4, 1 µM, conversion to T by (a) AKR1C3 expressed in transiently transfected 
HEK293 cells; and (b) AKR1C3 expressed in transiently transfected HEK293 cells in the presence of rooibos 
extract (4.3 mg/mL). The experiment was performed in triplicate and is expressed as the mean ±SEM (n=3). 
No substrate conversion was detected in the assay in which HEK293 cells were transfected with 
pCIneo containing no insert cDNA. 
The conversion of 11KA4 to 11KT by AKR1C3 was significantly inhibited (2-fold) in the presence of 
rooibos (fig. 4.13 b). While 77% of the substrate was converted in the absence of rooibos 
(fig. 4.13 a), only 36% 11KA4 was converted after 6 h when assayed in the presence of rooibos. 
Rooibos decreased the rate 11KA4 is metabolised to 11KT, as 50% conversion to 11KT at ±3 h 
was detected in the control assay, however, in the presence of rooibos 11KA4 did not reach 50% 
conversion to 11KT. A significant inhibition of the conversion rate of 11KA4 to 11KT by AKR1C3 
was detected as observed during the assay period, showing ±11%, ±26%, ±34% and ±42% 
inhibition of AKR1C3 activity towards 11KA4 by rooibos at 1 h, 2 h, 4 h and 6 h, respectively. 
 
Figure 4.13: Time course of 11KA4, 1 µM, conversion to 11KT by (a) AKR1C3 expressed in transiently 
transfected HEK293 cells; and (b) AKR1C3 expressed in transiently transfected HEK293 cells in the 
presence of rooibos extract (4.3 mg/mL). The experiment was performed in triplicate and is expressed as the 
mean ±SEM (n=3). 
No substrate conversion was detected in the assay in which HEK293 cells were transfected with 
pCIneo containing no insert cDNA. 
a b 
a 
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Conversion of T, 11KT and 11OHT in the presence of rooibos in HEK293 cells heterologously 
expressing 17βHSD2 
The influence of rooibos extract (4.3 mg/mL) on the catalytic activity of 17βHSD2 was investigated 
in HEK293 cells. In the presence of rooibos, the conversion of T, 11OHT and 11KT to A4, 11OHA4 
and 11KA4, respectively, by 17βHSD2 was significantly inhibited (fig. 4.14). Results showed ±13% 
inhibition of T conversion to A4, ±27% inhibition of 11OHT conversion to 11OHA4 and ±36% 
inhibition of 11KT conversion to 11KA4 after 12 h. Significant inhibition of the conversion of T-
metabolites to A4-metabolites by 17βHSD2 show efficient modulation of the catalytic activity of 
17βHSD2 by rooibos. Interestingly, these data show that while the lowest inhibition was detected 
with T as substrate, inhibition of the C11-keto C19 steroid was greater than that of the C11-hydroxy 
C19 steroid. Furthermore, these results demonstrate the ability of 17βHSD2 to metabolise the 
C11-keto as well as C11-hydroxy C19 steroids, compared to 17βHSD3 and AKR1C3 which are 
unable to metabolise the C11-hydroxy C19 steroid, 11OHA4, while readily catalysing the 
conversion of 11KA4. 
 
Figure 4.14: T, 11OHT and 11KT, 1 µM, conversions catalysed by 17βHSD2 in transiently transfected 
HEK293 cells in the absence (control) and presence of rooibos (4.3 mg/mL) after 12 h. The experiment was 
performed in triplicate and data was compared as shown and analysed by an unpaired t-test. Results are 
expressed as the mean ±SEM (**P<0.01, ***P<0.001, n=3). 
No endogenous conversion of T, 11OHT and 11KT in untransfected HEK293 cells were detected. 
Endogenous conversions of substrates by SRD5A in HEK293 cells were negligible, and the 
influence of rooibos on SRD5A could therefore not be determined. SRD5A1 was subsequently 
transiently transfected in U2OS cells to determine the influence of rooibos on SRD5A1. 
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4.3.5 The influence of unfermented rooibos extracts on SRD5A isoforms 
Conversion of T to DHT in the presence of rooibos in U2OS cells heterologously expressing 
SRD5A1 
The effect of rooibos (4.3 mg/mL) on the catalytic activity of SRD5A1 was determined and 
compared to that of dutasteride (10 µM), a dual inhibitor of SRD5A1 and SRD5A2. The activity of 
SRD5A1 towards T (1 µM) was assayed in U2OS cells transiently transfected with SRD5A1. After 
4 h, inhibition of T was minimal in the presence of rooibos, with 88.4% DHT being formed 
compared to the control, in which 92% of the substrate was converted to DHT (fig. 4.15). No DHT 
was detected in the presence of dutasteride. 
 
Figure 4.15: T, 1 µM, conversion by SRD5A1 in transiently transfected U2OS cells after 4 h. Assays were 
conducted in the presence of rooibos extract (4.3 mg/mL), and dutasteride (10 µM). The experiment was 
performed in triplicate and data was compared as shown and analysed by an unpaired t-test. Results are 
expressed as the mean ±SEM (*P<0.05, n=3). 
A control assay was included in which U2OS cells were transfected with a vector containing no 
insert cDNA. No conversion of T to DHT was detected, and minimal conversion of T to A4 (2%) 
detected. Interestingly, while U2OS cells are reported to be non-steroidogenic, data showed that 
these cells express endogenous 17βHSD activity, functioning primarily as reductases, converting 
A4 to T (data not shown).  
Following the initial investigation above, the investigation was continued in HEK293 cells, 
expressing no endogenous 17βHSDs, however, SRD5A2 has been reported to be endogenously 
expressed in these cells (Panter et al., 2005). The conversion of substrates A4 and T to 5α-
reduced derivatives by endogenous SRD5A2 was therefore monitored throughout. In order to 
investigate the influence of rooibos on the catalytic activity of SRD5As, a time course analysis, was 
carried out in HEK293 cells transfected with both SRD5A1 and SRD5A2. 
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Conversion of A4 and T in the presence of rooibos in HEK293 cells heterologously expressing 
SRD5A1 
Enzymatic assays were carried out in transiently transfected HEK293 cells to investigate whether 
rooibos influences the catalytic activity of SRD5A1 towards A4 and T. After 2 h full conversion of 
A4 and T to 5α-dione and DHT respectively, was detected, indicative of the efficiency of this 
enzyme (fig. 4.16 a/b). Rooibos (4.3 mg/mL) did not inhibit SRD5A1 and had no effect on the 
conversion rate of these substrates over the time course, as the data show 50% substrate 
conversion at 20 and 30 min in the absence and presence of rooibos for A4 and T conversions, 
respectively. 
  
Figure 4.16: Time course of substrate conversion (1 µM) by SRD5A1 in transiently transfected HEK293 
cells: (a) conversion of A4 as substrate (control) in the presence of rooibos extract (4.3 mg/mL); and (b) 
conversion of T (1 µM) as substrate (control) in the presence of rooibos extract (4.3 mg/mL) after 2 h. The 
experiment was performed in triplicate and is expressed as the mean ±SEM (n=3). 
The production of 5α-dione and DHT by SRD5A1 in the presence of dutasteride (10 µM) was also 
assayed. No 5α-dione or DHT were detected after 2 h (data not shown). In untransfected HEK293 
cells no significant conversions of A4 and T to 5α-reduced steroids were detected. 
Conversion of T in the presence of rooibos in HEK293 cells heterologously expressing SRD5A2 
The effect of rooibos was also investigated on SRD5A2 activity towards T, assayed in transiently 
transfected HEK293 cells. Although rooibos initially appears to inhibit the activity of SRD5A2, 
inhibition after 2 h is not significant (fig. 4.17 b). The trend observed suggests that rooibos may 
affect the rate of substrate conversion as 50% T conversion was reached after 90 min in the 
control assay with the substrate conversion being less than 40% in the presence of rooibos 
(fig. 4.17 a). This aspect will, however, need to be investigated in future studies.  
a b 
b 
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Figure 4.17: Time course of T, 1 µM, conversion to DHT by: (a) SRD5A2 expressed in transiently 
transfected HEK293 cells; and (b) SRD5A2 expressed in transiently transfected HEK293 cells in the 
presence of rooibos extract (4.3 mg/mL). The experiment was performed in triplicate and is expressed as the 
mean ±SEM (n=3). 
The conversion of T to DHT was also assayed in untransfected HEK293 cells and no SRD5A 
activity was detected. 
4.3.6 The influence of unfermented rooibos extracts on androgen metabolism in prostate 
cells 
A4 and T metabolism in PNT2 cells in the presence of rooibos 
The conversion of A4 and T was assayed in PNT2 cells in the presence of rooibos extracts 
(4.3 mg/mL) to determine the effect on the conversion by endogenous SRD5A in the normal 
cellular milieu. On completion of the assay metabolites were deconjugated after which total (free + 
conjugated) steroid metabolites were analysed. After 48 h, 70% of the A4 assayed had been 
metabolised to downstream products. The major products formed were 5α-dione (0.36 µM) and 
0.09 µM AST with 0.3 µM A4 remaining (fig. 4.18). Minimal conversion of A4 to T (0.05 µM) was 
detected, together with negligible levels of DHT (0.02 µM) and 3α-adiol (0.008 µM) being formed 
(fig. 4.18). However, the levels of latter two metabolites fell below the limit of quantification (LOQ) 
and the influence of rooibos on these steroid metabolites could therefore not be assessed. In the 
presence of rooibos, A4 metabolism yielded similar levels of 5α-dione (0.33 µM), indicating that 
rooibos did not influence the activity of SRD5A2, with the increased A4 levels indicative of AKR1C3 
inhibition. The levels of AST and T were markedly lower, with both being detected at 0.02 µM, 
indicating that rooibos not only inhibited AKR1C3 but may also have affected the activity of 
downstream AKR1C2 activity (fig. 4.18). 
a 
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Figure 4.18: A4, 1 µM, metabolism in PNT2 cells in the absence and presence of rooibos (4.3 mg/mL) after 
48 h. Patterned bars represent steroid substrate. The experiment was performed in triplicate and the data 
compared and analysed as shown by an unpaired t-test. Results are expressed as the mean ±SEM 
(**P<0.01, ***P<0.001, ns=not significant, n=3). 
The metabolism of T (±20%) was significantly lower than that of A4. Although 0.8 µM T remained, 
DHT (0.07 µM) and A4 (0.0354 µM) were detected together with negligible levels of 5α-dione, AST 
and 3α-adiol (fig. 4.19). Interestingly, in the metabolism of A4, 50% was converted to 5α-dione 
while in the case of T metabolism only 17% was converted to DHT indicating that SRD5A2 
preferentially catalyses the conversion of A4 over T. In addition it would appear that 17βHSD2 
activity is low in PNT2 cells since only ±10% was converted to A4. In the presence of rooibos T 
metabolism yielded 0.05 µM DHT and negligible levels of A4 and 5α-dione, indicating that rooibos 
influenced the endogenous conversion of T by SRD5A2 and 17βHSD. While ±35% of the 
metabolised T was detected as DHT, only 25% was detected in the presence of rooibos (fig. 4.19). 
Similar reduced levels were also detected in the presence of rooibos in HEK293 cells transiently 
expressing SRD5A2 (4.3.5). The reduced conversion of T to A4 detected in the presence of 
rooibos, denotes the inhibition of dehydrogenase activity of 17βHSDs activity. The influence of 
rooibos on 3α-adiol, 5α-dione and AST levels could not be assessed, as their levels were below 
the LOQ. 
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Figure 4.19: T, 1 µM, metabolism in PNT2 cells in the absence and presence of rooibos (4.3 mg/mL) after 
48 h. Patterned bars represent steroid substrate. The experiment was performed in triplicate and the data 
compared and analysed as shown by an unpaired t-test. Results are expressed as the mean ±SEM 
(**P<0.01, ***P<0.001, ns=not significant, n=3). 
In this study unconjugated and total steroids were analysed, following the deconjugation by β -
glucuronidase of steroid metabolites. The data showed no difference in the levels detected, 
indicating that steroids were not conjugated. Therefore, UGT activity is not prominent in PNT2 
cells. 
The metabolism of A4 and T in PNT2 cells was subsequently assayed in the presence of rooibos 
and dutasteride to further analyse the inhibition of SRD5A by the 5α-reductase inhibitor and 
rooibos. The production of 5α-dione in the presence of dutasteride (10 µM) was inhibited with no 
5α-dione detected after 48 h (fig. 4.20). Increased substrate level, A4 (0.97 µM) was detected in 
the presence of dutasteride, and the product of 17βHSD, T, was reduced in the presence of 
rooibos. 
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Figure 4.20: A4, 1 µM, conversion to 5α-dione by SRD5A in PNT2 cells in the absence (control) and 
presence of rooibos (4.3 mg/mL) and dutasteride (10 µM) after 48 h. Patterned bars represent steroid 
substrate. The experiment was performed in triplicate and data was compared to the control groups and 
analysed by one-way ANOVA, followed by a Dunnett‟s multiple comparison test. Results are expressed as 
the mean ±SEM (**P<0.01, ***P<0.001, ns=not significant, n=3). 
The production of DHT in the presence of dutasteride (10 µM) was inhibited with no DHT being 
detected after 48 h (fig. 4.21). Although an increased substrate level of T could not be detected in 
either the presence of rooibos or dutasteride, A4 levels together with DHT levels were reduced, in 
the presence of rooibos. 
 
Figure 4.21: T, 1 µM, conversion to DHT by SRD5A in PNT2 cells in the absence (control) and presence of 
rooibos (4.3 mg/mL) and dutasteride (10 µM) after 48 h. Patterned bars represent steroid substrate. The 
experiment was performed in triplicate and data was compared to the control groups and analysed by one-
way ANOVA, followed by a Dunnett‟s multiple comparison test. Results are expressed as the mean ±SEM 
(**P<0.01, ***P<0.001, ns=not significant, n=3). 
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A4 metabolism in BPH-1 cells in the presence of rooibos 
The conversion of A4 was assayed in BPH-1 cells, in the presence of rooibos extracts (4.3 mg/mL) 
to determine the influence of rooibos on endogenous A4 conversion to T via reductive 17βHSDs. 
On completion of the assay metabolites were deconjugated after which total steroids were 
analysed. A4 was primarily metabolised to T (±0.75 µM) with high levels of 5α-dione (±0.12 µM) 
also being detected, denoting preferred reductive 17βHSD activity as well as that of SRD5A, 
respectively (fig. 4.22). Levels of 3α-adiol were also significantly higher than AST levels which may 
be attributed to higher levels of substrate being available for the AKR1C2 reductive reactions. 
Rooibos resulted in a significant reduction (±43.5%) of T production, indicating inhibition of the 
catalytic activity of reductive 17βHSD towards A4. Reduced T levels in the presence of rooibos 
subsequently led to decreased levels of DHT (±47%) and 3α-adiol (±70%). Of interest with the 
decreased conversion of A4 to T, more A4 was channelled to produce 5α-dione (±46%) via 
SRD5A1/2 and AST (±26%) via AKR1C2.  
 
Figure 4.22: A4, 1 µM, conversion in BPH-1 cells in the absence; and in the presence of rooibos 
(4.3 mg/mL) after 48 h. Patterned bars represent steroid substrate. The experiment was performed in 
triplicate and results are expressed as the mean ±SEM (**P<0.01, ***P<0.001, n=3). 
In addition unconjugated and total steroids were also analysed, following a β-glucuronidase 
treatment of culture media from BPH-1 cells, and showed no difference in the levels of steroids 
were detected. UGT activity is therefore also not prominent in BPH-1 cells. 
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11KA4 conversion to 11KT in prostate cells in the presence of rooibos 
The conversion of 11KA4 to 11KT via reductive 17βHSDs endogenous to prostate cells was also 
investigated in the presence of rooibos (fig. 4.23). Rooibos resulted in a significantly reduced 
conversion of 11KA4 in LNCaP (±11.3% inhibition), PC-3 (±26% inhibition) and BPH-1 (±17.6% 
inhibition) cells, however, the difference was insignificant in PNT2 cells. PNT2 cells did not readily 
convert 11KA4 to 11KT, and therefore the influence of rooibos on the 17βHSD catalysed reaction 
regarding the C11-keto substrate could not be established. It is interesting to note that while A4 
was readily metabolised to T in PNT2 cells, the conversion of A4 and 11KA4 were both efficiently 
catalysed in BPH-1 cells. The conversion of 11KA4 to 11KT was catalysed more readily in BPH-1 
cells than by PC-3 cells, followed by LNCaP cells. These results suggests higher expression levels 
of reductive 17βHSD in BPH-1>PC-3>LNCaP cells, regarding the metabolism of the C11 keto-
steroid. Downstream metabolites of 11OHA4 due to SRD5A and AKR1C2 are also able to form in 
the aforementioned prostate cell models, however, the levels of these metabolites were negligible 
and as such are not shown. 
 
 
Figure 4.23: 11KA4, 1 µM, conversion to 11KT in LNCaP, PC-3, BPH-1 and PNT2 cells in the absence and 
in the presence of rooibos (4.3 mg/mL) after 48 h. The experiment was performed in triplicate and results are 
expressed as the mean ±SEM (**P<0.01, ***P<0.001, ns=not significant, n=3). 
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4.4 Discussion 
The physiological role of rooibos has, to date, been widely investigated in vivo and in vitro, with this 
polyphenol-rich extract exhibiting anti-mutagenic, antioxidant and anti-carcinogenic properties 
(Marnewick et al., 2000; Sasaki et al., 1993; Shimoi et al., 1996). Increasing evidence of the 
modulation of steroidogenic enzymes by rooibos as a possible mechanism of action has been 
reported, specifically regarding enzymes involved in adrenal steroidogenesis (Perold, 2009; 
Schloms et al., 2012; Schloms & Swart, 2014). These findings led to the present study and the 
hypothesis that rooibos may also modulate steroid metabolism in the prostate. The enzymes 
investigated in the present study are expressed in the prostate, with AKR1C3 and SRD5A1 up-
regulated in PCa. Both the 17βHSDs and SRD5As are intricately involved in the three prostate 
androgen pathways, the conventional C19 pathway, the 5α-dione pathway and the 11OHA4 
pathway.  
Cell viability assays in the presence of rooibos showed that cell viability was not affected in the 
experimental protocols employed in this study. The inhibitory effects detected are therefore due to 
rooibos-enzyme interactions with cell viability not being compromised. The data shows that the 
viability in LNCaP cells, after 96 h incubation period in the presence of the highest concentration 
was not affected by rooibos. However, in HEK293 cells, a decrease in cell viability was detected 
after the 12 h incubation period with rooibos, which necessitated normalising data to cell numbers. 
Another aspect which was addressed was the endogenous expression of steroidogenic enzymes 
in the cell model systems. Analyses of metabolites produced in experimental assays would be 
confounded by endogenous enzyme expression, catalysing either the added substrate or the 
formed product. In this study, assays were therefore firstly conducted in three different cell models 
transfected with the relevant enzymes to allow the analyses of substrate conversion by 
endogenous enzymes. HEK293 cells ultimately presented the best cell model for the investigation 
into the influence of rooibos on the steroidogenic enzymes as these cells exhibited negligible 
endogenous interference by 17βHSD or SRD5A. 
Investigations into the catalytic activity of 17βHSD3 and AKR1C3 towards A4 and 11KA4, were 
conducted since their products, T and 11KT, represent active androgens (Rege et al., 2013; 
Storbeck et al., 2013). The potential inhibition of the catalytic activity of the 17βHSD enzymes by 
rooibos may result in a decrease in the biosynthesis of active androgens. 17βHSD3 plays a central 
role in androgen biosynthesis, specifically in T production, in the testis and in prostatic tissue 
(Mindnich et al., 2004; Montgomery et al., 2008). Similarly AKR1C3 converts A4 metabolites to T 
metabolites, and while it is not expressed in the testis, AKR1C3 is expressed in prostatic tissue 
(Luu-The, 2001). 
The data presented in this chapter clearly shows that rooibos inhibits the catalytic activity of 
17βHSD3 and AKR1C3, blocking the biosynthesis of active androgens, suggesting a possible role 
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for rooibos in the prostate and possibly in PCa. Considering the inhibition of endogenously 
expressed 17βHSDs and transfected 17βHSDs in CHO-K1 cells by rooibos, the data shows 
rooibos not only inhibiting the catalytic activity of the expressed 17βHSD3 and AKR1C3 enzymes 
but also 17βHSD1 and 17βHSD7 activity endogenous to these cells. These results suggest that 
since rooibos inhibits the biosynthesis of T and 11KT, less ligand will be available to bind and 
activate the AR. In a recent study, the influence of rooibos was shown to decrease T production in 
mouse Leydig cells. TM3 cells were treated with unfermented and fermented rooibos (0.25, 0.5 
and 1 mg/mL) for 24 h and a significant reduction in T production was detected, suggestive of the 
inhibitory effect of rooibos on the catalytic activity of 17βHSD (Opuwari & Monsees, 2014).  
The inhibition by rooibos of 17βHSD3 and AKR1C3 detected may likely be attributed to the 
polyphenol compounds present in rooibos, with the flavonoid concentrations within the rooibos 
extract ranging between 12 µM and 652 µM. Quercetin, a flavonoid-derivate of rutin, present in 
rooibos, has been shown to inhibit AKR1C3 at concentrations ranging from 100 nM to 20 µM 
(Krazeisen et al., 2001). Rutin has also been suggested to inhibit both 17βHSD3 and AKR1C3, 
with a recent pharmacophore-based virtual screening study depicting the crystal structure of 
17βHSD3 and AKR1C3 in which rutin was bound at the base of the substrate binding domain 
(Schuster et al., 2011). Structural differences regarding the number and position of hydroxyl and 
glucosyl moieties as well as the structural flexibility of flavonoids have been implicated to contribute 
to their enzyme modulating properties. It was suggested that inhibitor potency increased with 
increasing hydroxyl groups (Krazeisen et al., 2001; Schloms & Swart, 2014). It is possible that the 
hydroxyl groups of the flavonol are involved in the binding of these compounds to the active site of 
17βHSD enzymes, with the formation of hydrogen bonds stabilizing the orientation of flavonoid 
compounds in the active site. In the present study 11KA4 was assayed in HEK293 cells transiently 
transfected AKR1C3, in the presence of rutin (10 µM) (quercetin-3-O-rutinoside). No significant 
inhibition was detected after 4 h (data not shown). It is possible that the rutinoside disaccharide 
moiety may interfere with the binding of the rutin in the active pocket. Quercetin, which is the 
aglycone of rutin, is present in trace amounts in unfermented rooibos, while isoquercetin and 
hyperoside, with C3 glucosyl and galactosyl moieties, respectively, are also present at low levels. 
Quercetin-3-O-robinoside and rutin are, however, present at markedly higher levels. In addition, 
gut flora allows the metabolism of quercetin-3-O-robinoside and rutin (Erlund et al., 2000; Hollman, 
2004 and references therein), with the subsequent bioavailability of quercetin at detectable levels 
in the body, suggesting possible cellular effects (Manach et al., 1995). 
Previous studies have reported that 17βHSD3 and AKR1C3 convert A4 to T, and that 17βHSD3 is 
substantially more efficient (Dufort et al., 1999; Storbeck et al., 2013). Steroid conversion assays in 
HEK293 cells clearly show that 17βHSD3 is more efficient in metabolising A4 in comparison to 
AKR1C3. However, in CHO-K1 cells ±35-40% conversion of A4 by both enzymes was detected. 
AKR1C3 readily catalysed the conversion of 11KA4, with 11KT being 2-fold higher than T, which is 
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in agreement with previous studies (Storbeck et al., 2013). In addition, AKR1C3 catalysed the 
conversion of 11KA4 more efficiently than 17βHSD3, with a 4-fold greater production of 11KT. In 
contrast, 17βHSD3 metabolised A4 and 11KA4 to their respective products equally efficiently.  
Analyses of the data obtained in the two cell model systems, CHO-K1 and HEK293 cells 
transiently transfected with 17βHSD3 and AKR1C3 showed marked differences in the catalytic 
conversion of the substrates assayed. In CHO-K1 cells the conversion rate of the substrates 
assayed was not efficient, regardless of the incubation period, with the exception of the 
heterologously expressed AKR1C3 converting 11KA4. In the subsequent assay in HEK293 cells, in 
which substrate conversions ranged from 50%-95%, the conversion rates were dependent on the 
incubation period. The variance obtained in the data set could be due to many factors. It has been 
reported, as previously mentioned, that CHO-K1 cells express 17βHSD1 and 7 endogenously, 
while HEK293 cells express low levels of SRD5A2. It is therefore possible that oxidative/reductive 
enzymes, which may also be substrate specific, are expressed in these cell lines that will accept 
C19 steroids as substrates, unfortunately influencing the outcome of the data set. In addition it is 
likely that the presence of NAD(P)+/NADP(H) and regenerating systems may differ in these cell 
models which would also affect the catalytic activities of the enzymes. Nevertheless, this study set 
out to investigate the possible inhibition of 17βHSD3 and AKR1C3 by rooibos, and even though 
the conversion rate was low, analyses of substrate and product levels indicated that rooibos, in 
CHO-K1 cells elicited a ±50% inhibition of both enzymes. 
In the prostate 17βHSD2 metabolises T, 11OHT and 11KT to their inactive A4 derivatives and in 
this manner modulates levels of available AR ligands. The data obtained in this study showed that 
rooibos inhibited the catalytic activity of 17βHSD2 towards these substrates with the highest 
inhibition observed being towards C11 derivatives, 11KT>11OHT>T (40%, 20% and 15%). 
Interestingly, the inhibition of CYP11B1 by flavonoids, vitexin, orientin and rutin, was recently 
reported to be substrate specific. In the presence of the aforementioned flavonoids the inhibition of 
DOC conversion was shown to be negligible, while the inhibition of deoxycortisol conversion was 
significantly higher (Schloms & Swart, 2014), supporting substrate specific inhibition of rooibos and 
its flavonoids.  
The above findings, together with reports that show SRD5As produce steroids that are capable of 
agonist activity towards the AR (Bruchovsky & Wilson, 1968), led to further investigation into the 
influence of rooibos on the conversion of A4 and T by SRD5A1 and SRD5A2. Possible modulation 
of SRD5A activity towards A4 and T could lead to decreased active androgen formation and 
decreased activation of AR-driven genes, as both SRD5A1 and SRD5A2 play a central role in 
prostate androgen metabolism.  
The inhibition of SRD5As by phytoestrogens and flavonoids has not been extensively researched 
to date, specifically considering the prostate as peripheral target tissue. Considerable research into 
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the development of inhibitors of SRD5A activity has been conducted, with the present study 
reporting for the first time on the influence of rooibos on SRD5A1 and SRD5A2. Rooibos inhibited 
the conversion of T to DHT by SRD5A1 in U2OS cells, but was insignificant in comparison to the 
inhibition by dutasteride. In addition, these assays also showed, for the first time, that endogenous 
17βHSD in U2OS cells, a non-steroidogenic cell model, exhibited reductive 17βHSD activity, which 
necessitated SRD5A assays to be completed in HEK293 cells. Rooibos did not inhibit the catalytic 
activity of SRD5A1 in the HEK293 cell system as the 5α-reduction of A4 and T was not influenced. 
It, however, appears that rooibos may influence the catalytic activity of SRD5A2 towards T, 
affecting the rate at which T is converted to DHT.  
It is reported that SRD5A1 preferentially converts A4 over T, and in the present study, assays with 
SRD5A1 confirm that this enzyme preferably metabolises A4, while also metabolising T more 
readily than SRD5A2. This study also show the preference of the endogenous expressed SRD5A 
in PNT2 cells towards the conversion of A4 to 5α-dione (±45%), 5-fold more than the conversion of 
T to DHT (±7%), possibly denoting the reduction of A4 by PNT2 cells to SRD5A2, reflecting the 
expression of SRD5A2 reported to be expressed in normal epithelial cells of the prostate (Luu-The 
et al., 2008), although both SRD5A1 and SRD5A2 has been reported in normal prostatic epithelial 
cells (Iehle et al., 1999).  
Further analysis of A4 and T metabolism in PNT2 cells, showed that while it appears that rooibos 
did not inhibit the catalytic activity of SRD5A towards A4, the conversion of T to DHT in this 
prostate cell model was inhibited significantly, confirming an inhibitory effect by rooibos of 
SRD5A2, and corroborates the inhibitory effect of rooibos on SRD5A2 activity towards T reported 
in HEK293 cells. The inhibitory effect of rooibos on SRD5A2 in PNT2 cells was also confirmed in 
additional conversion assays conducted in the presence of dutasteride, showing significant 
reduced conversion of T to DHT. A study by Evans et al. (1995), also reported on dietary lignans 
and isoflavonoids inhibiting SRD5A in BPH tissue homogenates. However, both isoforms were 
inhibited with SRD5A1 being more sensitive to inhibition compared to SRD5A2 (Evans et al., 
1995). This aforementioned study therefore supports the possible interference of flavonoids and 
rooibos on the catalytic activity of SRD5A, but also of 17βHSD, as this study showed the inhibition 
of 17βHSD by the compounds tested. However, none of the compounds assayed have been 
shown to be present in rooibos. 
The analysis of the influence of rooibos on the metabolism of A4 and T in PNT2 cells also showed 
that while SRD5A metabolised A4 more readily than T, both reductive and oxidative 17βHSD 
activities were detected, albeit it at low levels, evident in the low levels of T and A4, respectively. 
Rooibos nevertheless inhibited both significantly. In addition, AKR1C2 activity was evident, 
converting 5α-dione to AST, with findings also suggesting that rooibos inhibited the production of 
AST significantly, as negligible levels were detected in the presence of extracts. The inhibitory 
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effect of rooibos on AKR1C2 could, however, not be corroborated with a significant increase in 5α -
dione levels and warrants further investigations.  
While SRD5A, 17βHSD and AKR1C2 enzyme activities towards the steroid substrates above were 
clearly shown, no UGT activity was detected. It is interesting to note that PNT2 cells represent 
epithelial cells derived from normal prostate tissue and it has been shown that UGT2B17 is 
expressed exclusively in the basal epithelial cells and UGT2B15 in the epithelial luminal cells 
(Bélanger et al., 2003). UGTs expressed in prostate cells, would conjugate T, DHT, 3α-adiol and 
AST. However, in these assays described above, no UGT activity was detected in this cell line 
upon analyses of the free steroids in the media. The assays completed in PNT2 cells were 
conducted concurrently with assays in LNCaP cells, with UGT activity being detected in LNCaP 
cells, also indicating efficient deconjugation of steroids following a β-glucuronidase assay.  
Although UGT activity was also not detected in BPH-1 cells, these cells were an ideal prostate cell 
model for the investigation into the influence of rooibos on the reductive activity of 17βHSD which 
was more prominent than that of SRD5A towards A4. Rooibos resulted in a significantly reduced 
conversion of A4 to T, and the subsequent conversion to metabolites, DHT and 3α-adiol. This 
inhibition, however, shunted the increased A4 substrate to 5α-dione and AST. Analyses of the 
conversion of 11KA4 to 11KT in BPH-1, LNCaP, PC-3 and PNT2 cells in the presence of rooibos 
show that while higher levels of product were detected in BPH-1 cells, inhibition by rooibos was 
greater in LNCaP and PC-3 cells. While the metabolism of C11-hydroxy- and C11-keto A4 and T 
metabolites have been shown in the 11OHA4 pathway in LNCaP cells (Storbeck et al., 2013; Swart 
et al., 2013a), this study also shows for the first time that the C11-keto steroid is metabolised in 
PNT2 , BPH-1 and PC-3 prostate cells, suggesting that the 11OHA4 pathway may be relevant in 
normal, benign and cancerous prostatic cells. 
Taken together, rooibos inhibited the catalytic activity of 17βHSD3, AKR1C3 and 17βHSD2 and 
appears to affect the rate at which SRD5A2 metabolises T in transiently transfected cell models. In 
addition rooibos inhibited the conversion of T to DHT, suggestive of endogenous SRD5A activity 
modulation, as well as the conversion of A4 to T, suggesting rooibos inhibits endogenous reductive 
17βHSD in PNT2 and in BPH-1 cells. Furthermore rooibos appears to inhibit AKR1C2 activity, with 
a reduced conversion of 5α-dione to AST being detected in PNT2 cells. Rooibos also inhibited the 
17βHSD catalysed conversion of 11KA4 to 11KT in LNCaP, BPH-1 and PC-3 prostate cells. As 
such, rooibos may have significant implications in PCa, as well as in CRPC - perhaps even more 
so the inhibition of reductive 17βHSDs, such as AKR1C3, as this enzyme is  up-regulated as PCa 
progresses. Inhibition of the catalytic activity of reductive 17βHSDs will impede the production of 
active androgens, and precursor steroids for SRD5A. Decreased production of active androgens 
will lead to reduced AR activation and subsequently reduced transcription of AR-regulated genes, 
impacting favourably on cell growth and proliferation. The progression of PCa is dependent on 
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androgen biosynthesis catalysed by an intricate system of enzymes and the modulation of these 
enzymes by rooibos may therefore aid treatment strategies. In combination with general treatment 
regimes against PCa, including ADT and the use of AR antagonists, using rooibos as a natural 
herbal supplement could have beneficial anti-carcinogenic effects in hormone driven diseases. 
However, the inhibitory effect of 17βHSD2 and AKR1C2 by rooibos cannot be ignored, as the 
inhibition of these enzymes would result in increased levels of active androgens with rooibos thus 
having deleterious effects. 
This line of investigation and the influence of rooibos on prostate androgen metabolism in LNCaP 
cells will be further developed in chapter 5. 
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Chapter 5 
An investigation into the influence of rooibos on androgen metabolism in 
LNCaP cells 
5.1 Introduction 
Diseases of the prostate such as BPH and PCa are prevalent in the aging male, and are androgen 
dependent at the time when circulating gonadal T declines, suggesting that the local or intracrine 
production of androgens may drive these diseases (Labrie et al., 2000; Labrie et al., 1995). Indeed 
both BPH and PCa are considered hormone-dependent diseases and require androgens for their 
secretory function with cancerous cells retaining this sensitivity to androgens (Gianfrilli et al., 
2014). It has been reported that a complement of androgen-producing enzymes are expressed in 
human PCas, and are as such involved in the local production of the potent androgen, DHT, 
playing important roles in biological behaviour of prostate carcinoma cells (Nakamura et al., 2005). 
Androgen metabolism pathways, which include the conventional C19 (3.4.1), the „alternative‟ 5α-
dione (3.4.2) and the 11OHA4 pathways (3.4.3), are indeed intricately involved in active androgen 
production. Androgens from testicular and adrenal origin are utilized in these pathways given the 
expression of steroid-metabolizing enzymes, viz.: 3βHSDs, 17βHSDs, 11βHSDs, SRD5As, 
3αHSDs and UGTs. 
The balance between androgen induced cell proliferation and apoptosis is proposed to be a major 
regulator of growth of the normal and cancerous prostate. In normal conditions a steady state 
exists between synthesis and inactivation of active androgens, however, tissue transformation can 
be associated with an alteration of this balance. In both prostate disease, BPH and PCa, there is 
an imbalance between prostate cell growth and apoptosis, possibly because certain factors 
minimize cell apoptosis while others stimulate proliferation. Intrinsic (in particular growth factors) 
and extrinsic (in particular steroid hormones) factors directly and indirectly regulate prostate tissue 
growth and differentiation (Nelson et al., 2003). 
Increasing evidence suggests that PCa cells alter local and paracrine steroid hormone metabolism 
(Gianfrilli et al., 2014). In the past decade, a growing number of studies have explored the role of 
local androgen production in cancer progression and transformation into CRPC. Widely accepted 
is the hypothesis that the progression of PCa during ADT is not due to the development of an 
androgen insensitive tumour clone but rather to the fact that cancer cells acquire mechanisms to 
escape systemic androgen deprivation while still taking advantage of signalling through the AR 
(Harkonen et al., 2003; Locke et al., 2008; Risbridger, Davis et al., 2010; Scher et al., 2004). 
Importantly, the AR can undergo point mutations, becoming more promiscuous, allowing activation 
by non-androgenic ligands (Scher & Sawyers, 2005). In addition, ERβ once bound to its ligand, 
acts via the AR regulating AR-driven genes in PCa cells (Muthusamy et al., 2011). 
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It is estimated that 233,000 new cases of PCa will be diagnosed annually in the USA and that 
29,480 deaths, as a result of PCa, will occur per year (American Cancer Society, 2014). In BPH 
and PCa treatment by androgen deprivation, to deprive the AR of its ligand, include inhibitors of 
steroidogenesis and AR antagonists. The former approach requires a detailed knowledge of the 
extra-gonadal biosynthesis and metabolism of androgens and the discrete enzymes involved 
(Penning, 2010). A recent study considered both benign and malignant intact prostatic tissue to 
investigate individual profiling of prostate intracrinology, ex vivo, with the specific focus on 
17βHSDs. The study showed 17βHSD3 is expressed in both BPH and PCa tissues at similar 
levels, and while 17βHSD2 was also expressed in BPH samples, 17βHSD2 was not expressed in 
PCa tissues. PCa samples expressed more reductive 17βHSD activity, such as AKR1C3 and 
17βHSD7 compared to BPH samples, but decreased reductive 17βHSD activity compared to 
oxidative 17βHSD activity, such as 17βHSD type 4/8/10 was , however, detected in PCa samples. 
Furthermore, BPH samples showed decreased de novo enzymatic production of androgens, 
suggestive of predominant oxidative 17βHSD activity (Gianfrilli et al., 2014). 
In prostate androgen metabolism, 3α-reduction of steroids entails steroid potency modulation, 
similar to 17βHSDs, through modifications between hydroxy and ketone groups at C3 of the four 
carbon ring backbone structure common to all steroids. Following this first step of inactivation, 
phase II metabolism is characterised by a conjugation reaction of a charged moiety with the 
hydroxy-group at the C3 and C17, and is almost universally associated with a decrease in steroid 
potency (Gosetti et al., 2013). The addition of glucuronidated moieties to androgens has the net 
effect of lowering receptor activation through both decreased potency and increased secretion 
(Barry et al., 1952; Klyne et al., 1945; Nozaki, 2001). Of interest, sulfation of androgens can also 
occur and is also classified under phase II metabolism of steroids. Glucuronidated steroids, in 
contrast to sulfated steroids, have been studied in the context of the downstream metabolism of 
active androgens with glucuronidated steroids derived from DHT being detectable in the serum of 
men (Bélanger et al., 1998; Moghissi et al., 1984). The enzymes responsible for the 
glucuronidation of androgens in prostatic tissue are UGT2B15 and UGT2B17 (Barbier & Bélanger, 
2008), with the expression of UGT2B17 reported to be up-regulated while UGT2B15 expression is 
down-regulated in the progression of cancer from benign disease to lymph node metastasis 
(Paquet et al., 2012). Characterizing phase II metabolism of steroid derivatives are, however, still 
understudied and could possibly be a future target for CRPC (McNamara et al., 2013). 
In a study by Byrns et al., (2012), the quantification of the downstream metabolites of A4 in 
AKR1C3 transfected LNCaP cells showed that AKR1C3 redirects the metabolism of A4 to 
testosterone-glucuronide (T-G). In addition, the cells became resistant to the growth inhibitory 
effects of finasteride, a specific SRD5A1 inhibitor. Importantly, the conversion of A4 to T-G was 
blocked by indomethacin, a selective AKR1C3 inhibitor, indicating the inhibition of the formation of 
active androgens in PCa cells by this drug. The authors concluded that the beneficial effects of 
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SRD5A inhibitors in the treatment of PCa would depend on whether AKR1C3 is expressed or not, 
and that an AKR1C3 inhibitor would be beneficial for the treatment of PCa to inhibit the conversion 
of A4 and 5α-dione, to T and DHT, respectively. This study therefore highlights the potential role of 
AKR1C3 inhibitors in PCa, as well as the intricate catalyses of androgen metabolism by 17βHSDs 
and UGTs in prostate cell systems (Byrns et al., 2012). 
Many treatment strategies, such as castration and ADT, are currently employed against PCa, but 
irrespective of the treatment regimen, in ±30–40% of cases the cancer can re-emerge (2–5 years 
later) with a tell-tale increase in PSA. PSA is an important clinical marker, which is commonly used 
for early diagnosis and to monitor treatment response, prognosis, and progression in patients with 
PCa (Lieberman, 2004). In a recent study, PSA levels for enrolled subjects with BPH were 
approximately ±4 ng/mL compared to ±10 ng/mL for those with PCa (Gianfrilli et al., 2014). 
Although PSA levels can be distinguished between BPH and PCa patients, the PSA index (free 
PSA: total PSA) would increase the screening accuracy of PSA and the subsequent discrimination 
between BPH and PCa. However, it has been suggested that the application of this classical 
monitoring factor of PCa is less effective in the attempts to distinguish among multiple stages of 
the disease. In the on-going fight against PCa, there exist economic and socioeconomic costs of 
overtreatment, as well as complications associated with the current available treatments (including 
ADT). Together with these factors, the overall quality of life and life expectancy of affected subjects 
should be considered (Gianfrilli et al., 2014), advocating new treatment approaches against PCa 
progression. 
In recent years, the shift by the general public towards natural and herbal medicinal products, away 
from mainstream pharmaceuticals, has led to increased interest in natural plant products. An 
investigation in LNCaP and PC-3 cell lines, showed polyphenol compounds exhibiting 
phytoestrogenic activity inhibiting cell growth in both cell lines, suggesting a diet rich in polyphenols 
as a possible approach in the treatment of PCa (Mitchell et al., 2009). However, the relationship 
between diets rich in polyphenol compounds and cancer incidence is controversial with some 
studies indicating positive correlation while others indicate no association. Rooibos which is rich in 
polyphenol compounds has, however, been shown to possess anti-carcinogenic and anti-
mutagenic properties in skin tumours (Marnewick et al., 2005). Rooibos may therefore play a role 
in the modulation of the development and progression of hormone-dependent cancers, given that 
rooibos has also been shown to influence steroidogenic enzymes (Perold, 2009; Schloms & Swart, 
2014; Schloms et al., 2013). 
The aim of this study was to determine steroid conversion as it occurs in the C19 pathway, as well 
as in the 11OHA4 pathway in LNCaP cells, through steroid quantification using UPLC-MS/MS. The 
metabolism of A4, T, DHT and AST in the presence of rooibos was subsequently assayed in order 
to determine the influence of rooibos on endogenous 17βHSDs, SRD5As and 3αHSDs expressed 
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in LNCaP cells. The metabolism of 11OHA4 in the presence of rooibos, and two of its flavonoids, 
isoorientin and rutin, was also assayed. Since evidence of possible modulation of UGT activity in 
LNCaP cells was detected, the influence of rooibos on endogenous UGTs expressed in LNCaP 
cells was further investigated. In this approach T, DHT and AST metabolism was assayed in the 
presence of rooibos. The possible modulation of cancer markers in prostate cells by rooibos was 
subsequently investigated and PSA levels in the absence and presence of DHT in LNCaP cells 
were assayed in the presence of rooibos. 
5.2 Materials and methods 
5.2.1 Materials  
Unfermented rooibos plant material was provided by the South African Rooibos Council (Rooibos 
LTD-BPK, Clanwilliam, South Africa). Steroid metabolites (T, A4, DHT, 5α-dione, 3α-adiol and 
AST), D-(+)-Glucose, β-glucuronidase (Type VII-A from E.coli; 5,292,000 units/g), RPMI-1640, 
phenol free RPMII-1640 medium and rutin were purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Isoorientin was purchased from Extrasynthese (Genay, France) and indomethacin and 
dutasteride were purchased from Sequoia Research Products Ltd (Pangbourne, UK). HEPES 
buffer (1 M) and sodium pyruvate (100 mM) were purchased from Biochrom (Berlin, Germany). 
11OHA4, 11OHT, 11KA4, 11KT and DHT-G were purchased from Steraloids (Wilton, USA) and 
Corning®CellBIND® Surface 24-well plates were purchased from Corning® Life Sciences (Corning, 
NY, USA). LNCaP cells were obtained from the Sigma‟s European Collection of Cell Cultures (St.  
Louis, MO, USA). Penicillin-streptomycin, fetal calf serum and trypsin-EDTA were obtained from 
Gibco BRL (Gaithersburg, MD, USA). Charcoal-treated fetal calf serum was obtained from 
Highveld Biologicals (Lyndhurst, RSA). Deuterated cortisol (9,11,12,12-D4-cortisol) and deuterated 
testosterone (Testosterone 1,2-D2, 98%) were purchased from Cambridge isotopes (Andover, MA, 
USA). Dimethyl sulfoxide and pH indicator strips (non-bleeding) was obtained from Merck 
(Darmstadt, Germany). All other chemicals were of the finest quality and supplied by reliable 
scientific supply houses. 
5.2.2 Methanol extraction of unfermented rooibos 
Unfermented rooibos plant material was sequentially extracted with chloroform and methanol using 
a glass soxhlet extractor and aliquots (1 mL) prepared and stored as previously described (4.2.3). 
Rooibos polyphenols were subsequently identified and quantified using HPLC as previously 
described (4.2.4). 
5.2.3 Steroid conversion assays in LNCaP cells 
LNCaP cells were cultured in RPMI-1640 media, pH 7, supplemented with 10% fetal bovine serum, 
1.5 g NaHCO3/L, 2.5 g D-(+)-Glucose, 1% penicillin-streptomycin, 1% HEPES and 1% sodium 
pyruvate using Corning® CellBIND® surface plates at 37°C, in an atmosphere of 90% humidity and 
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5% CO2. Cells were plated into 24-well Corning
® CellBIND® surface plates (2 x 105 cells/mL, 
0.5 mL/well) and incubated for 48 h. The medium was removed and replaced with 0.5 mL RPMI-
1640 medium containing the following steroid substrates (1 µM): A4, T, DHT, AST, 3α-adiol and 
11OHA4. Steroids (2 mg/mL) were diluted in culture medium to the desired concentration after 
which cell were exposed to steroid substrates added to the cells, without and in the presence of 
unfermented rooibos extracts (4.3 mg/mL). Duplicate aliquots (0.5 mL) were removed at 6 h, 24 h, 
36 h and 48 h and steroid metabolites extracted, after β-glucuronidase treatment (5.2.4). Steroid 
metabolites were extracted by liquid-liquid extraction using 10:1 volume of dichloromethane to 
culture medium. The samples were vortexed for 10 min, centrifuged at 3500 rpm for 5 min after 
which the media was aspirated and dichloromethane phase dried at 45°C under nitrogen. The 
dried steroid residue was redissolved in 150 µL methanol prior to analysis by UPLC-MS/MS. 
Cortisol-D4 (15 ng) and testosterone-D2 (15 ng), were added to each samples prior to extraction. 
Control assays included steroid conversion assays carried out in the presence of inhibitors, 
indomethacin (20 µM; in DMSO), a 17βHSD inhibitor, dutasteride (10 µM; in ethanol), a SRD5A 
inhibitor and DMSO. The latter was shown to have no effect on steroid conversion assays at the 
experimental concentration. 
5.2.4 β-glucuronidase assay 
Analyses of total (free + conjugated) steroids was conducted following steroid conversion assays in 
prostate cells by treating the steroids in the collected aliquots with β-glucuronidase, as previously 
described (4.2.9), prior to steroid extraction. 
5.2.5 PSA chemiluminescent immunoassay 
LNCaP cells were cultured as described in 5.2.3. Cells were plated into 24-well Corning® 
CellBIND® surface plates (4 x 104 cells/mL, 0.5 mL/well) in phenol free RPMI-1640 media 
supplemented with 5% charcoal stripped fetal calf serum and 1% penicillin-streptomycin and 
incubated for 48 h. The medium was removed and replaced with 0.4 mL/well phenol free RPMI-
1640 supplemented with 1% penicillin-streptomycin only. After a 24 h incubation period, phenol 
free RPMI-1640 media containing DHT ranging from 0.001, 0.01, 0.1 and 1 µM was added in 
0.1 mL/well. Cells were also incubated with DHT in the presence of rooibos extracts (1 mg/mL and 
4.3 mg/mL). The cells were incubated for 96 h after which medium (0.5 mL) aliquots were removed 
and analysed for PSA levels using an Access Hybritech PSA chemiluminescent immunoassay 
(Coulter, 2010). 
5.2.6 Separation and quantification of steroid metabolites using UPLC-MS/MS 
Stock solutions of A4, T, DHT, DHT-G, 5α-dione, 3α-adiol, AST, 11OHA4, 11OHT, 11KA4 and 
11KT were dissolved in ethanol (2 mg/mL) and a series of standards (0.2 - 20 ng/mL) were 
prepared in methanol. 
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Steroid metabolites were separated by UPLC (ACQUITY UPLC, Waters, Milford, USA) using a 
Phenomenex UPLC Kinetex PFP column (2.1 mm x 100 mm, 2.6 µm) (Torrance, CA, USA) as 
previously described (4.2.10). All experiments were performed in triplicate and the subsequent 
results are given as means ± SEM, and statistics were calculated as previously described (4.2.11). 
5.3 Results 
5.3.1 Analysis of polyphenols in methanolic extracts of unfermented rooibos 
In this study LNCaP cells were exposed to rooibos extracts at two concentrations, 1 mg/mL and 
4.3 mg/mL. Analyses of the major polyphenol compounds show that the flavonoids ranged from 
2.9 µM to 152 µM for 1 mg/mL rooibos extract and 12.6 µM to 652 µM for 4.3 mg/mL rooibos 
extract (table 4.1). The dihydrochalcones were present at the highest concentrations (794.08 µM), 
4-fold higher than the flavones (183.9 µM) and 22-fold higher than the flavonols (35.6 µM). 
5.3.2 Analyses of steroid metabolism in LNCaP cells 
An investigation into steroid metabolism in LNCaP cells was conducted and the steroid metabolites 
quantified using UPLC-MS/MS. The endogenous pathways were thus assessed to determine the 
steroid flux prior to investigating the effect of rooibos on steroid metabolism. 
5.3.2.1 Analyses of steroid metabolism in the C19 pathway 
The metabolism of A4, T, DHT, AST and 3α-adiol was assayed in LNCaP cells and the steroid 
metabolites analysed using UPLC-MS/MS (fig. 5.1). Analyses of the conversion of A4 in LNCaP 
cells showed that, in the conversion by 17βHSD and SRD5A, the latter was the preferred route as 
higher levels of 5α-dione than T being detected (fig. 5.1 a). In addition, AST was also a major 
product indicating the 3αHSD reduction to be the preferred metabolic route compared to the 
reduction to DHT by 17βHSD.  
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Figure 5.1: Steroid substrate (1 µM) conversions in LNCaP cells after 48 h. Steroid metabolites shown as 
total (free + conjugated): (a) A4 metabolism, (b) T metabolism, (c) DHT metabolism, (d) AST metabolism, (e) 
3α-adiol metabolism and (f) diagram representing androgen metabolism in LNCaP cells. Substrates assayed 
represented in patterned bars; black arrows, conversions assayed; bold black arrows, preferred conversion; 
bold and grey arrows, preferred 5α-dione conversion within androgen metabolism. 
a b 
c d 
e f 
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Subsequent analyses of T conversion (fig. 5.1 b) showed that most of the steroid was in the 
conjugated form after 48 h, with very low levels of A4 being detected. The data thus shows that the 
conversion of A4 to T is more efficient compared to the conversion of T to A4 in LNCaP cells, 
indicating a predominant reductive 17βHSD activity (fig. 5.1 a/b). The minor oxidative activity is 
also evident considering the conversion of DHT, as negligible 5α-dione levels were detected after 
48 h (fig. 5.1 c). While ±50% DHT was conjugated low levels of 3α-adiol were also detected 
showing further conversion by the reductive activity of AKR1C2. The analyses of the conversion of 
AST and 3α-adiol (fig. 5.1 d, fig 5.1 e) clearly indicate that these steroids are in the conjugated 
form after 48 h with negligible levels of other metabolites being detected, 3α-adiol in the case of 
AST conversion and AST and DHT in the case of 3α-adiol conversion. The production of DHT 
suggests dehydrogenase activity, possibly 17βHSD6, catalysing the conversion of 3α-adiol 
(fig. 5.1 e). UGT activity by UGT2B15 and UGT2B17 was prominent in LNCaP cells and showed 
conjugation of T, DHT, 3α-adiol and AST. Conjugated steroid levels were as follows: 3α-adiol 
(±0.99 µM) > AST (±0.97 µM) > T (±0.89 µM) > DHT (±0.75 µM). Steroid levels below the LOQ 
were not shown. 
5.3.2.2 Analyses of 11OHA4 metabolism in LNCaP cells 
In this study the conversion of 11OHA4 by 11βHSD2 and 17βHSD was analysed. 11βHSD2 is 
endogenously expressed in LNCaP cells and it has been shown in our laboratory that 11βHSD2 
preferentially catalyses 11OHA4 since negligible levels of 11OH-5α-dione (produced by SRD5A 
activity) was detected after 72 h (unpublished data). In addition, it has been shown that the 
conversion of 11OHA4 by 17βHSD is negligible (Storbeck et al., 2013). Analyses of 11OHA4 
metabolism in LNCaP cells (fig. 5.2), showed that 11OHA4 is preferentially converted to 11KA4 by 
11βHSD2, which is subsequently converted to 11KT by reductive 17βHSD. Negligible levels of 
11OHT were detected as 11OHA4 was not readily reduced by 17βHSD.  
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Figure 5.2: 11OHA4, 1 µM, metabolism in LNCaP cells after 36 h; (a) 11OHA4 metabolism and its 
metabolites, and (b) diagram representing androgen metabolism in LNCaP cells. Substrate assayed 
represented in patterned bar; black arrows,  conversions assayed; bold black arrows, preferred conversion; 
and grey arrows, conversions occurring within androgen metabolism. 
5.3.3 The influence of unfermented rooibos on steroidogenic enzymes catalysing androgen 
metabolism in LNCaP cells 
5.3.3.1 The analyses of the metabolism of A4, T, DHT and AST in the presence of rooibos 
extracts 
The metabolism of A4, T, DHT and AST was assayed in the presence of rooibos extracts 
(4.3 mg/mL) in LNCaP cells. In this study it was shown that rooibos inhibits 17βHSD3 and AKR1C3 
activity heterologously expressed in CHO-K1 and HEK293 cells (4.3.4). In order to confirm these 
data in a prostate cell model, the conversion of A4 was assayed. Analyses of the steroid 
metabolites showed that the presence of rooibos resulted in a significant increase in A4 levels 
(1.9-fold, ±0.11 µM). While rooibos did not inhibit SRD5A activity lower levels of AST were 
detected. It appears therefore that rooibos inhibited AKR1C2 activity, however, the influence of 
rooibos on AKR1C2 needs to be investigated in isolation in order to draw accurate conclusions. T, 
DHT and 3α-adiol levels were below LOQ, and as such the influence of rooibos could not be 
accurately established. 
a b 
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Figure 5.3: A4, 1 µM, metabolism in LNCaP cells in the presence of rooibos (4.3 mg/mL) after 48 h. 
Steroids are shown as total (free + conjugated) steroids. Patterned bars represent steroid substrate. The 
experiment was performed in triplicate and results are expressed as the mean ±SEM (*P<0.05, **P<0.01, 
n=3). 
Further investigations into the influence of rooibos on reductive 17βHSD expressed in LNCaP cells 
were subsequently conducted. Rooibos (4.3 mg/mL) resulted in A4 conversion being reduced in 
LNCaP cells, after 24 h (fig. 5.4). In the presence of rooibos a ±30.7% inhibition of A4 conversion 
was detected, similar to the inhibition detected in the presence of indomethacin (±29.7%), a known 
AKR1C3 inhibitor (Byrns et al., 2012). Taken together these results therefore denote the inhibitory 
effect of rooibos on reductive 17βHSD and AKR1C3 activity endogenous to LNCaP cells. 
 
Figure 5.4: Analysis of A4 levels in LNCaP cells after 24 h. A4, 1 µM, was assayed in the presence of 
rooibos (4.3 mg/mL) and indomethacin (20 µM). The experiment was performed in triplicate and results are 
expressed as the mean ±SEM (*P<0.05, ns=not significant, n=2). 
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The analysis of T metabolism in the presence of rooibos (fig. 5.5) showed that the levels of T were 
reduced significantly (1.2-fold, ±0.2 µM), however, due to the low levels of downstream steroid 
metabolites detected, being below the LOQ, the influence of rooibos could not be accurately 
assessed. These results suggest rooibos possibly inhibits the glucuronidation of T, and as such 
more T is channelled to A4 and DHT, as in the presence of rooibos T levels are reduced, but A4 
and DHT levels are increased. These data suggest an amount of T possible to override any 
inhibition that may occur on 17βHSD2 and SRD5A (4.3.4, 4.3.5). 
 
Figure 5.5: T, 1 µM, metabolism in LNCaP cells in the presence of rooibos (4.3 mg/mL) after 48 h. Steroid 
metabolites are shown as total (free + conjugated) steroids. Patterned bars represent steroid substrate. The 
experiment was performed in triplicate and results are expressed as the mean ±SEM (*P<0.05, n=3). 
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DHT and AST metabolism was also assayed to determine the effect of rooibos on downstream 
metabolism in LNCaP cells. DHT levels increased significantly (1.9-fold, ± 0.5 µM) in the presence 
of rooibos while a significant decrease (± 0.03 µM) was detected in 3α-adiol levels (fig. 5.6), 
suggesting inhibition of AKR1C2 activity by rooibos. The increased DHT level may allow more DHT 
to be glucuronidated, or inactivated to form 5α-dione1 via 17βHSD2. This incubation period of 6 h, 
however, might be too soon to allow speculation and a 48 h incubation period might be more 
accurate in assessing the influence of rooibos on DHT metabolism.  
 
Figure 5.6: DHT, 1 µM, conversions in LNCaP cells in the absence and in the presence of rooibos 
(4.3 mg/mL) after 6 h. Steroids are shown as total (free + conjugated) steroids. Patterned bars represent 
steroid substrate. The experiment was performed in triplicate and results are expressed as the mean ±SEM 
(**P<0.01, NA=not assayed, n=3). 
Since the biosynthesis of AST appeared to be inhibited by rooibos the metabolism of AST was also 
assayed. Rooibos decreased the levels of AST significantly (1.1-fold, ± 0.1 µM), while increased 
3α-adiol (± 0.02 µM) was detected (fig 5.7). If, as with the case of T, rooibos inhibited the 
glucuronidation of AST, more substrate would be available to be converted to form 3α-adiol via 
17βHSD, especially, if the rate of reduction by 17βHSD trumps the rate of AST-G formation. The 
influence of rooibos on the catalytic activity of 17βHSD towards AST was not investigated in this 
study and it is possible that the effect of rooibos on the enzyme‟s activity towards AST is minimal, 
as in the case of T shown above. 
                                                                 
1 At the time of this study, the steroid was unavailable for analyses.  
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Figure 5.7: AST, 1 µM, conversions in LNCaP cells in the absence and in the presence of rooibos 
(4.3 mg/mL) after 48 h. Steroids are shown as total (free + conjugated) steroids. Patterned bars represent 
steroid substrate. The experiment was performed in triplicate and results are expressed as the mean ±SEM 
(*P<0.05, n=3). 
5.3.3.2 The analyses of the metabolism of 11OHA4 in the presence of rooibos extracts 
The metabolism of 11OHA4 in the presence of rooibos allowed further analyses of not only the 
modulation by rooibos of 17βHSD3 and AKR1C3 which catalyses the conversion of 11KA4 to 
11KT but also that of 11βHSD2 which catalyse the conversion of 11OHA4 to 11KA4, thus 
supplying the substrate for the 17βHSD isoforms expressed in LNCaP cells. In the presence of 
rooibos no significant modulation of 11OHA4 or 11KA4 levels were detected, denoting no inhibition 
of 11βHSD2 (fig. 5.8). A reduction in 11KT levels (3.7-fold, ± 0.03 µM) were detected, 
corroborating the modulation of reductive 17βHSD by rooibos, as was also shown in HEK293 cells 
(4.3.4). It should be noted that increased 11KA4 levels are expected in the presence of rooibos, 
however, this was not clearly detected and warrants further investigation. Isoorientin, a flavone and 
rutin, a flavonol, did not decrease the levels of 11OHA4 or 11KT significantly. In contrast, 
increased 11KA4 levels (1.5-fold, ± 0.25 µM) were detected in the presence of rutin, denoting 
possible modulation of 11βHSD2 by this flavonoid (fig. 5.8). It should be noted that the metabolism 
by SRD5A of 11OHA4 and its metabolites as well as the subsequent catalyses by downstream 
steroidogenic enzymes may contribute to the steroid levels detected in these assays. 
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Figure 5.8: 11OHA4, 1 µM, metabolism in LNCaP cells in the presence of rooibos (4.3 mg/mL), isoorientin 
(10 µM) and rutin (10 µM) after 36 h. Patterned bars represent steroid substrate. The experiment was 
performed in triplicate and results are expressed as the mean ±SEM (*P<0.05, ns=not significant, n=3). 
The data shown above suggests possible modulation of the inactivation and conjugation of T, DHT 
and AST in LNCaP cells by rooibos. The influence of rooibos on the conjugating activity of UGTs in 
LNCaP cells was therefore assayed. 
5.3.3.3 Rooibos inhibits the conjugation of T, DHT and AST by UGT2B15 and UGT2B17 in 
LNCaP cells 
The investigation of unfermented rooibos extract (4.3 mg/mL) on the conjugation of DHT, T and 
AST by endogenously expressed UGT2B15 and UGT2B17 was investigated in LNCaP cells. While 
UGT2B15 catalyses the conjugation of glucuronic acid at C17 of the steroid molecule, UGT2B17 
catalyses conjugation at both the C3 and C17, enabling thus the conjugation of the downstream A4 
metabolite, AST. The decreased levels of T and AST shown above suggested that rooibos 
influenced the catalytic activity of the UGTs. However, increased DHT levels were detected, which 
could not be attributed solely to the decrease in 3α-adiol levels (fig. 5.6).  
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UGT activity was thus investigated by analysing both free and total steroids in the medium with the 
latter analyses carried out following deconjugation using a β-glucuronidase assay. β-glucuronidase 
deconjugates conjugated steroids, to allow total (free + conjugated) steroid analysis using UPLC-
MS/MS. Free steroid levels were determined and quantified by UPLC-MS/MS and following a β-
glucuronidase assay, total steroid levels were also quantified. Analyses of the free and total steroid 
levels in the metabolism of DHT showed that ±27.4% of DHT was conjugated with ±0.6 µM 
remaining in the free form after 6 h (fig. 5.9). In the presence of rooibos extracts, free DHT levels 
being significantly increased (±0.4 µM) with the levels of total DHT being similar to the levels of 
free DHT. This result shows that rooibos inhibited the conjugation of DHT by UGT2B15 and 
UGT2B17 in LNCaP cells. 
 
Figure 5.9: DHT, 1 µM, conversion in LNCaP cells in the absence (control) and presence of rooibos 
(4.3 mg/mL) after 6 h. Steroids are shown as free steroid
a
 and total (free + conjugated) steroid
b
. The 
experiment was performed in triplicate and data was compared as shown and analysed by an unpaired 
t-test. Results are expressed as the mean ±SEM (*P<0.05, **P<0.01, ns=not significant, n=3). 
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An investigation into the influence of rooibos on the glucuronidation of T catalysed by both 
UGT2B15 and UGT2B17 and the glucuronidation of AST catalysed by UGT2B17 only, was 
subsequently conducted. The metabolism of T and AST in LNCaP cells was assayed in the 
presence of rooibos resulted in increased levels of free T and AST indicating a decrease in the 
glucuronidation of T (fig. 5.10 a) and AST (fig. 5.10 b) in LNCaP cells. In the absence of rooibos 
both T and AST were fully metabolised, with no detectable level of either steroid remaining. 
Following a β-glucuronidase assay, the steroid levels detected, T (± 0.89 µM) and AST 
(± 0.99 µM), indicated that both T and AST are conjugated after 48 h with negligible levels of 
substrate remaining. In the presence of rooibos, the levels of free T and AST are significantly 
increased, with ±0.2 µM T and ±0.4 µM AST being detected after 48 h. Analyses of the total T and 
AST suggests rooibos modulates the conjugating activity of UGT2B15 and UGT2B17 towards T 
and UGT2B17 towards AST in LNCaP cells, since ±84.4% T and ±49.3% AST were in the 
conjugated form after 48 h. 
 
Figure 5.10: Influence of rooibos on steroid conjugation in LNCaP cells after 48 h: (a) T, 1 µM, conversion; 
and (b) AST, 1 µM, conversion. Assays were conducted in the absence (control) and in the presence of 
rooibos (4.3 mg/mL) and steroids analysed by UPLC-MS/MS following a β-glucuronidase assay. Steroids are 
shown as unconjugated steroid
a
 and total steroid
b
. The experiment was performed in triplicate and data was 
compared as shown and analysed by an unpaired t-test. Results are expressed as the mean ±SEM 
(*P<0.05, **P<0.01, n=3). 
  
a b 
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Upon closer inspection comparisons of the detected levels of T and AST (total steroid) in the 
assays conducted in the presence of rooibos, following the β-glucuronidase assay indicated a 
possible interference of rooibos with the β-glucuronidase assay. A β-glucuronidase assay using 
DHT and the glucuronidated DHT (DHT-G) as substrates was subsequently conducted in the 
presence of rooibos (4.3 mg/mL). The addition of rooibos at 4.3 mg/mL did not result in 
interference with the assay as the levels of steroids detected in the case of DHT (fig. 5.11 a) and 
DHT-G (fig. 5.11 b) were not statistically different. Furthermore, the presence of rooibos did not 
result in a reduction in steroid recovery following the β-glucuronidase assay (fig. 5.11 b). 
 
Figure 5.11: Influence of rooibos on steroid recovery: (a) DHT, 1 µM; and (b) DHT-G, 1 µM. Assays were 
conducted in the absence (control) and in the presence of rooibos (4.3 mg/mL) and steroids analysed by 
UPLC-MS/MS following a β-glucuronidase assay. Steroids are shown as free steroid
a
 and total steroid
b
.  The 
experiment was performed in triplicate and results are expressed as the mean ±SEM (ns=not significant, 
n=3). 
5.3.4 Rooibos inhibits PSA levels in LNCaP cells 
Further investigations were conducted to determine whether rooibos influences PSA levels which 
may subsequently modulate downstream cellular processes. 
Stimulation of PSA levels by DHT in LNCaP cells 
A preliminary investigation was conducted in which LNCaP cells were incubated in the presence of 
DHT, 0.1 and 1 µM, for 96 h, after which PSA levels were determined. PSA levels were increased, 
at both concentrations of DHT (fig. 5.12). However, at 1 µM, DHT resulted in PSA levels reaching 
the upper limit (150 ng/mL) of the immunoassay. The influence of rooibos on PSA levels was 
therefore investigated using DHT concentrations lower than 1 µM. 
a b 
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Figure 5.12: PSA levels in LNCaP cells after 96 h. Control, culture media without DHT; culture media with 
DHT
a
, 0.1 µM; and culture media with DHT
b
, 1 µM. The experiment was performed in triplicate and 
compared as shown by a one-way ANOVA, followed by a Dunnett‟s multiple comparison test. Results are 
expressed as the mean ±SEM (**P<0.01, ***P<0.001, n=3).  
Inhibition of PSA levels by rooibos in LNCaP cells 
The influence of rooibos extracts was firstly assessed on basal PSA levels in LNCaP cells prior to 
determining the effect of DHT-stimulated production of PSA. Incubating LNCaP cells in the 
presence of rooibos (4.3 mg/mL) for 96 h resulted in significant decreases in basal PSA levels. 
While PSA levels decreased significantly (P<0.01) when cells were incubated in the presence of 
the higher concentration of rooibos (4.3 mg/mL), at a lower concentration (1 mg/mL), the decrease 
in PSA levels was less apparent with the 2-fold decrease approaching significance (P=0.0517) 
(fig. 5.13). 
 
Figure 5.13: Influence of rooibos on basal PSA serum levels in LNCaP cells after 96 h. Control, culture 
media without rooibos; rooibos
a
, 1 mg/mL; and rooibos
b
, 4.3 mg/mL. PSA normalised to 60 000 live cells per 
mL. The experiment was performed in triplicate and data was compared as shown and analysed by an 
unpaired t-test. Results are expressed as the mean ±SEM (**P<0.01, approaching significance P=0.0517, 
n=3). 
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The influence of rooibos (4.3 mg/mL) on DHT-stimulated PSA levels was subsequently determined 
in LNCaP cells, assayed in the presence of DHT, 0.001, 0.01 and 0.1 µM after 96 h. The data 
shows that while DHT stimulated PSA levels in a dose-dependent manner rooibos (4.3 mg/mL) 
decreased the levels significantly in the case of, 0.001 µM DHT (P<0.01) (fig. 5.14 a) and in the 
case of 0.01 µM DHT (P<0.05) (fig. 5.14 b). In contrast rooibos (4.3 mg/mL) did not result in a 
significant decrease in PSA levels at 0.1 µM DHT (fig. 5.14 c). In addition, rooibos (1 mg/mL) did 
not decrease PSA levels significantly in the presence of 0.001, 0.01 or 0.1 µM DHT (data not 
shown). 
 
Figure 5.14: Influence of rooibos on PSA levels in LNCaP cells after 96 h. Assays were conducted in the 
absence (control) and in the presence of rooibos (4.3 mg/mL): (a) DHT, 0.001 µM; (b) DHT, 0.01 µM; and (c) 
DHT, 0.1 µM. PSA was normalised to 60 000 live cells per mL. The experiment was performed in triplicate 
and data was compared as shown and analysed by an unpaired t-test. Results are expressed as the mean 
±SEM (*P<0.05, **P<0.01, ns=not significant, n=3). 
The influence of rooibos (4.3 mg/mL) on DHT-stimulated PSA levels was subsequently calculated 
as a ratio, represented by the PSA levels in the control assay: the PSA levels in the presence of 
rooibos (fig. 5.15). Rooibos reduced PSA levels at 0.001 µM and 0.01 µM DHT concentrations, 
resulting in a ratio of ±7. This ratio decreased dramatically, ±7 fold, at the highest concentration 
assayed. 
b a c 
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Figure 5.15: Ratios depicting the influence of rooibos on PSA concentrations in LNCaP cells assayed after 
96 h without and in the presence of rooibos. Assays were conducted in the absence (control) and in the 
presence of rooibos (4.3 mg/mL) at DHT concentrations 0.001 µM, 0.01 µM and 0.1 µM. PSA was 
normalised to 60 000 live cells per mL. The experiment was performed in triplicate and data was compared 
as shown and analysed by an unpaired t-test. Results are expressed as the mean ±SEM (**P<0.01, ns=not 
significant, n=3). 
 
5.4 Discussion 
The determination of androgen pathways and enzymatic conversions were undertaken in LNCaP 
cells as it is important to examine in detail the status of in situ androgen metabolism and/or 
synthesis before modulation thereof by rooibos can be ascertained. This study showed that A4 is 
readily converted to 5α-dione, indicative of the preferred conversion of A4 by SRD5A in the 
„alternative‟ 5α-dione pathway within LNCaP cells, corroborating previous reports (Chang et al., 
2011; Sharifi, 2012). In addition, the data show that predominant conjugation of T, DHT, AST and 
3α-adiol occurs in LNCaP cells, and will contribute to androgen production in these cells. The 
11OHA4 pathway describing the metabolism of 11OHA4 has been reported (Storbeck et al., 2013; 
Swart et al., 2013b), with this study confirming that 11OHA4 is readily metabolised by 11βHSD2, 
but not by reductive 17βHSD. As mentioned previously the catalytic activity of UGT towards the 
C19 steroids within the 11OHA4 pathway has not, to date, been determined. It is possible that the 
hydroxy- or keto-groups on C11 hinders conjugation of these steroids. The glucuronidation of both 
11KA4 and 11KT was investigated in this study and upon analyses of free and total steroid 
metabolites it was found that neither steroid was conjugated (data not shown), which indicates the 
inability of the UGTs present in LNCaP cells to conjugate these C11 steroids.  
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Evidence of an inhibitory effect on expressed 17βHSD in cells systems by rooibos (4.3.4) led to the 
subsequent investigation into the possible attenuation of endogenously expressed 17βHSD in 
LNCaP cells, by rooibos. Investigations into preferred oxidative or reductive 17βHSD activity in 
LNCaP cells showed predominant reductive 17βHSD activity to be present. 17βHSD expression 
has been reported in LNCaP cells, as 17βHSDs are intricately involved in the favoured activation 
or inactivation of androgen ligands. Predominant AKR1C3 mRNA expression in LNCaP cells have 
been reported, with minimal 17βHSD3 mRNA expression also reported (Luu-The et al., 2008). A 
recent study also reported on AKR1C3 and 17βHSD3 expression in PCa tissue, together with the 
presence of reductive 17βHSD7 (Gianfrilli et al., 2014). Another study, however, reported that the 
expression of AKR1C3 was minimal in LNCaP cells (Byrns et al., 2012; Fung et al., 2006), with 
others suggesting the presence of 17βHSD1 and 17βHSD7 (Laplante & Poirier, 2008). 17βHSD1 
has been shown to exhibit negligible reductive activity towards A4 (Nokelainen et al., 1996; 
Puranen et al., 1997). Reductive 17βHSDs, specifically AKR1C3, are responsible for the increased 
T levels in PCa tissue, resulting in the progression of PCa (Nakamura et al., 2005). Possible 
modulation of reductive 17βHSD activity, such as AKR1C3, in prostate cells by rooibos therefore 
may indicate a potential beneficial effect in androgen-dependent diseases.  
In this study, evidence of the inhibition of the catalytic activity of endogenous reductive 17βHSD in 
LNCaP cells by rooibos was shown with the metabolism of A4 significantly inhibited by rooibos. 
Indomethacin, a selective AKR1C3 inhibitor, blocked A4 conversion to the same extent as that 
obtained with rooibos, denoting the specific inhibition of AKR1C3 in LNCaP cells. This finding 
suggests that rooibos inhibited endogenously expressed AKR1C3 in LNCaP cells, and confirms 
results obtained in heterologously expressed AKR1C3 in CHO-K1 and HEK293 cells (4.3.4). Upon 
analyses of total steroids in the metabolism of A4 in the presence of rooibos in LNCaP cells, an 
increase in A4 levels were detected together with a decrease in T levels, however, the latter was 
not significant. In the presence of rooibos the change in 5α-dione levels were not significant, 
suggesting that rooibos did not modulate SRD5A activity. Higher levels of SRD5A1 compared to 
SRD5A2 have been reported to be present in LNCaP cells, denoting the conversion of A4 to 5α -
dione to be catalysed by SRD5A1 (Iehle et al., 1999). Interestingly, a decrease in AST was 
detected suggesting rooibos inhibited endogenous AKR1C2 activity in LNCaP cells. The decrease 
in AST formation may, however, yield 5α-dione as substrate for 17βHSD resulting in the formation 
of DHT via 5α-dione pathway. Interestingly, no increase in DHT levels was detected in the 
presence of rooibos, showing that the metabolism of A4 in LNCaP cells yields s teroids which 
exhibit minimal agonist activity towards the AR. 
In addition to the increased A4 levels in the presence of rooibos being comparable to those in the 
presence of indomethacin, reduced conversion of 11KA4 to 11KT was also detected, suggesting 
the inhibition of reductive 17βHSD. Reports on the expression of 17βHSD isoforms in prostate 
cells are contradictory and therefore the endogenously expressed 17βHSDs in LNCaP cells may 
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include 2 or more of the 14 human isoforms identified to date (Penning & Byrns, 2009; Persson et 
al., 2009; Prehn, Möller, & Adamski, 2009; Schuster et al., 2011). The influence of rooibos on a 
specific isoform in LNCaP cells can therefore only be assumed at this time and conclusions can 
only be drawn in terms of what has been published, specifically in terms of the reductive or 
oxidative capacity of the 17βHSD isoforms.  
The inhibition by rooibos of 17βHSDs can most likely be attributed to the polyphenols present in 
rooibos. As previously mentioned both quercetin and rutin has been suggested to alter the 
reductive activity of AKR1C3 and 17βHSD3 activity, respectively, however, in this study rutin 
exhibited no inhibitory effect (data not shown). Aspalathin and isoorientin were also assayed and 
were shown to have no inhibitory effect at 10 µM. It should be noted that the flavonoid 
concentrations of the extracts ranged between 12 µM and 652 µM and as such the inhibitory effect 
may be due to flavonoids present at higher concentrations. Interestingly, in the presence of rooibos 
no inhibition of 11βHSD2, converting 11OHA4 to 11KA4, was detected. This result was expected 
as it has been reported that rooibos inhibits the catalytic activity of 11βHSD1 only, while having no 
effect on 11βHSD2 (Schloms et al., 2013). Furthermore, in the presence of rutin, increased 
conversion of 11OHA4 to 11KA4 occurred, suggesting stimulation of 11βHSD2 activity, prompting 
further investigation. 
Having shown the inhibitory effects of 17βHSDs by rooibos and negligible inhibition of SRD5A2 
while SRD5A1 activity was unaffected, AKR1C2 and UGTs were additional downstream enzymes 
considered in the C19 pathway of prostate androgen metabolism (fig. 5.1 f). Data does suggest 
that rooibos attenuates AKR1C2 activity - rooibos decreased the conversion of DHT to 3α-adiol, 
however, the influence of rooibos on the catalytic activity of AKR1C2 was not the focus of this 
study. 
In this study it was reported for the first time that rooibos inhibits the conjugation of T, DHT and 
AST in LNCaP cells. The inhibition of T-G, DHT-G and AST-G formation in the presence of rooibos 
suggests interference with both UGT2B15 and UGT2B17 activity. Rooibos would therefore result in 
higher levels of T, DHT and AST within prostatic tissue. Although AST is considered to be an 
inactive AR ligand, T once converted to DHT becomes a potent AR ligand. Rooibos hinders phase 
II inactivation of steroids, therefore placing rooibos in an unfavourable position in terms of aiding in 
treatment regimes against PCa progression. PCa is driven by androgens, and reduced inactivation 
of AR ligands will lead to subsequent increased cell proliferation and growth. It is possible that the 
polyphenol compounds in rooibos may hamper the conjugation of androgens with UGT2B15 and 
UGT2B17 binding flavonoids and conjugating these compounds rather than steroids, resulting in 
reduced steroid conjugation. Phase II enzymes, such as UGT1A1, UGT1A8 and UGT1A9 have 
been suggested to be involved in the glucuronidation of green tea catechins (Lu et al., 2003), 
however, UGT2B15 and UGT2B17 have only been reported to catalyse androgen conjugation. 
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Although flavonoids are also methylated and sulphonated, it has, however, been suggested that 
tea polyphenols are preferentially glucuronidated. The levels of phase II enzymes and their 
activities towards tea polyphenols therefore determine the metabolic profile in vivo (Lambert & 
Yang, 2003; Lu et al., 2003). It has been shown in Japanese males that the main circulating 
glucuronidated steroids, AST-G and 3α-adiol-G, were present at lower levels than in Western 
males. This finding led to the suggestion that lower peripheral steroid biosynthesis could account 
for the lower PCa risk in Japanese males (Ross et al., 1992). This begs the question as to whether 
diet and lifestyle differences could account for the lower peripheral steroid biosynthesis, since 
Western diets include high fat foods and Japanese diets are more soy based foods (Messina & 
Barnes, 1991; Messina et al., 1994; Nair et al., 1984). It is possible that the soy based diets, high in 
polyphenols, could result in decreased peripheral steroid biosynthesis, in that these compounds 
may serve either as substrates for, or inhibitors of steroidogenic enzymes. The aforementioned 
study, however, did not consider UGTs specifically. Although this study showed that rooibos 
inhibited the glucuronidation of T, DHT and AST further downstream metabolism of these steroids 
to 3α-adiol, could yield a metabolite which may be glucuronidated more efficiently, as results have 
shown. The levels of 3α-adiol in the presence of rooibos were not specifically analysed in this 
study. The modulation by rooibos of the UGTs expressed in the prostate is the focus of future 
studies in which the possible glucuronidation of rooibos flavonoids will also be investigated. 
In this study the influence of rooibos on PSA levels were also investigated, in order to elucidate the 
possible effects of rooibos‟ inhibitory action of steroidogenic enzymes on cellular processes. 
Rooibos resulted in a significant reduction in basal PSA levels, which appears to be dose 
dependent, however, further studies will be conducted. While rooibos resulted in a significant 
reduction in PSA levels in DHT-stimulated PSA production in LNCaP cells at concentrations below 
0.01 µM, the inhibitory effect of rooibos dissipated at the higher DHT levels (0.1 µM). The inhibitory 
effect of rooibos suggests less activation of the AR by DHT and subsequently less AR-activated 
PSA secretion. DHT can be metabolised by 17βHSD (to 5α-dione), AKR1C2 (to 3α-adiol) and 
UGT2B15/17 (to DHT-G) (fig. 5.16). Reduced PSA levels suggest reduced DHT levels in the 
presence of rooibos, however, this study shows rooibos reduced UGT2B15 and UGT2B17 activity, 
oxidative 17βHSD (in HEK293 cells) and AKR1C2 activity. The PSA levels therefore suggest 
antagonist activity towards the AR in LNCaP cells, specifically as the down-regulation of basal PSA 
secretion was also detected in the absence of DHT. 
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Figure 5.16: DHT metabolism by 17βHSD, AKR1C2 and UGT2B15/17. DHT is also able to bind the AR. 
The potential role of phytoestrogens and AR interaction has been reported, with the mutated AR 
present in LNCaP cells suggestive of promiscuous ligand specificity, allowing other ligands such as 
phytoestrogens to bind (Mitchell et al., 2009). It has been shown that the T877A mutation in the AR 
ligand binding domain (Veldscholte et al., 1990) present in LNCaP cells is a common mutation that 
occurs in about 18% of PCas (Heinlein & Chang, 2004; Shi et al., 2002). In addition, flavonoids 
have been reported to inhibit PSA levels in breast cancer and PCa cells, the latter transfected with 
human AR (Zand et al., 2001, 2000). Although mutations of the AR occur in PCa progression, 
increased ER expression occurs concurrently. It has therefore been suggested that the action of 
phytoestrogens were mediated through AR as well as ER dependent pathways (Kumar et al., 
2011). Indeed in LNCaP cells, steroid hormone-induced PSA secretion was decreased by blocking 
AR or ERβ, suggesting interaction or „„cross-talk‟‟ between the mutant AR and ERβ in the 
regulation of PSA mRNA expression in these cells (Arnold et al., 2007). Phytoestrogens have been 
reported to be ERβ agonist, which act through the AR and thereby down regulate AR expression 
and AR-dependent gene expression (Kumar et al., 2011). The possibility therefore exists that 
rooibos may have either AR antagonist or ERβ agonist activity in LNCaP cells. Furthermore, 
rooibos significantly reduces PSA levels at lower DHT concentrations, an effect that, however, 
diminishes at higher concentrations, signifying an androgen level of 0.1 µM that activates the AR 
and AR-driven genes overriding the inhibitory effect of rooibos. 
Attributing the effects of rooibos on PSA levels, in terms of receptor interaction, to flavonoids 
present in the extract would be purely speculative as specific rooibos flavonoids were not assayed 
in this study. Quercetin, however, has been shown to inhibit AR protein expression in a dose-
dependent manner, as well as inhibiting the secretion of PSA and human glandular kallikrein. The 
study showed PSA mRNA levels were down-regulated, with quercetin also inhibited AR-mediated 
PSA expression at the transcriptional level (Xing et al., 2001). Interestingly, quercetin has also 
been shown to down-regulate ER expression (Miodini et al., 1999). Rooibos has been reported to 
contain quercetin (Beelders et al., 2012; Beltrán-Debón et al., 2011) and together with quercetin-3-
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robinobioside and rutin, which may be metabolised to quercetin (Kim et al., 1998), could therefore 
possibly contribute toward the effect of rooibos on PSA levels. 
While rooibos decreased glucuronidation of T and decreased DHT-stimulated PSA secretion in 
LNCaP cells, researchers have shown with the exposure of LNCaP cells to biochanin A, an 
isoflavone, glucuronidation of T is increased and PSA levels decreased. In this study PSA levels 
were determined after an incubation period of 6 days in media containing 5 µM biochanin A (Sun et 
al., 1998). It should be noted that in the current study rooibos, contains more than 47 polyphenolic 
compounds with a ranges of flavonoids present at appreciably higher concentrations. These 
compounds may exhibit different levels of bioactivity, with some being inhibitory while others may 
have stimulatory effects, possibly accounting for the decreased glucuronidation of T detected in 
this study. Both this study and the study above detected reduced PSA secretion, with Sun et al., 
(1998), suggesting indirect and direct mechanisms, at transcription level, by which biochanin A 
mediated its effects. The comparative study also reported on preliminary studies detecting minor 
changes in AR binding sites and AR protein levels, as to account for the reduction in PSA levels 
(Sun et al., 1998). 
In summary, whether rooibos may impact positively on PCa and impede the progression of PCa 
remains uncertain. Inhibition of reductive 17βHSD activity in prostate cells will reduce active 
androgen production, however, inhibition of UGTs and AKR1C2 will lead to increased active 
androgens. Homeostasis between proliferative and apoptotic pathways is maintained in prostate 
cells, with a disruption of this balance leading to PCa initiation. Progression of PCa is androgen 
dependent, with ADT treatment strategies employed to reduce active androgen production. 
Rooibos would have to reduce potent androgen production, with no toxic effects for rooibos to be 
used as a possible herbal supplement in PCa. This study highlights a possible role for rooibos in 
PCa – inhibition of reductive 17βHSD activity, reducing the production of steroids  such as T while 
potentially binding the ERβ and/or the AR, thereby modulating AR activation. Together these 
results indicate a role for rooibos in aiding treatment strategies employed in PCa. This study, 
however, also shows altered inactivation and phase II metabolism of steroids in LNCaP cells in the 
presence of rooibos. Although rooibos resulted in reduced glucuronidation of metabolites assayed, 
together with increased DHT levels due to the inhibition of AKR1C2 activity, PSA levels were 
decreased both basally and in DHT-stimulated LNCaP cells, indicating positive effects at cellular 
level. 
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Chapter 6 
Conclusion 
 
The central aim of this study was to investigate whether rooibos influences the catalytic activity of 
enzymes involved in prostate androgen metabolism. Prostate androgen metabolism involves 
intricate enzyme pathways that interconvert inactive and active androgens, with the latter driving 
prostate cell growth and proliferation. These same pathways drive PCa, and progression to CPRC. 
Treatment regimes include, ADT (chemical or medical castration), together with AR antagonists as 
well as enzyme inhibitors. However, with all these treatments at hand, and on-going research 
being conducted into new possible treatment strategies, PCa is still a devastating disease. In this 
scenario, herbal supplements aiding therapeutic approaches may yet have a role to play. Although 
natural plant products are considered by many to be unscientific and untested, there is growing 
interest and support for natural approaches in the treatment of diseases. This study therefore 
investigated the effects of rooibos on PCa, seeking scientific evidence for medicinal uses 
supporting a potential role for rooibos in supplementing clinical strategies. 
This study reports on the inhibitory effect of rooibos on the catalytic activity of 17βHSD3, AKR1C3, 
17βHSD2 and modulation of SRD5A2, heterologously expressed in cell systems. The mode of 
action by which rooibos inhibited the catalytic activity of these enzymes was not the focus of this 
study and will, as such be discussed briefly. Muto et al., (2001) reported the inhibition of CYP450 
enzymes by green tea catechins, which was achieved by the inhibition of CYP450 together with the 
inhibition of POR (Muto et al., 2001). CYP450 enzymes form a complex with NADPH-POR which 
enables P450 enzymes to receive electrons from NADPH via POR (Miller, 2005). Middleton et al., 
(2000), also suggested enzymes of importance as targets of polyphenols are enzymes with 
NADPH as a cofactor, as would be the case for CYP450 enzymes as well as reductive 17βHSDs 
and SRD5As (Middleton Jr. et al., 2000). The possibility therefore exists for rooibos to not only 
influence the catalytic activity of 17βHSD, but to also influence the complex that forms when 
17βHSDs receive electrons from NADPH. Therefore, modulation of the catalytic activity of 17βHSD 
by rooibos would depend on the levels of 17βHSD expressed in the cell system, the compounds 
present in rooibos, and the expression and availability of relevant cofactors. 
This study also reported on the inhibitory effect of indomethacin on the catalytic activity of reductive 
17βHSD towards A4 endogenously expressed in LNCaP cells, to the same extent as in the 
presence of rooibos. Indeed, it has been proposed that indomethacin, a known AKR1C3 inhibitor, 
forms an inhibitory complex with AKR1C3, and the redox-partner (NADPH) (fig. 6.1). The reverse 
reaction may also be inhibited by indomethacin. The mode of action by which rooibos inhibits 
17βHSDs, and by which rooibos modulates SRD5A2, may be similar to that of indomethacin. 
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Figure 6.1: Proposed formation of inhibitory complexes by indomethacin during the ordered bi bi reaction 
catalysed by AKR1C3. Abbreviations as follows: E, enzyme; I, inhibitor; S, substrate; and P, product . 
Reproduced with permission from (Byrns, Steckelbroeck, & Penning, 2008). 
The aforementioned mode of action is further supported as rooibos inhibits the catalytic activity of 
11βHSD1, but not that of 11βHSD2 (Schloms et al., 2013), as previously mentioned. The reduction 
reaction catalysed by 11βHSD1 utilizes the co-factor NADPH, compared to 11βHSD2 which 
utilizes NAD
+ 
(Miller & Auchus, 2011). In contrast, however, this study also reports on the inhibitory 
effect of rooibos on the catalytic activity of 17βHSD2, catalysing oxidative reactions dependent on 
NAD+. This suggests a more complicated role for rooibos - especially if substrate, as well as the 
aforementioned co-factor specificities, contribute to the inhibitory mode of action of rooibos. Indeed 
substrate specific inhibition by rooibos of CYP21A2 and CYP11B1, enzymes involved in adrenal 
steroidogenesis, have been reported (Schloms & Swart, 2014), suggesting that the manner in 
which rooibos would inhibit the enzyme in question would be dependent on the availability of a 
specific substrate. 
Although the influence of rooibos on androgen metabolism in the prostate cannot be attributed to a 
single flavonoid, the data presented in this study may indicate synergistic effects by the 
polyphenolic compounds present in rooibos. In order to determine whether a specific flavonoid 
compound was contributing to the inhibitory effect of rooibos on steroidogenic enzymes catalysing 
androgen metabolism in transfected cell systems and in prostate cell models, selected flavonoids 
were investigated. These included rutin, aspalathin and isoorientin, which, however, exhibited no 
inhibitory effects. These results demonstrates either that the specific flavonoid compounds were 
not the contributing compounds, or that the concentrations at which these compounds were 
assayed, were ineffectual as a compound such as aspalathin was only assayed at 10 µM, while 
being present at a significantly higher concentration in the extract. It should, however, be 
considered that the inhibition elicited by rooibos may be due to synergistic effects of the 
polyphenols present in rooibos. Kumar et al., (2011), showed a significant increase in the 
bioactivity of three polyphenolic compounds once used in combination. Genistein, quercetin 
together with biochanin A inhibited the growth of PCa cells, more so than compared to growth in 
the presence of individual compounds or compounds assayed in dual combinations (Kumar et al., 
2011). Rooibos compounds may therefore act synergistically to inhibit the catalytic activity of 
steroidogenic enzymes in prostate cells.  
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Although studies reporting on the effects of flavonoid compounds present in rooibos on PCa are 
limited, one flavonoid compound which has been the subject of many investigations is quercetin. 
From the results of this study, it appears as if quercetin may be one of the flavonoids involved in 
the inhibitory effects that rooibos exhibits towards the 17βHSDs as well as the possible AR 
interaction resulting in reduced PSA levels. It has been suggested that quercetin interferes with the 
binding of 17βHSDs in the active pocket as well as with AR binding. It should be noted that 
aglycones of the flavonoids present in rooibos viz.: quercetin (from rutin) and apigenin (from vitexin 
and isovitexin) have been shown to have adverse side-effects (Singh et al., 2012; van der Woude 
et al., 2003), and therefore not all polyphenol compounds present in rooibos are necessarily 
beneficial. In this study, however, rutin and vitexin together with isovitexin were not present in high 
concentrations. Cells to which rooibos was administered received ±12.65 µM rutin and a 
cumulative ±30.11 µM vitexin and isovitexin. In the consumption of rooibos, rutin may be 
metabolised to quercetin with vitexin and isovitexin being metabolised to apigenin, and considering 
further in vivo metabolism and conjugation, compounds reaching target tissue may be present at 
markedly lower levels. It has been suggested in literature that the concentrations of flavonoids 
used in experimental protocols in cell culture systems far exceed the plasma concentrations that 
would be reached in human studies (Lambert & Yang, 2003), questioning the effectiveness of 
supplementation of rooibos and/or individual flavonoids. Furthermore, the levels of these flavonoid 
compounds pale in comparison to the dihydrochalcones, which accounted for ±794.08 µM to which 
cells were exposed and to which the bioactivity could be attributed. None the less, it is not to say 
that rutin, vitexin and isovitexin might not play a role in the inhibitory effects of rooibos observed in 
this study, as studies have reported cellular effects in the presence of 10 µM of these flavonoids 
(Schloms & Swart, 2014; Schloms et al., 2013). Considering rooibos as a herbal supplement is 
tempting, however, dosage amount of flavonoid levels should be considered. Although high levels 
of flavonoids in rooibos have been reported, these are affected by manufacturing processes which 
leads to discrepancies in end product and flavonoid levels. Processing together with polyphenol 
levels being influenced by climate, soil and harvesting methods of the plant, results in marked 
variations between rooibos production batches (Breiter et al., 2011; Stalmach et al., 2009). 
This study reported on the inhibition of PSA levels by rooibos in the absence and presence of DHT. 
The data suggested that rooibos may act as an AR antagonist or ERβ agonist. ERβ once bound to 
its ligand, acts via the AR and regulates AR-dependent genes in prostatic tissue (Arnold et al., 
2007). In the prostate, ERβ is activated by 3β-adiol and exerts its anti-proliferative activity, while 
the proliferative action of the AR is driven by DHT. Prostate growth is thus governed by the 
balance between AR and ERβ activation. 3β-adiol, a product of DHT catalysed by 3-keto 
reductase, is a high-affinity ligand and agonist of ERβ. Muthusamy et al., (2011), showed that 
17βHSD6 converts DHT to 3β-adiol which activates the ERβ reporter in cell models, expressing an 
estrogen response element-luciferase reporter constructs. This study, however, also showed that 
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in PCa tissue (Gleason grade higher than 3), both ERβ and 17βHSD6 are undetectable. They 
concluded therefore that the formation of 3β-adiol via 17βHSD6 from DHT is an important growth 
regulatory pathway that is lost in PCa (Muthusamy et al., 2011). This raises issues regarding the 
ERβ agonist role rooibos may play in PCa, to when and if the ERβ is down-regulated in PCa and 
that the interaction of rooibos and ERβ may not be relevant. It may be that rooibos interacts with 
the AR and ER in normal prostatic tissue and in BPH, but it is the interaction of rooibos with the AR 
that would contribute to the effect of rooibos in PCa. 
In a recent report emanating from our laboratory, investigating the physiological role of 11OHA4 in 
PCa, it was shown that the androgenic activity of the C11-keto forms of A4, T and DHT were more 
androgenic than their respective C11-hydroxy forms (Storbeck et al., 2013). In this study it was 
shown that 11KT was not conjugated, compared to T which is readily conjugated in LNCaP cells, 
suggesting 11KT, once formed, would be efficiently channelled to 11KDHT. As previously 
mentioned 11KDHT possesses agonist activity towards the AR comparable to DHT and may thus 
have implications in CRPC. As the glucuronidation of C11-keto and C11-hydroxy steroids have, to 
date, not been elicited, the findings of this study prompt further investigations into the inactivation 
and conjugation of these compounds since the hydroxyl and keto moieties at the C11 of the steroid 
carbon backbone may hinder conjugation of these C19 steroids. 
It is worth mentioning that the preferred conversions of specific substrates by enzymes were also 
reported in this study. SRD5A1 was shown to preferentially convert A4 to 5α-dione, compared to 
the conversion of T to DHT, with the preferential conversion of A4 also being observed in the 
prostate cell models, viz.: PNT2 (4.3.6), LNCaP (5.3.2.1) and BPH-1 and PC-3 (data not shown). 
As such the „alternative‟ 5α-dione pathway is supported, and places this pathway as a dominant 
pathway in prostate androgen metabolism in these cells. 
This study reports on the inhibition of the catalytic activity of 17βHSD3, AKR1C3, 17βHSD2, 
UGT2B15 and UGT2B17 by rooibos, together with reduced PSA secretion, possibly mediated via 
AR and/or ER involvement. Although this study could not establish an inhibitory effect on SRD5A1 
by rooibos, it appears as if rooibos inhibited SRD5A2 activity towards T, together with possibly 
inhibiting AKR1C2. This study also showed the modulation of prostate androgen metabolism in 
PNT2, BPH-1, PC-3 and LNCaP prostate cell models, regarding the C19 steroids involved in both 
the conventional C19 and in the 11OHA4 pathways. This study therefore provides insight into the 
influence of rooibos on androgen metabolism in normal prostate cells and in PCa cells, and 
provides evidence of prostate androgen metabolism modulation and enzymatic inhibition by 
rooibos extracts.  
As reported in this study, the presence of rooibos inhibited the catalytic activity of AKR1C2 in PCa 
cells, however, this was not tested in an isolated system away from competing enzymes. Future 
studies would include investigating the effect of rooibos on the catalytic activity of AKR1C2 as well 
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as that of UGT2B15 and UGT2B17 in transfected cell systems. In addition the ability of the UGTs 
to conjugated flavonoids compounds in rooibos will also be studied. The ability of rooibos and 
flavonoid compounds to interfere with the transfer of electrons between redox partners and the 
enzymes catalysing androgen metabolism will also be explored. Since rooibos interferes with the 
catalytic activity of steroidogenic enzymes in the prostate cell models, it is possible that it may also 
interfere with the expression of relevant enzymes. Further investigations can therefore be 
conducted utilizing both qPCR and Western blot, in order to elucidate the effects of rooibos. Within 
this approach, 17βHSDs and SRD5As could be included together with AKR1C2 and UGTs. Further 
investigations would also be included to determine interactions with the AR, AR binding sites and 
ERβ to fully characterise the influence of rooibos at molecular and cellular levels. 
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Chapter 7 
Research protocols 
7.1 Introduction 
The completion of this study relied on multiple experimental procedures together with tissue culture 
techniques, UPLC-MS/MS analysis and data analysis for steroid quantification. This chapter will 
discuss experimental activities and procedures conducted in the investigation into the influence of 
rooibos on normal and PCa cells. 
7.2 Experimental procedures 
7.2.1 Methanol extraction of unfermented rooibos 
A rooibos extract was prepared by extracting 20 g unfermented plant material with chloroform 
(200 mL) for 8 h, followed by a methanol (200 mL) extraction for 8 h using a Soxhlet extractor fitted 
with a double-wall condenser as previously described (Schloms et al., 2012). Unfermented rooibos 
plant material, 20 g, was placed in a glass Soxhlet extractor fitted with a double-wall condenser 
and a drying tube packed with granular calcium chloride. The extractor was fitted to a round-bottom 
flask containing 200 mL chloroform. The plant material was extracted for approximately 8 h at 
±61.15°C, until the effluent from the Soxhlet apparatus was clear. The plant material was 
subsequently extracted with 200 ml methanol for 8 h at ±64.7°C. The extract was dried at reduced 
pressure in a rotating evaporator and the vacuum released under nitrogen. The dried extract was 
redissolved in analytical quality deionised water (Milli-Q
TM
 water purification system), to a final 
concentration of 86 mg extract/mL and centrifuged at 10 000 x g for 5 min at 4°C. The supernatant 
was stored in 1 mL aliquots at -20°C. The extract was protected from light and oxygen at all times 
to avoid any compositional changes. All extracts were centrifuged with a bench-top centrifuge 
(HeraeusTM BiofugeTM, Thermo Scientific, USA) prior to use, to separate any undissolved matter. 
7.2.2 Identification and quantification of rooibos polyphenols 
Unfermented rooibos extracts were analysed using HPLC coupled to a diode-array-detector 
(HPLC-DAD) to identify and quantify polyphenolic compounds, as previously described (Beelders 
et al., 2012). Aspalathin, nothofagin, 3, 4 dihydroxybenzoic acid, caffeine acid, luteolin, vitexin, 
quercetin 3-β-D-glucoside, quercetin dehydrate, ferulic acid, rutin hydrate, syringic acid, vanillic 
acid and p-coumaric acid standards were prepared in methanol. Retention times were determined 
and UV spectra were recorded. All analyses were performed using a mobile phase consisting of 
(A) 2% acetic acid in water (v/v) and (B) acetonitrile. HPLC analyses were conducted on an Agilent 
1200 series instrument (maximum pressure 400bar) equipped with an in-line degasser, quaternary 
pump, autosampler, column thermostat and diode-array detector (standard 13 µL flow cell, 10 mm 
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path length) controlled by Chemostation software (Agilent Technologies). The dwell volume of this 
system was measured as 0.82 mL. 
7.2.3 Plasmid preparation 
Luria-Bertani (LB) medium (100 mL), containing ampicillin (100µg/mL), was inoculated with freezer 
stocks of plasmid-containing E.coli cells, 100 µL, overnight at 37°C at 230 rpm (Innova shaking 
incubator, New Brunswick). The plasmid DNA was isolated using the Nucleobond® Midiprep DNA 
isolation kit, according to the manufacturer‟s instructions (Machery-Nagal). After precipitation, the 
DNA pellet was redissolved in nuclease free water, 200 µL, and the plasmid yield was calculated 
by UV spectrophotometry (Cary 60 UV-VIS; Agilent technologies), 260/280 nm. The average yield 
ranged from 100 µg - 200 µg per 100 mL. 
7.2.4 Enzymatic assays in transiently transfected HEK293, CHO-K1 and U2OS cells 
HEK293 cells were cultured in growth medium, DMEM containing 10% fetal bovine serum, 1.5 g 
NaHCO3/L (pH 7), and 1% penicillin-streptomycin at 37°C, 5.0% CO2 and 90% relative humidity for 
2 to 3 days until 80% confluent. Cells were collected by trypsinization (0.1% trypsin and 0.04% 
EDTA, 1mL/100mm plate) and centrifuged at 2000 rpm for 5 min, after which the supernatant was 
discarded and cells pellet resuspended in DMEM. After centrifugation the cells were resuspended 
in DMEM and replated in a Corning® CellBIND® surface 75 cm2 flask. This process was repeated 
over a period of two weeks. After 3-5 passages, cells were replated into 24-well Corning® 
CellBIND® surface plates at a concentration of 2 x 10⁵ cells/mL, 0.5 mL/well and incubated for 
24 h. Stocks were also prepared and stored in liquid nitrogen until further use according to ATCC 
instructions. The replated cells were subsequently transiently transfected with the appropriate 
plasmid constructs, 1 µg/µL, using the Mirus TransIT®-LT1/XtremeGene HP® DNA transfection 
reagents, according to the manufacturer‟s instructions. Cells were transfected by adding 
transfection reaction mix, 50µL culture media without fetal calf serum or penicillin-streptomycin, 
which contained plasmid DNA, 0.5 µL, and transfection reagent, 1.5 µL. pCIneo (Promega, 
Madison, USA), containing no insert cDNA, was included as a negative control in experiments. The 
cells were incubated for 72 h, after which 1 µM of the appropriate steroid substrates was added to 
the medium. Steroid stock solutions dissolved in absolute ethanol (2 mg/mL) were diluted in culture 
medium to the desired concentration. In all assays conducted, ethanol added to cells did not 
exceed 0.01%. Steroid substrates were also added to the cells in the presence of unfermented 
rooibos extracts (4.3 mg/mL). After the appropriate incubation period medium (500 µL) was 
removed and the steroid metabolites were extracted by liquid-liquid extraction using 10:1 volume of 
dichloromethane to culture medium. The samples were vortexed for 10 min, centrifuged at 
3500 rpm for 5 min after which the media was aspirated and dichloromethane phase dried at 45°C 
under nitrogen. The dried steroid residue was redissolved in 150 µL methanol prior to analysis by 
UPLC-MS/MS. Protocols in which rooibos was assessed included assays in the presence of the 
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inhibitor, dutasteride (10 µM) in the case of SRD5A catalysed reactions. Experimental volume 
changes with the addition of rooibos extract were compensated for with the addition of equal 
volume of deionised water. CHO-K1 (growth and experimental medium, Ham‟s F12K) and U2OS 
(growth and experimental medium, DMEM) cells were cultured, replated and transfected using the 
same experimental protocols. Steroid conversion assays were also conducted in the same manner 
as the assays conducted in HEK293 cells. 
7.2.5 Steroid conversion assays in PNT2, BPH-1, PC-3 and LNCaP cells 
PNT2 and BPH-1 cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine 
serum, 1.5 g NaHCO3/L (pH 7), 1% penicillin-streptomycin at 37°C, in an atmosphere of 90% 
humidity and 5% CO2. PC-3 cells were grown in supplemented Ham‟s F12K medium. Cells were 
cultured and maintained as described in the aforementioned section. After 3-4 passages confluent 
cells were plated into 24-well plates (1 x 10
5
 cells/mL, 0.5 mL/well) and incubated for 48 h. The 
medium was removed and replaced with 0.5 mL culture medium containing steroid substrates 
(1 µM). Steroid stock solutions in absolute ethanol (2 mg/mL) were diluted in culture medium to the 
desired concentration. In all assays conducted, ethanol added to cells did not exceed 0.01%. 
Steroid substrates were also added to the cells in the presence of unfermented rooibos extracts 
(4.3 mg/mL). The cells were incubated for 48 h after which 0.5 mL aliquots were removed and 
steroid metabolites extracted as described above. Cortisol-D4 (15 ng) and testosterone-D2 (15 ng), 
were added to each sample as internal standards. Protocols included assays carried out in the 
presence of dutasteride (10 µM). Experimental volume changes with the addition of rooibos extract 
was compensated for with the addition of equal volume of deionised water. 
LNCaP cells were cultured in RPMI-1640 media supplemented with 10% fetal bovine serum, 1.5 g 
NaHCO3/L (pH 7), 2.5 g D-(+)-Glucose, 1% penicillin-streptomycin, 1% HEPES and 1% sodium 
pyruvate using Corning® CellBIND® surface plates at 37°C, in an atmosphere of 90% humidity and 
5% CO2. Cells were plated into 24-well Corning
® CellBIND® surface plates (2 x 105 cells/mL, 
0.5 mL/well) and incubated for 48 h. The medium was removed and replaced with 0.5 mL RPMI-
1640 medium containing the following steroid substrates (1 µM): A4, 11OHA4, 11KA4, T, DHT, 
AST, 3α-adiol. Steroid stock solutions dissolved in absolute ethanol (2 mg/mL) were diluted in 
culture medium to the desired concentration. In all assays conducted, ethanol added to cells did 
not exceed 0.01%. Steroid substrates were also added to the cells in the presence of unfermented 
rooibos extracts (4.3 mg/mL). The cells were incubated for 6 h, 12 h, 24 h and 48 h after which 
duplicate aliquots (0.5 mL) were removed. Steroids were extracted from one of the aliquots as 
described above, while steroid metabolites extracted from the other extracted as described above 
after β-glucuronidase treatment (7.2.8). Cortisol-D4 (15 ng) and testosterone-D2 (15 ng), were 
added to each sample as internal standards prior to extraction. Protocols included assays in which 
steroid conversions were assessed in the presence of inhibitors, indomethacin (20 µM; in DMSO), 
a 17βHSD inhibitor and dutasteride (10 µM; in ethanol), a SRD5A inhibitor. Experimental volume 
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changes with the addition of rooibos extract was compensated for with the addition of equal 
volume of deionised water. 
7.2.6 Cell viability 
The trypan blue exclusion assay was used in this study to assess the influence of unfermented 
methanolic rooibos extracts on cell viability. Polyphenolic compounds have been shown to interfere 
with reagents (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) used in the MTT cell 
viability assay which is commonly used to assess cell viability (Wisman et al., 2008). It is possible 
to assess cell viability with the MTT assay even if polyphenolic compounds are added to the cell 
media, controls are, however, required to be in place. In order to assess cell viability and exclude 
possible interference by the polyphenolic compounds in the rooibos extracts, the trypan blue 
exclusion method was the preferred method in this study. This method will allow the assessment of 
the total number of cells present and will enable analysis of live cells and non-viable cells. Viable 
cells are expressed as a % of the total number of cells counted. Following steroid conversion 
assays in cells trypsin-EDTA (0.5 mL) was used to collect the cells. The cells of each well were 
pipetted into individual micro-centrifuge tubes and centrifuged at 13,000 x g for 10 min using a 
bench-top centrifuge (HeraeusTM BiofugeTM, Thermo Scientific, USA). The trypsin-EDTA was 
aspirated and the cell pellet was redissolved in PBS (250 µL). Cell counts were subsequently 
carried out, with 10 µL of cell solutions to which 10 µL trypan blue stain were added, using the 
Countess® automated cell counter (Invitrogen, Eugene, USA).  
7.2.7 Protein determination 
On completion of steroid conversion assays cells, collected in PBS, were centrifuged at 13,000 x g 
for 10 min using a bench-top centrifuge (HeraeusTM BiofugeTM, Thermo Scientific, USA), the PBS 
aspirated, the cells lysed with 50 µL passive lysis buffer (Promega, Madison, USA) and stored at -
20°C overnight, prior to determining the protein concentration using the BCA method (Pierce 
Chemical, Rockford, USA) according to the manufacturer‟s instructions. Control analysis included 
the BSA standards, 2 mg/mL, 1.5 mg/mL and 1 mg/mL prepared in PBS (according to the 
manufacturer‟s instructions), together with rooibos 1 mg/mL (5.815 µL) and 4.3 mg/mL (25 µL) also 
prepared in 0.5 mL PBS. BSA standards 2 mg/mL, 1.5 mg/mL and 1 mg/mL (20 µL), in the 
presence of rooibos extracts (20 µL), using 20 µL for the assay, were compared to the standard 
BSA curve using the BCA protein determination kit according to the manufacturer‟s instructions. 
Experimental volume changes with the addition of rooibos extract was compensated for with the 
addition of equal volume of PBS (20 µL) to the BSA standards. 
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7.2.8 β-glucuronidase assay 
The liquid-liquid steroid extraction described allows only for the isolation of free unconjugated 
steroids. In order to analyse the conjugated steroid metabolites present in the media, a β-
glucuronidase protocol was conducted, according to the manufacturer‟s instructions to deconjugate 
steroids. Subsequent UPLC-MS/MS analyses will enable the quantification of all the metabolites 
present (free and conjugated) in these samples.  
Following steroid conversion assays in prostate cells, the pH of the media aliquot (0.5 mL) was 
adjusted to 6.5 by the addition of 1% acetic acid (± 20 µL) using pH indicator strips (Merck 
Millipore, Germany). The samples were subsequently treated with 400 units (76 µL) of β -
glucuronidase (E.coli Type VII-A; Sigma-Aldrich) at 37°C for 24 h to deconjugate glucuronidated 
steroids prior to liquid-liquid extraction, as described above. β-glucuronidase was prepared in 
analytical quality deionised water (1 mg/mL) and stored at -20°C prior to assay. Control analysis 
included DHT and DHT-G (1 µM) added to culture media, prior to a β-glucuronidase treatment 
followed by steroid extraction. Both DHT and DHT-G were subjected to a β-glucuronidase 
treatment, and DHT quantified using UPLC-MS/MS. Recovery of 1 µM DHT and unconjugated 
DHT from DHT-G (fig. 7.1) was detected, denoting complete deconjugation of conjugated steroids. 
The amount of conjugated steroids were determined by subtracting the amount of free steroids 
from the amount of total steroids detected using UPLC-MS/MS, and presenting the difference as a 
% over the total (free + conjugated) amount of steroids. 
 
Figure 7.1: DHT and DHT-G (1 µM) analysis representing free steroida analysis by UPLC-MS/MS, and total 
steroid
b
 (free + conjugated) analysis by UPLC-MS/MS following a β-glucuronidase treatment. The 
experiment was performed in triplicate and results are expressed as the mean ±SEM (ns=not significant). 
Further control analysis included the aforementioned control analysis in the presence of rooibos 
(1 mg/mL and 4.3 mg/mL), to determine whether rooibos interfered with the β-glucuronidase 
assay.  
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7.2.9 PSA chemiluminescent immunoassay 
LNCaP cells were cultured as described in 7.2.5. Cells were plated into 24-well Corning® 
CellBIND® surface plates (4 x 104 cells/mL, 0.5 mL/well) in phenol free RPMI-1640 media 
supplemented with 5% charcoal stripped FCS and 1% penicillin-streptomycin. After a 48 h 
incubation period, the medium was removed and replaced with 0.4 mL/well phenol free RPMI-1640 
supplemented with 1% penicillin-streptomycin only. After a 24 h incubation period, phenol free 
RPMI-1640 media containing steroid substrate DHT (0.001, 0.01, 0.1, 1 µM; 0.1 mL/well) was 
added to make up 0.5 mL/well. DHT stock solution dissolved in absolute ethanol (2 mg/mL) was 
diluted in culture medium to the desired concentration. DHT was also added to LNCaP cells in the 
presence of unfermented rooibos extracts (1 mg/mL and 4.3 mg/mL). The cells were incubated for 
96 h after which medium (0.5 mL) was removed and PSA levels analysed using an Access 
Hybritech PSA chemiluminescent immunoassay, for the quantitative determination of total PSA 
levels (Access Immunoasay Systems). Briefly, the assay is a two-site immunoenzymatic „sandwich‟ 
assay, using mouse monoclonal anti-PSA alkaline phosphatase conjugate and paramagnetic 
particles coated with a second mouse monoclonal anti-PSA antibody. The PSA in the sample binds 
to the monoclonal anti-PSA on the solid phase, while the monoclonal anti-PSA alkaline 
phosphatase conjugate reacts with a different antigenic site on the bound PSA. After an incubation 
period, bound PSA are held in a magnetic field and unbound materials are washed away. Light is 
subsequently emitted upon addition of the chemiluminescent substrate, Lumi-Phos*530, which 
reacts with the bound PSA. Emission is measured with a luminometer, and is proportional to the 
concentration of PSA in the sample. The amount of PSA in the sample is determined from a 
stored, multi-point calibration curve, with detection limits between 0.008 ng/mL and 150 ng/mL 
(Coulter, 2010). Experimental volume changes with the addition of rooibos extract was 
compensated for with the addition of equal volume of deionised water. Culture media spiked with 
rooibos equivalent to the concentration used in the assay was shown not to interfere with the PSA 
immunoassay. 
7.2.10 Separation and quantification of steroid metabolites using UPLC-MS/MS 
Stock solutions of A4, 11OHA4, 11OHT, 11KA4, 11KT, T, DHT, DHT-G, 5α-dione, 3α-adiol and 
AST were dissolved in ethanol (2 mg/mL). A series of standards (0.2 - 20 ng/mL) were prepared in 
methanol. In the analyses the limit of quantification (LOQ) was set at the lowest standard 
(0.2 ng/mL) µM value (± 0.017 – 0.025 µM). 
Steroid metabolites were separated by UPLC (ACQUITY UPLC, Waters, Milford, USA) using a 
Phenomenex UPLC Kinetex PFP column (2.1 mm x 100 mm, 2.6 µm) (Torrance, CA, USA) as 
previously described (Storbeck et al., 2013). The mobile phases consisted of 1% formic acid (A) 
and 49%: 49%: 2% methanol: acetonitrile: isopropanol (B). As mentioned previously the separation 
of the C19 steroids in the 11OHA4 pathway were analyses on a separate method to the C19 
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steroids in the conventional C19 pathway. C19 steroids in the conventional pathway were eluted at 
a flow rate of 0.4 mL/min, using a linear gradient from 15% B to 40% B in 1.0 min, followed by a 
linear gradient to 55% B in 3.5 min and a subsequent linear gradient to 100% B in 0.1 min. C19 
steroids in the 11OHA4 pathway were eluted at a flow rate of 0.4 mL/min, using a linear gradient 
from 15% B to 38.5% B in 3.5 min, followed by a linear gradient to 100% B in 0.1 min. The injection 
volume was 5 µL and the total run time was 5 min per sample injection for both separation 
methods. A Xevo triple quadrupole mass spectrometer (Waters, Milford, USA) was used for 
quantitative mass spectrometric detection and all steroids were analysed in multiple reaction 
monitoring (MRM) mode. An electrospray in the positive ionization mode (ESI+) was utilized in the 
MRM mode. The capillary voltage of 3.5 kV, cone voltage of 15-35 V and collision energy of 
4-36 eV was set during this quantification (table 7.1). The following settings were used: source 
temperature 120°C, desolvation temperature 400°C, desolvation gas 900 L h-1 and cone gas 
50 L h-1. Calibration curves were constructed using weighted (1/x2) linear least squares regression 
and the data was collected with the MassLynx 4.1 software program. 
Table 7.1: Parameters for the detection and quantification of C19 steroids by UPLC-MS/MS: retention times 
(RT, min), cone voltages (CV) and collision energy (CE). 
Steroid 
metabolite 
RT 
(min) 
Precursor 
ion 
CV 
Product 
ion A 
CE 
Product 
ion B 
CV 
Product 
ion C 
CE 
conventional C19 method 
A4 3.12 287.2 30 96.9 15 108.8 15 - - 
T 2.97 289.2 30 97.2 22 109.0 22 - - 
5α-dione 3.55 289.2 30 119.2 35 171.2 35 - - 
DHT 3.33 291.2 25 255 15 273 20 - - 
AST 3.57 273.2 15 105.3 30 147 25 - - 
3α-adiol 3.24 275.2 15 161 15 175 15 257 15 
11OHA4 method 
11OHA4 3.15 303.2 30 121 30 267.2 15 - - 
11OHT 3.00 305.3 35 121 20 269 15 - - 
11KA4 3.31 301.2 35 241 30 257 25 - - 
11KT 2.97 303.2 30 121 20 267 20 - - 
 
Possible interference by rooibos in the analysis of steroids by UPLC-MS/MS was investigated, and 
no interference was detected when rooibos (1 mg/mL and 4.3 mg/mL) in culture media only, was 
analysed by UPLC-MS/MS. No change to the base line spectra was detected (fig. 7.2 a/b). 
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Figure 7.2: UPLC-MS/MS chromatogram of: (a) rooibos (1 mg/mL) in culture media; and (b) rooibos 
(4.3 mg/mL) in culture media. Cluster of peaks detected at ±4.1-4.5 min represents the background „noise‟ 
generated by the UPLC-MS/MS. 
7.2.11 Statistical analysis 
All experiments were performed in triplicate and the subsequent results are given as means 
± SEM. Statistics were calculated by an unpaired t-test or by a one-way ANOVA, followed by a 
Dunnett‟s  multiple comparison test using GraphPad Prism (version 5) software (GraphPad 
Software, San Diego, California). Differences were considered statistically significant at P<0.05. 
  
a b 
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